<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Branched‐chain amino acids for people with hepatic encephalopathy - Gluud, LL - 2017 | Cochrane Library</title> <meta content="Branched‐chain amino acids for people with hepatic encephalopathy - Gluud, LL - 2017 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001939.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Branched‐chain amino acids for people with hepatic encephalopathy - Gluud, LL - 2017 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001939.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD001939.pub4" name="dc.identifier" scheme="DOI"/> <meta content="Branched‐chain amino acids for people with hepatic encephalopathy" name="citation_title"/> <meta content="Lise Lotte Gluud" name="citation_author"/> <meta content="Copenhagen University Hospital Hvidovre" name="citation_author_institution"/> <meta content="Lise.lotte.gluud.01@regionh.dk" name="citation_author_email"/> <meta content="Gitte Dam" name="citation_author"/> <meta content="Aarhus University Hospital" name="citation_author_institution"/> <meta content="Iñigo Les" name="citation_author"/> <meta content="Hospital Universitario Araba" name="citation_author_institution"/> <meta content="Giulio Marchesini" name="citation_author"/> <meta content="University of Bologna" name="citation_author_institution"/> <meta content="Mette Borre" name="citation_author"/> <meta content="Aarhus University Hospital" name="citation_author_institution"/> <meta content="Niels Kristian Aagaard" name="citation_author"/> <meta content="Aarhus University Hospital" name="citation_author_institution"/> <meta content="Hendrik Vilstrup" name="citation_author"/> <meta content="Aarhus University Hospital" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="5" name="citation_issue"/> <meta content="10.1002/14651858.CD001939.pub4" name="citation_doi"/> <meta content="2017" name="citation_date"/> <meta content="2017/05/18" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001939.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001939.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001939.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Administration, Oral; Amino Acids, Branched‐Chain [adverse effects, *therapeutic use]; Bias; Diarrhea [etiology]; Hepatic Encephalopathy [*drug therapy, mortality]; Injections, Intravenous; Nausea [etiology]; Quality of Life; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001939.pub4&amp;doi=10.1002/14651858.CD001939.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001939.pub4&amp;doi=10.1002/14651858.CD001939.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001939.pub4&amp;doi=10.1002/14651858.CD001939.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001939.pub4&amp;doi=10.1002/14651858.CD001939.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001939.pub4&amp;doi=10.1002/14651858.CD001939.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001939.pub4&amp;doi=10.1002/14651858.CD001939.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001939.pub4&amp;doi=10.1002/14651858.CD001939.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001939.pub4&amp;doi=10.1002/14651858.CD001939.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001939.pub4&amp;doi=10.1002/14651858.CD001939.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001939.pub4&amp;doi=10.1002/14651858.CD001939.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001939.pub4&amp;doi=10.1002/14651858.CD001939.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001939.pub4&amp;doi=10.1002/14651858.CD001939.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001939.pub4&amp;doi=10.1002/14651858.CD001939.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001939.pub4&amp;doi=10.1002/14651858.CD001939.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001939.pub4&amp;doi=10.1002/14651858.CD001939.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001939.pub4&amp;doi=10.1002/14651858.CD001939.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001939.pub4&amp;doi=10.1002/14651858.CD001939.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001939.pub4&amp;doi=10.1002/14651858.CD001939.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001939.pub4&amp;doi=10.1002/14651858.CD001939.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001939.pub4&amp;doi=10.1002/14651858.CD001939.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001939.pub4&amp;doi=10.1002/14651858.CD001939.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001939.pub4&amp;doi=10.1002/14651858.CD001939.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001939.pub4&amp;doi=10.1002/14651858.CD001939.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="7a2tKMcJ";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD001939\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD001939\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001939\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001939\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","ms","ja","hr","pl","zh_HANS","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD001939.pub4",title:"Branched\\u2010chain amino acids for people with hepatic encephalopathy",firstPublishedDate:"May 18, 2017 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Hepato‐Biliary Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=7a2tKMcJ&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001939.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD001939.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD001939.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD001939.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001939.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD001939.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;アブストラクト&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD001939.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD001939.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD001939.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD001939.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>7874 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD001939.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001939.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001939.pub4/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001939.pub4/full#CD001939-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001939.pub4/full#CD001939-sec-0090"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001939.pub4/full#CD001939-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001939.pub4/full#CD001939-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001939.pub4/full#CD001939-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001939.pub4/full#CD001939-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001939.pub4/full#CD001939-sec-0064"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001939.pub4/full#CD001939-sec-0084"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001939.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001939.pub4/appendices#CD001939-sec-0095"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001939.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001939.pub4/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/table_n/CD001939StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/table_n/CD001939StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001939.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001939.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001939.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD001939.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD001939.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD001939.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2020 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Branched‐chain amino acids for people with hepatic encephalopathy</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001939.pub4/information#CD001939-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Lise Lotte Gluud</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001939.pub4/information#CD001939-cr-0003">Gitte Dam</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001939.pub4/information#CD001939-cr-0004">Iñigo Les</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001939.pub4/information#CD001939-cr-0005">Giulio Marchesini</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001939.pub4/information#CD001939-cr-0006">Mette Borre</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001939.pub4/information#CD001939-cr-0007">Niels Kristian Aagaard</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001939.pub4/information#CD001939-cr-0008">Hendrik Vilstrup</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/information/en#CD001939-sec-0105">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 18 May 2017 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD001939.pub4">https://doi.org/10.1002/14651858.CD001939.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD001939-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001939-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD001939-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD001939-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ja#CD001939-abs-0002">日本語</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD001939-abs-0011">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD001939-abs-0001" lang="en"> <section id="CD001939-sec-0001"> <h3 class="title" id="CD001939-sec-0001">Background</h3> <p>Hepatic encephalopathy is a brain dysfunction with neurological and psychiatric changes associated with liver insufficiency or portal‐systemic shunting. The severity ranges from minor symptoms to coma. A Cochrane systematic review including 11 randomised clinical trials on branched‐chain amino acids (BCAA) versus control interventions has evaluated if BCAA may benefit people with hepatic encephalopathy. </p> </section> <section id="CD001939-sec-0002"> <h3 class="title" id="CD001939-sec-0002">Objectives</h3> <p>To evaluate the beneficial and harmful effects of BCAA versus any control intervention for people with hepatic encephalopathy. </p> </section> <section id="CD001939-sec-0003"> <h3 class="title" id="CD001939-sec-0003">Search methods</h3> <p>We identified trials through manual and electronic searches in The Cochrane Hepato‐Biliary Group Controlled Trials Register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, Science Citation Index Expanded and Conference Proceedings Citation Index – Science, and LILACS (May 2017). </p> </section> <section id="CD001939-sec-0004"> <h3 class="title" id="CD001939-sec-0004">Selection criteria</h3> <p>We included randomised clinical trials, irrespective of the bias control, language, or publication status. </p> </section> <section id="CD001939-sec-0005"> <h3 class="title" id="CD001939-sec-0005">Data collection and analysis</h3> <p>The authors independently extracted data based on published reports and collected data from the primary investigators. We changed our primary outcomes in this update of the review to include mortality (all cause), hepatic encephalopathy (number of people without improved manifestations of hepatic encephalopathy), and adverse events. The analyses included random‐effects and fixed‐effect meta‐analyses. We performed subgroup, sensitivity, regression, and trial sequential analyses to evaluate sources of heterogeneity (including intervention, and participant and trial characteristics), bias (using The Cochrane Hepato‐Biliary Group method), small‐study effects, and the robustness of the results after adjusting for sparse data and multiplicity. We graded the quality of the evidence using the GRADE approach. </p> </section> <section id="CD001939-sec-0006"> <h3 class="title" id="CD001939-sec-0006">Main results</h3> <p>We found 16 randomised clinical trials including 827 participants with hepatic encephalopathy classed as overt (12 trials) or minimal (four trials). Eight trials assessed oral BCAA supplements and seven trials assessed intravenous BCAA. The control groups received placebo/no intervention (two trials), diets (10 trials), lactulose (two trials), or neomycin (two trials). In 15 trials, all participants had cirrhosis. We classed seven trials as low risk of bias and nine trials as high risk of bias (mainly due to lack of blinding or for‐profit funding). In a random‐effects meta‐analysis of mortality, we found no difference between BCAA and controls (risk ratio (RR) 0.88, 95% confidence interval (CI) 0.69 to 1.11; 760 participants; 15 trials; <i>moderate quality of evidence</i> )<i>.</i> We found no evidence of small‐study effects. Sensitivity analyses of trials with a low risk of bias found no beneficial or detrimental effect of BCAA on mortality. Trial sequential analysis showed that the required information size was not reached, suggesting that additional evidence was needed. BCAA had a beneficial effect on hepatic encephalopathy (RR 0.73, 95% CI 0.61 to 0.88; 827 participants; 16 trials; <i>high quality of evidence</i> )<i>.</i> We found no small‐study effects and confirmed the beneficial effect of BCAA in a sensitivity analysis that only included trials with a low risk of bias (RR 0.71, 95% CI 0.52 to 0.96). The trial sequential analysis showed that firm evidence was reached. In a fixed‐effect meta‐analysis, we found that BCAA increased the risk of nausea and vomiting (RR 5.56; 2.93 to 10.55; <i>moderate quality of evidence</i>). We found no beneficial or detrimental effects of BCAA on nausea or vomiting in a random‐effects meta‐analysis or on quality of life or nutritional parameters. We did not identify predictors of the intervention effect in the subgroup, sensitivity, or meta‐regression analyses. In sensitivity analyses that excluded trials with a lactulose or neomycin control, BCAA had a beneficial effect on hepatic encephalopathy (RR 0.76, 95% CI 0.63 to 0.92). Additional sensitivity analyses found no difference between BCAA and lactulose or neomycin (RR 0.66, 95% CI 0.34 to 1.30). </p> </section> <section id="CD001939-sec-0007"> <h3 class="title" id="CD001939-sec-0007">Authors' conclusions</h3> <p>In this updated review, we included five additional trials. The analyses showed that BCAA had a beneficial effect on hepatic encephalopathy. We found no effect on mortality, quality of life, or nutritional parameters, but we need additional trials to evaluate these outcomes. Likewise, we need additional randomised clinical trials to determine the effect of BCAA compared with interventions such as non‐absorbable disaccharides, rifaximin, or other antibiotics. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD001939-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001939-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD001939-abs-0005">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD001939-abs-0010">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD001939-abs-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD001939-abs-0008">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD001939-abs-0007">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD001939-abs-0006">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD001939-abs-0009">Polski</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD001939-abs-0012">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD001939-abs-0004" lang="en"> <h3>Branched‐chain amino acids improve symptoms of hepatic encephalopathy</h3> <p><b>Background</b> </p> <p>Hepatic encephalopathy is a brain dysfunction associated with liver disease. Cirrhosis, which is a condition where scar tissue (fibrosis) replaces the normal liver tissue, is the most common cause of hepatic encephalopathy. The severity of the symptoms range from minor signs to coma. The minor changes are known as minimal hepatic encephalopathy. Overt hepatic encephalopathy refers to the more severe stages with clinically apparent manifestations such as changes in the level of consciousness or neuropsychiatric abnormalities. Many people with cirrhosis lack amino acids, which are building blocks of proteins. The amino acids with a side‐chain (a branch) are known as branched‐chain amino acids (BCAA). The BCAA play an important part of the generation muscles and of the signalling chemicals in the brain. These effects may benefit people with hepatic encephalopathy. </p> <p><b>Study characteristics</b> </p> <p>We identified 16 randomised clinical trials (trials where participants are randomly allocated to treatment groups) including 827 participants. The included people had cirrhosis often due to alcoholic liver disease or viral hepatitis (liver infection due to a virus). The trials compared BCAA with placebo (a pretend treatment), no intervention, diets, lactulose (a liquid sugar often used to treat constipation), or neomycin (an antibiotic). The evidence is current to October 2014. </p> <p><b>Key results</b> </p> <p>The analyses found no effect on mortality, but that BCAA had a beneficial effect on symptoms and signs of hepatic encephalopathy. BCAA did not increase the risk of serious adverse events, but was associated with nausea and diarrhoea. When excluding trials on lactulose or neomycin, BCAA had a beneficial effect on hepatic encephalopathy. When analysing trials with a lactulose or neomycin control, we found no beneficial or detrimental effect of BCAA. </p> <p><b>Quality of the evidence</b> </p> <p>We assessed the quality of the evidence to evaluate aspects that can lead to errors in the judgment of intervention effects. We concluded that we had high quality evidence in our analyses about the effect of BCAA on hepatic encephalopathy. We concluded that we had moderate or low quality evidence in the remaining analyses because the number of participants in the trials was too small and the risk of bias (systematic errors) was unclear or high. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD001939-sec-0090" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD001939-sec-0090"></div> <h3 class="title" id="CD001939-sec-0091">Implications for practice</h3> <section id="CD001939-sec-0091"> <p>This review found that branched‐chain amino acid (BCAA) was associated with a beneficial effect on hepatic encephalopathy associated with cirrhosis. The evidence suggested that BCAA should be considered in the management of people with hepatic encephalopathy. Adverse events were non‐serious and mainly included gastrointestinal symptoms. There was no evidence to support or refute an effect of BCAA on mortality, quality of life, or nutritional outcomes. </p> </section> <h3 class="title" id="CD001939-sec-0092">Implications for research</h3> <section id="CD001939-sec-0092"> <p>We need additional high‐quality trials to evaluate the effect of BCAA combined with interventions that are used in clinical practice such as antibiotics and lactulose (<a href="./references#CD001939-bbs2-0024" title="VilstrupH , AmodioP , BajajJ , CordobaJ , FerenciP , MullenKD , et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology (Baltimore, Md.)2014;60:715‐35. ">AASLD and EASL guideline 2014a</a>; <a href="./references#CD001939-bbs2-0025" title="American Association for the Study of Liver Diseases, European Association for the Study of the Liver. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases. Journal of Hepatology2014;61:642‐59. ">AASLD and EASL guideline 2014b</a>). We also need trials on people with minimal hepatic encephalopathy and trials with data on the quality of life and nutritional parameters. Additional research is also needed to evaluate if BCAA has a beneficial effect on hepatic encephalopathy in people with acute liver failure without cirrhosis and to identify if specific subgroups of people benefit from treatment with BCAA. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD001939-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD001939-sec-0022"></div> <div class="table" id="CD001939-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Branched‐chain amino acids (BCAA) versus control for hepatic encephalopathy</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>BCAA versus control for hepatic encephalopathy.</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with hepatic encephalopathy.<br/> <b>Settings:</b> <br/> <b>Intervention:</b> BCAA versus control. </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>BCAA versus control</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Mortality</b><br/> Clinically<br/> Follow‐up: 1 to 104 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.88</b> <br/> (0.69 to 1.11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>760<br/> (15 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>226 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>199 per 1000</b><br/> (156 to 251) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>171 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>150 per 1000</b><br/> (118 to 190) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Hepatic encephalopathy</b><br/> Psychometric and clinical assessments<br/> Follow‐up: 1 to 104 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.73</b> <br/> (0.61 to 0.88) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>827<br/> (16 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>633 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>462 per 1000</b><br/> (386 to 557) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>624 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>456 per 1000</b><br/> (381 to 549) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Nausea and diarrhoea</b><br/> Clinically<br/> Follow‐up: 1 to 104 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 3.39</b> <br/> (0.7 to 16.46) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>945<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>22 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>74 per 1000</b><br/> (15 to 360) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>35 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>119 per 1000</b><br/> (24 to 576) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Albumin</b><br/> Laboratory assessment<br/> Follow‐up: 1 to 104 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean albumin in the intervention groups was<br/> <b>0.6 higher</b><br/> (0.9 lower to 2.09 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>176<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>4,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Nitrogen balance</b><br/> Laboratory assessment<br/> Follow‐up: 1 to 104 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean nitrogen balance in the intervention groups was<br/> <b>0.81 standard deviations higher</b><br/> (0.07 to 1.56 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>108<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>4,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD 0.81 (95% CI 0.07 to 1.56)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g., the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>BCAA:</b> branched‐chain amino acids; <b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>SMD:</b> standardised mean difference. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> The trial sequential analysis showed that additional evidence is needed and that we have not yet reached the required information size.<br/> <sup>2</sup> An analysis of trials with a low risk of bias (RR 0.71; 95% CI 0.52 to 0.96) and trial sequential analysis confirmed the result. No publication bias detected in funnel plots or regression analyses. </p> <p><sup>3</sup> Downgraded due to imprecision and lack of trials with a low risk of bias in the overall assessment.<br/> <sup>4</sup> Indirect outcome used as a surrogate estimate of nutritional status.<br/> <sup>5</sup> Due to the small number of trials, we were unable to determine the risk of publication bias. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD001939-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD001939-sec-0023"></div> <section id="CD001939-sec-0024"> <h3 class="title" id="CD001939-sec-0024">Description of the condition</h3> <p>Hepatic encephalopathy is a brain dysfunction associated with significant liver insufficiency or portal‐systemic shunting (<a href="./references#CD001939-bbs2-0045" title="GueritJM , AmantiniA , FischerC , KaplanPW , MecarelliO , SchnitzlerA , et al. Neurophysiological investigations of hepatic encephalopathy: ISHEN practice guidelines. Liver International2009;29(6):789‐96. [PUBMED: 19638107] ">Guerit 2009</a>; <a href="./references#CD001939-bbs2-0067" title="RandolphC , HilsabeckR , KatoA , KharbandaP , LiYY , MapelliD , et al. Neuropsychological assessment of hepatic encephalopathy: ISHEN practice guidelines. Liver International2009;29(5):629‐35. [PUBMED: 19302444] ">Randolph 2009</a>; <a href="./references#CD001939-bbs2-0030" title="BajajJS , CordobaJ , MullenKD , AmodioP , ShawcrossDL , ButterworthRF , et al. Review article: the design of clinical trials in hepatic encephalopathy ‐ an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement. Alimentary Pharmacology &amp; Therapeutics2011;33(7):739‐47. [PUBMED: 21306407] ">Bajaj 2011</a>). The symptoms include neurological and psychiatric changes and the severity ranges from minor symptoms to coma (<a href="./references#CD001939-bbs2-0032" title="BleiAT , CórdobaJ , Practice Parameters Committee of the American College of Gastroenterology. Hepatic encephalopathy. American Journal of Gastroenterology2001;96:1986‐76. ">Blei 2001</a>). People with minimal hepatic encephalopathy have no clinically overt signs, but have neuropsychiatric deficiencies that are diagnosed through psychometric tests (<a href="./references#CD001939-bbs2-0026" title="AmodioP , CampagnaF , OlianasS , IannizziP , MapelliD , PenzoM , et al. Detection of minimal hepatic encephalopathy: normalization and optimization of the Psychometric Hepatic Encephalopathy Score. A neuropsychological and quantified EEG study. Journal of Hepatology2008;49(3):346‐53. [PUBMED: 18602716] ">Amodio 2008</a>). Overt hepatic encephalopathy in people with cirrhosis generally occurs due to an event such as variceal bleeding or infections. Mortality approaches 50% among people who are hospitalised with severe hepatic encephalopathy (<a href="./references#CD001939-bbs2-0037" title="FichetJ , MercierE , GenéeO , GarotD , LegrasA , DequinPF , et al. Prognosis and 1‐year mortality of intensive care unit patients with severe hepatic encephalopathy. Journal of Critical Care2009;24:364‐70. ">Fichet 2009</a>), and 3% to 14% among people diagnosed with minimal hepatic encephalopathy (<a href="./references#CD001939-bbs2-0010" title="MarchesiniG , BianchiG , MerliM , AmodioP , PanellaC , LoguercioC , et al. Nutritional supplementation with branched‐chain amino acids in advanced cirrhosis: a double‐blind, randomized trial. Gastroenterology2003;124:1980‐2. ">Marchesini 2003</a>; <a href="./references#CD001939-bbs2-0012" title="Horie‐TakashiI . Effects of oral branched‐chain amino acid granules on event‐free survival in patients with liver cirrhosis. Clinical Gastroenterology and Hepatology2005; Vol. 3:705‐13 (additional information and data received November 2011). MutoY , SatoS , WatanabeA , MoriwakiH , SuzukiK , KatoA , et al. Effects of oral branched‐chain amino acid granules on event‐free survival in patients with liver cirrhosis. Clinical Gastroenterology and Hepatology2005;3:705‐13. SatoS , WatanabeA , MutoY , SuzukiK , KatoA , MoriwakiH , et al. Clinical comparison of branched‐chain amino acid (l‐Leucine, l‐Isoleucine, l‐Valine) granules and oral nutrition for hepatic insufficiency in patients with decompensated liver cirrhosis (LIV‐EN study). Hepatology Research2005;31:232‐40. ">Muto 2005</a>). Both overt and minimal hepatic encephalopathy are associated with physical symptoms and have a considerable impact on the quality of life (<a href="./references#CD001939-bbs2-0077" title="WeinC , KochH , PoppB , OehlerG , SchauderP . Minimal hepatic encephalopathy impairs fitness to drive. Hepatology (Baltimore, Md.)2004;39:739‐45. ">Wein 2004</a>; <a href="./references#CD001939-bbs2-0028" title="BajajJS . Minimal encephalopathy matters in daily life. World Journal of Gastroenterology2008;14(23):3609‐15. ">Bajaj 2008</a>). </p> </section> <section id="CD001939-sec-0025"> <h3 class="title" id="CD001939-sec-0025">Description of the intervention</h3> <p>The three branched‐chain amino acids (BCAA) leucine, isoleucine, and valine are essential amino acids with a carbon chain (<a href="./references#CD001939-bbs2-0051" title="HolecekM . Three targets of branched‐chain amino acid supplementation in the treatment of liver disease. Nutrition (Burbank, Los Angeles County, Calif.)2010;26(5):482‐90. [PUBMED: 20071143] ">Holecek 2010</a>). Nutritional supplements containing BCAA can be administered orally or intravenously. The available products also differ in terms of the content as is illustrated in randomised clinical trials on BCAA with products containing different amounts of BCAA (<a href="./references#CD001939-bbs2-0019" title="MalaguarneraM , RisinoC , CammalleriL , MalaguarneraL , AstutoM , VecchioI , et al. Branched chain amino acids supplemented with L‐acetylcarnitine versus BCAA treatment in hepatic coma: a randomized and controlled double blind study. European Journal of Gastroenterology &amp; Hepatology2009;21:762‐70. ">Malaguarnera 2009</a>; <a href="./references#CD001939-bbs2-0008" title="LesI , DovalE , Garcia‐MartinezR , PlanasM , CardenasG , GomezP , et al. Effects of branched‐chain amino acids supplementation in patients with cirrhosis and a previous episode of hepatic encephalopathy: a randomized study. American Journal of Gastroenterology2011;106:1081‐8. ">Les 2011</a>; <a href="./references#CD001939-bbs2-0027" title="AmodioP , CanessoF , MontagneseS . Dietary management of hepatic encephalopathy revisited. Current Opinion in Clinical Nutrition and Metabolic Care2014;17(5):448‐52. [PUBMED: 25025262] ">Amodio 2014</a>; <a href="./references#CD001939-bbs2-0069" title="RomanE , TorradesMT , NadalMJ , CardenasG , NietoJC , VidalS , et al. Randomized pilot study: effects of an exercise programme and leucine supplementation in patients with cirrhosis. Digestive Diseases and Sciences2014;59(8):1966‐75. [PUBMED: 24599772] ">Roman 2014</a>). </p> </section> <section id="CD001939-sec-0026"> <h3 class="title" id="CD001939-sec-0026">How the intervention might work</h3> <p>The pathogenesis of hepatic encephalopathy is not completely understood. Ammonia plays a central role (<a href="./references#CD001939-bbs2-0054" title="HolecekM . Evidence of a vicious cycle in glutamine synthesis and breakdown in pathogenesis of hepatic encephalopathy‐therapeutic perspectives. Metabolic Brain Disease2014;29(1):9‐17. [PUBMED: 23996300] ">Holecek 2014</a>). Most interventions for hepatic encephalopathy are directed against a reduction of ammonia (<a href="./references#CD001939-bbs2-0083" title="WrightG , JalanR . Management of hepatic encephalopathy in patients with cirrhosis. Best Practice &amp; Research Clinical Gastroenterology2007;21:95‐110. ">Wright 2007</a>; <a href="./references#CD001939-bbs2-0038" title="García‐MartínezR , CórdobaJ . Acute‐on‐chronic liver failure: the brain. Current Opinion in Critical Care2011;17(2):177‐83. ">Garcia‐Martinez 2011</a>). Hyperammonaemia is one of the main causes of decreased levels of BCAA in liver cirrhosis (<a href="./references#CD001939-bbs2-0052" title="HolecekM , KandarR , SisperaL , KovarikM . Acute hyperammonemia activates branched‐chain amino acid catabolism and decreases their extracellular concentrations: different sensitivity of red and white muscle. Amino Acids2011;40(2):575‐84. [PUBMED: 20614225] ">Holecek 2011</a>). In cirrhosis, BCAA are consumed in skeletal muscle (<a href="./references#CD001939-bbs2-0034" title="DamG , KeidingS , MunkOL , OttP , BuhlM , VilstrupH , et al. Branched‐chain amino acids increase arterial blood ammonia in spite of enhanced intrinsic muscle ammonia metabolism in patients with cirrhosis and healthy subjects. American Journal of Physiology. Gastrointestinal and Liver Physiology2011;301(2):G269‐77. [PUBMED: 21636533] ">Dam 2011</a>; <a href="./references#CD001939-bbs2-0053" title="HolecekM . Branched‐chain amino acids and ammonia metabolism in liver disease: therapeutic implications. Nutrition (Burbank, Los Angeles County, Calif.)2013;29(10):1186‐91. [PUBMED: 23756281] ">Holecek 2013</a>). Biochemically, BCAA supply muscle tissue with carbon skeletons for replenishment of α‐ketoglutarate, which may be depleted during hyperammonaemia through enhanced amination to glutamate and, subsequently, amidation of glutamate to glutamine. BCAA and glutamate concentrations in plasma and muscle tissue are reduced in people with cirrhosis and hyperammonaemia, and the removal of ammonia in muscle is proportional to the removal of BCAA in people with cirrhosis. Skeletal muscle is believed to play a key role in ammonia detoxification in people with cirrhosis and several studies have indicated that BCAA enhance this detoxification (<a href="./references#CD001939-bbs2-0034" title="DamG , KeidingS , MunkOL , OttP , BuhlM , VilstrupH , et al. Branched‐chain amino acids increase arterial blood ammonia in spite of enhanced intrinsic muscle ammonia metabolism in patients with cirrhosis and healthy subjects. American Journal of Physiology. Gastrointestinal and Liver Physiology2011;301(2):G269‐77. [PUBMED: 21636533] ">Dam 2011</a>; <a href="./references#CD001939-bbs2-0053" title="HolecekM . Branched‐chain amino acids and ammonia metabolism in liver disease: therapeutic implications. Nutrition (Burbank, Los Angeles County, Calif.)2013;29(10):1186‐91. [PUBMED: 23756281] ">Holecek 2013</a>). However, the effects of BCAA supplements are complex. BCAA supplementation may reduce malnutrition and revert the loss of muscle cell mass that is common in severe liver disease and the breakdown of protein that occurs in people with hepatic encephalopathy (<a href="./references#CD001939-bbs2-0033" title="CórdobaJ , López‐HellínJ , PlanasM , SabínP , SanpedroF , CastroF , et al. Normal protein diet for episodic hepatic encephalopathy: results of a randomized study. Journal of Hepatology2004;41:38‐43. ">Córdoba 2004</a>; <a href="./references#CD001939-bbs2-0056" title="KachaamyT , BajajJS . Diet and cognition in chronic liver disease. Current Opinion Gastroenterology2011;27:174‐9. ">Kachaamy 2011</a>). The increased muscle mass may increase extrahepatic ammonia detoxification (<a href="./references#CD001939-bbs2-0065" title="Olde DaminkSW , JalanR , RedheadDN , HayesPC , DeutzNE , SoetersPB . Interorgan ammonia and amino acid metabolism in metabolically stable patients with cirrhosis and a TIPSS. Hepatology (Baltimore, Md.)2002;36(5):1163‐71. [PUBMED: 12395326] ">Olde 2002</a>). Glutamine synthetase activity is high in muscle tissue, which promotes detoxification of ammonia to glutamine. BCAA supplementation also increases plasma levels of BCAA and reduce the ratio between aromatic amino acids and BCAA (<a href="./references#CD001939-bbs2-0051" title="HolecekM . Three targets of branched‐chain amino acid supplementation in the treatment of liver disease. Nutrition (Burbank, Los Angeles County, Calif.)2010;26(5):482‐90. [PUBMED: 20071143] ">Holecek 2010</a>). BCAA may further enhance detoxification of ammonia in skeletal muscle by the amidation process for glutamine synthesis (<a href="./references#CD001939-bbs2-0057" title="KawaguchiT , TaniguchiE , SataM . Effects of oral branched‐chain amino acids on hepatic encephalopathy and outcome in patients with liver cirrhosis. Nutrition in Clinical Practice2013;28(5):580‐8. [PUBMED: 23945292] ">Kawaguchi 2013</a>). The addition of BCAA reduces cerebral efflux of aromatic amino acids across the blood‐brain barrier and the imbalance of the synthesis of dopamine, noradrenaline, and serotonin (<a href="./references#CD001939-bbs2-0031" title="BakLK , SchousboeA , WaagepetersenHS . The glutamate/GABA‐glutamine cycle: aspects of transport, neurotransmitter homeostasis and ammonia transfer. Journal of Neurochemistry2006;98:641‐53. ">Bak 2006</a>). </p> </section> <section id="CD001939-sec-0027"> <h3 class="title" id="CD001939-sec-0027">Why it is important to do this review</h3> <p>Cognitive impairment associated with cirrhosis results in larger utilisation of healthcare resources in adults more than any other manifestations of liver disease (<a href="./references#CD001939-bbs2-0066" title="RakoskiMO , McCammonRJ , PietteJD , IwashynaTJ , MarreroJA , LokAS , et al. Burden of cirrhosis on older Americans and their families: analysis of the health and retirement study. Hepatology (Baltimore, Md.)2012;55(1):184‐91. [PUBMED: 21858847] ">Rakoski 2012</a>). Diagnostic tools range from simple scales to sophisticated psychometric tests. The value of the individual tools and the selection of the best diagnostic strategy depend on the clinical situation. Accordingly, investigators in clinical trials on hepatic encephalopathy have used a variety of scales and tests in their assessments of the diagnosis and improved manifestations of hepatic encephalopathy (<a href="./references#CD001939-bbs2-0003" title="EgbertsEH , HamsterW , SchomeerusH , JürgensP . Effect of branched chain amino acids on latent porto‐systemic‐encephalopathy (PSE). JPEN. Journal of Parenteral and Enteral Nutrition1981;5:5. EgbertsEH , SchomeerusH , HamsterW , JürgensP . Effective treatment of latens porto‐systemic encephalopathy with oral branched chain amino acids. In: CapocacciaL , FischerJE , Rossi‐FanelliF editor(s). Hepatic Encephalopathy in Chronic Liver Failure. New York: Plenum Press, 1984:351‐7. EgbertsEH , SchomerusH , HamsterW , JurgensP . Branched chain amino acids in the treatment of latent portosystemic encephalopathy. A double‐blind placebo‐controlled crossover study. Gastroenterology1985;88:887‐95. EgbertsEH , SchomerusH , HamsterW , JürgensP . Branched‐chain amino acids in the treatment of latent porto‐systemic encephalopathy. A placebo‐controlled double‐blind cross‐over study [Verzweigtkettige Aminosäuren bei der behandlung der latenten portosystemischen enzephalopathie. Eine placebokontrollierte doppelblind‐cross‐over‐studie]. Zeitschrift für Ernährungswissenschaft1986;25:9‐28. HamsterW , EgbertsEH , HamsterH . Treatment with branched‐chain amino acids and effect on psycho‐physical capacity functions in latent porto‐systemic encephalopathy [Behandlung mit verzweigtkettigen aminosäuren und ihre auswirkung auf psychophysische leistungsfunktionen bei latenter portosystemischer enzephalopathie]. Arzneimittelforschung1982;32:901‐2. ">Egberts 1985</a>; <a href="./references#CD001939-bbs2-0009" title="BianchiGP , MarchesiniG , ZoliM , AbbiatiR , FerrarioE , FabbriA , et al. Oral BCAA supplementation in cirrhosis with chronic encephalopathy: effects on prolactin and estradiol levels. Hepato‐gastroenterology1992;39:443‐6. MarchesiniG , BianchiG , MerliM , AmodioP , PanellaC , LoguercioC , et al. Nutritional supplementation with branched‐chain amino acids in advanced cirrhosis: a double‐blind, randomized trial. Gastroenterology2003;124:1792‐801. MarchesiniG , DioguardiFS , BianchiGP , ZoliM , BellatiG , RoffiL , et al. Long‐term oral branched‐chain amino acid treatment in chronic hepatic encephalopathy. A randomized double‐blind casein controlled trial. The Italian Multicenter Study Group. Journal of Hepatology1990;11:92‐101. ">Marchesini 1990</a>; <a href="./references#CD001939-bbs2-0010" title="MarchesiniG , BianchiG , MerliM , AmodioP , PanellaC , LoguercioC , et al. Nutritional supplementation with branched‐chain amino acids in advanced cirrhosis: a double‐blind, randomized trial. Gastroenterology2003;124:1980‐2. ">Marchesini 2003</a>; <a href="./references#CD001939-bbs2-0008" title="LesI , DovalE , Garcia‐MartinezR , PlanasM , CardenasG , GomezP , et al. Effects of branched‐chain amino acids supplementation in patients with cirrhosis and a previous episode of hepatic encephalopathy: a randomized study. American Journal of Gastroenterology2011;106:1081‐8. ">Les 2011</a>). The assessment of clinically relevant improvement in hepatic encephalopathy is an essential outcome, irrespective of the severity of symptoms (<a href="./references#CD001939-bbs2-0029" title="BajajJS . Review article: the modern management of hepatic encephalopathy. Alimentary Pharmacology &amp; Therapeutics2010;31(5):537‐47. [PUBMED: 20002027] ">Bajaj 2010</a>; <a href="./references#CD001939-bbs2-0030" title="BajajJS , CordobaJ , MullenKD , AmodioP , ShawcrossDL , ButterworthRF , et al. Review article: the design of clinical trials in hepatic encephalopathy ‐ an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement. Alimentary Pharmacology &amp; Therapeutics2011;33(7):739‐47. [PUBMED: 21306407] ">Bajaj 2011</a>; <a href="./references#CD001939-bbs2-0024" title="VilstrupH , AmodioP , BajajJ , CordobaJ , FerenciP , MullenKD , et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology (Baltimore, Md.)2014;60:715‐35. ">AASLD and EASL guideline 2014a</a>; <a href="./references#CD001939-bbs2-0025" title="American Association for the Study of Liver Diseases, European Association for the Study of the Liver. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases. Journal of Hepatology2014;61:642‐59. ">AASLD and EASL guideline 2014b</a>). Based on the available evidence, the 2014 joint guidelines from the American Association for the Study of Liver Diseases (<a href="./references#CD001939-bbs2-0024" title="VilstrupH , AmodioP , BajajJ , CordobaJ , FerenciP , MullenKD , et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology (Baltimore, Md.)2014;60:715‐35. ">AASLD and EASL guideline 2014a</a>), and the European Association for the Study of the liver (<a href="./references#CD001939-bbs2-0025" title="American Association for the Study of Liver Diseases, European Association for the Study of the Liver. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases. Journal of Hepatology2014;61:642‐59. ">AASLD and EASL guideline 2014b</a>), recommend treatment of any precipitating factors and non‐absorbable disaccharides as the initial treatment. The guidelines recommend BCAA as an alternative or additional agent to treat people who do not respond to the initial therapy. Previous meta‐analyses of randomised trials and observational studies suggested that the evidence on BCAA supplements is inconclusive due to methodological concerns, small sample sizes, and short follow‐up (<a href="./references#CD001939-bbs2-0076" title="TygstrupN , VilstrupH . Effect of branched chain amino acids on the outcome of hepatic encephalopathy. Advances in Hepatic Encephalopathy and Urea Cycle Diseases. Basel: Karger, 1984:11‐4. ">Tygstrup 1984</a>; <a href="./references#CD001939-bbs2-0064" title="NaylorCD , O'RourkeD , DetskyAS , BakerJP . Parenteral nutrition with branched‐amino acids in hepatic encephalopathy. A meta‐analysis. Gastroenterology1989;97:1033‐42. ">Naylor 1989</a>; <a href="./references#CD001939-bbs2-0039" title="GluudC . Branched‐chain amino acids for hepatic encephalopathy?. Hepatology (Baltimore, Md.)1991;13(4):812‐3. ">Gluud 1991</a>; <a href="./references#CD001939-bbs2-0084" title="Als‐NielsenB , KoretzRL , GluudLL , GluudC . Branched‐chain amino acids for hepatic encephalopathy. Cochrane Database of Systematic Reviews2003, Issue 1. [DOI: 10.1002/14651858.CD001939] ">Als‐Nielsen 2003</a>; <a href="./references#CD001939-bbs2-0062" title="MetcalfeEL , AvenellA , FraserA . Branched‐chain amino acid supplementation in adults with cirrhosis and porto‐systemic encephalopathy: systematic review. Clinical Nutrition (Edinburgh, Scotland)2014;33(6):958‐65. [PUBMED: 24656171] ">Metcalfe 2014</a>). Subsequent randomised trials are likely to contain important new information (<a href="./references#CD001939-bbs2-0010" title="MarchesiniG , BianchiG , MerliM , AmodioP , PanellaC , LoguercioC , et al. Nutritional supplementation with branched‐chain amino acids in advanced cirrhosis: a double‐blind, randomized trial. Gastroenterology2003;124:1980‐2. ">Marchesini 2003</a>; <a href="./references#CD001939-bbs2-0012" title="Horie‐TakashiI . Effects of oral branched‐chain amino acid granules on event‐free survival in patients with liver cirrhosis. Clinical Gastroenterology and Hepatology2005; Vol. 3:705‐13 (additional information and data received November 2011). MutoY , SatoS , WatanabeA , MoriwakiH , SuzukiK , KatoA , et al. Effects of oral branched‐chain amino acid granules on event‐free survival in patients with liver cirrhosis. Clinical Gastroenterology and Hepatology2005;3:705‐13. SatoS , WatanabeA , MutoY , SuzukiK , KatoA , MoriwakiH , et al. Clinical comparison of branched‐chain amino acid (l‐Leucine, l‐Isoleucine, l‐Valine) granules and oral nutrition for hepatic insufficiency in patients with decompensated liver cirrhosis (LIV‐EN study). Hepatology Research2005;31:232‐40. ">Muto 2005</a>; <a href="./references#CD001939-bbs2-0008" title="LesI , DovalE , Garcia‐MartinezR , PlanasM , CardenasG , GomezP , et al. Effects of branched‐chain amino acids supplementation in patients with cirrhosis and a previous episode of hepatic encephalopathy: a randomized study. American Journal of Gastroenterology2011;106:1081‐8. ">Les 2011</a>). In particular, systematic reviews on intervention for hepatic encephalopathy found essential information on orally administered BCAA supplements (<a href="./references#CD001939-bbs2-0041" title="GluudLL , DamG , BorreM , LesI , CordobaJ , MarchesiniG , et al. Oral branched‐chain amino acids have a beneficial effect on manifestations of hepatic encephalopathy in a systematic review with meta‐analyses of randomized controlled trials. Journal of Nutrition2013;143:1263‐8. [PUBMED: 23739310] ">Gluud 2013a</a>; <a href="./references#CD001939-bbs2-0042" title="GluudLL , DamG , BorreM , LesI , CordobaJ , MarchesiniG , et al. Lactulose, rifaximin or branched chain amino acids for hepatic encephalopathy: what is the evidence?. Metabolic Brain Disease2013;28(2):221‐5. [PUBMED: 23275147] ">Gluud 2013b</a>). Therefore, we performed this updated systematic review. In the updated review, we changed the methods and reporting to reflect current guidelines in the Cochrane Hepato‐Biliary Group Module (<a href="./references#CD001939-bbs2-0043" title="GluudC , NikolovaD , KlingenbergSL , AlexakisN , Als‐NielsenB , ColliA , et al. Cochrane Hepato‐Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)). 2017, Issue 4. Art. No.: LIVER. ">Gluud 2017</a>), the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD001939-bbs2-0049" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011a</a>), and the Methodological Expectations of Cochrane Intervention Reviews (MECIR) guidelines (<a href="./references#CD001939-bbs2-0061" title="Methodological Expectations of Cochrane Intervention Reviews (MECIR). www.editorial‐unit.cochrane.org/mecir (accessed 25 August 2015). ">MECIR 2014</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD001939-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD001939-sec-0028"></div> <p>To evaluate the beneficial and harmful effects of BCAA versus any control intervention for people with hepatic encephalopathy. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD001939-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD001939-sec-0029"></div> <section id="CD001939-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD001939-sec-0031"> <h4 class="title">Types of studies</h4> <p>We included randomised clinical trials irrespective of blinding, publication status, or language in our primary analyses and attempted to identify quasi‐randomised and observational studies for the analyses of adverse events. </p> </section> <section id="CD001939-sec-0032"> <h4 class="title">Types of participants</h4> <p>People with overt or minimal hepatic encephalopathy associated with acute or chronic liver disease (<a href="./references#CD001939-bbs2-0024" title="VilstrupH , AmodioP , BajajJ , CordobaJ , FerenciP , MullenKD , et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology (Baltimore, Md.)2014;60:715‐35. ">AASLD and EASL guideline 2014a</a>; <a href="./references#CD001939-bbs2-0025" title="American Association for the Study of Liver Diseases, European Association for the Study of the Liver. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases. Journal of Hepatology2014;61:642‐59. ">AASLD and EASL guideline 2014b</a>). The diagnosis could be made based on clinical evaluations (e.g., using standardised scores), psychometric and neurophysiological scores, electroencephalography, or laboratory testing (ammonia). We based the diagnosis on the criteria reported in the individual trials. </p> </section> <section id="CD001939-sec-0033"> <h4 class="title">Types of interventions</h4> <p>Any form of BCAA, irrespective of dose or duration. People in the control groups could receive placebo, no intervention, diets, non‐absorbable disaccharides, antibiotics, or any other intervention with a potential effect on hepatic encephalopathy. </p> </section> <section id="CD001939-sec-0034"> <h4 class="title">Types of outcome measures</h4> <p>As recommended (<a href="./references#CD001939-bbs2-0043" title="GluudC , NikolovaD , KlingenbergSL , AlexakisN , Als‐NielsenB , ColliA , et al. Cochrane Hepato‐Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)). 2017, Issue 4. Art. No.: LIVER. ">Gluud 2017</a>), we included adverse events as our primary outcome measure and changed all outcomes to unwanted events (when possible). We evaluated outcomes at the maximum duration of follow‐up. </p> <section id="CD001939-sec-0035"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD001939-list-0001"> <li> <p>Mortality (all‐cause).</p> </li> <li> <p>Hepatic encephalopathy (number of people without improved manifestations of hepatic encephalopathy). </p> </li> <li> <p>Adverse events: any untoward medical occurrence that, at any dose, resulted in death, was life‐threatening, required hospitalisation or prolongation of existing hospitalisation, resulted in persistent or significant disability or incapacity, or was a congenital anomaly/birth defect, or any medical event that might have jeopardised the person, or required intervention to prevent it (<a href="./references#CD001939-bbs2-0055" title="International Conference on Harmonisation Expert Working Group. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice CFR &amp; ICH Guidelines. Vol. 1, Philadelphia (PA): Barnett International/PAREXEL, 1997. ">ICH GCP 1997</a>). </p> </li> </ol> </p> </section> <section id="CD001939-sec-0036"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD001939-list-0002"> <li> <p>Quality of life.</p> </li> <li> <p>Markers of nutritional status including albumin and nitrogen balance (the nitrogen input minus the nitrogen output). </p> </li> </ol> </p> </section> </section> </section> <section id="CD001939-sec-0037"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD001939-sec-0038"> <h4 class="title">Electronic searches</h4> <p>We performed the electronic searches in the Cochrane Hepato‐Biliary Group Controlled Trials Register (<a href="./references#CD001939-bbs2-0043" title="GluudC , NikolovaD , KlingenbergSL , AlexakisN , Als‐NielsenB , ColliA , et al. Cochrane Hepato‐Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)). 2017, Issue 4. Art. No.: LIVER. ">Gluud 2017</a>), the Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library, MEDLINE Ovid, Embase Ovid, Science Citation Index Expanded and Conference Proceedings Citation Index – Science (Web of Science), and Lilacs (Bireme) (<a href="./references#CD001939-bbs2-0070" title="RoyleP , MilneR . Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches. International Journal of Technology Assessment in Health Care2003;19(4):591‐603. ">Royle 2003</a>). <a href="./appendices#CD001939-sec-0096">Appendix 1</a> displays the search strategies with the time spans of the searches. We did not have access to Chinese, Russian, and Japanese databases, which is a limitation when searching for randomised trials of possible interest to the review. We hope that helped by The CHBG Trials Search Co‐ordinator, we will be able to search for further trials also in these databases next time when we update our review. </p> </section> <section id="CD001939-sec-0039"> <h4 class="title">Searching other resources</h4> <p>The authors conducted manual searches included scanning of reference lists in relevant papers, specialist journals, conference proceedings, and searches in the World Health Organization online trial meta‐register (<a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch/</a>). We also searched Google Scholar (using the terms 'branched chain amino acids' AND 'cirrhosis* AND random*) and wrote to experts for information about any additional published or unpublished trials. </p> </section> </section> <section id="CD001939-sec-0040"> <h3 class="title" id="CD001939-sec-0040">Data collection and analysis</h3> <p>At least two authors (LG, GD, and GB) independently extracted data from the published trial reports. We wrote to authors of included trials for additional information including data that would allow recalculation of outcomes when necessary. For trials described in more than one record, we used the record with the most complete information (the largest number of participants and events and the longest duration of follow‐up). </p> <section id="CD001939-sec-0041"> <h4 class="title">Selection of studies</h4> <p>We listed trials identified through the electronic and manual searches, selected trials using the criteria described above and listed excluded trials with the reason for exclusion (see <a href="./references#CD001939-sec-0112" title="">Characteristics of excluded studies</a>). </p> </section> <section id="CD001939-sec-0042"> <h4 class="title">Data extraction and management</h4> <p>We extracted the following data:</p> <p> <ul id="CD001939-list-0003"> <li> <p>participant characteristics: inclusion criteria, mean age, proportion of men, and type of underlying liver disease; </p> </li> <li> <p>intervention characteristics: type, dose, and duration of interventions;</p> </li> <li> <p>trial characteristics: setting (hospital or outpatient), number of clinical sites, country of origin, patient inclusion period, and funding. </p> </li> </ul> </p> </section> <section id="CD001939-sec-0043"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Authors independently assessed the risk of bias in included trials based on individual domains according to the Cochrane Hepato‐Biliary Group Module (<a href="./references#CD001939-bbs2-0043" title="GluudC , NikolovaD , KlingenbergSL , AlexakisN , Als‐NielsenB , ColliA , et al. Cochrane Hepato‐Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)). 2017, Issue 4. Art. No.: LIVER. ">Gluud 2017</a>). We classed each domain as having a low, uncertain, or high risk of bias based on the definitions described below. As recommended, we included an analysis that combined all domains and categorised trials as low risk of bias if none of the domains were classed as high or unclear risk of bias. </p> <section id="CD001939-sec-0044"> <h5 class="title">Allocation sequence generation</h5> <p> <ul id="CD001939-list-0004"> <li> <p>Low risk of bias: sequence generation was achieved using computer random number generation or a random number table. Drawing lots, tossing a coin, shuffling cards, and throwing dice were adequate if performed by an independent person not otherwise involved in the trial. </p> </li> <li> <p>Unclear risk of bias: the method of sequence generation was not specified.</p> </li> <li> <p>High risk of bias: the sequence generation method was not random.</p> </li> </ul> </p> </section> <section id="CD001939-sec-0045"> <h5 class="title">Allocation concealment</h5> <p> <ul id="CD001939-list-0005"> <li> <p>Low risk of bias: the participant allocations could not have been foreseen in advance of, or during, enrolment. Allocation was controlled by a central and independent randomisation unit. The allocation sequence was unknown to the investigators (e.g., if the allocation sequence was hidden in sequentially numbered, opaque, and sealed envelopes). </p> </li> <li> <p>Unclear risk of bias: the method used to conceal the allocation was not described so that intervention allocations may have been foreseen in advance of, or during, enrolment. </p> </li> <li> <p>High risk of bias: the allocation sequence was likely to be known to the investigators who assigned the participants. </p> </li> </ul> </p> </section> <section id="CD001939-sec-0046"> <h5 class="title">Blinding of participants, personnel, and outcome assessors</h5> <p> <ul id="CD001939-list-0006"> <li> <p>Low risk of bias: blinding was performed adequately, or the assessment of outcomes was not likely to be influenced by lack of blinding. We defined the outcome all‐cause mortality and laboratory assessments as unlikely to be influenced by lack of blinding (<a href="./references#CD001939-bbs2-0071" title="SavovicJ , JonesHE , AltmanDG , HarrisRJ , JuniP , PildalJ , et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Annals of Internal Medicine2012;157(6):429‐38. [PUBMED: 22945832] ">Savovic 2012</a>). </p> </li> <li> <p>Unclear risk of bias: there was insufficient information to assess whether blinding was likely to induce bias on the results. </p> </li> <li> <p>High risk of bias: no blinding or incomplete blinding, and the assessment of outcomes were likely to be influenced by lack of blinding. </p> </li> </ul> </p> </section> <section id="CD001939-sec-0047"> <h5 class="title">Blinding of outcome assessors</h5> <p> <ul id="CD001939-list-0007"> <li> <p>Low risk of bias: outcome assessment was carried out blinded for all relevant outcomes, and the method of blinding was described, so that knowledge of allocation was prevented. </p> </li> <li> <p>Unclear risk of bias: blinding of outcome assessment was not described, or the outcome assessment was described as blinded, but the method of blinding was not described, so that knowledge of allocation was possible. </p> </li> <li> <p>High risk of bias: outcome assessment was not blinded, so that the allocation was known to outcome assessors. </p> </li> </ul> </p> </section> <section id="CD001939-sec-0048"> <h5 class="title">Incomplete outcome data</h5> <p> <ul id="CD001939-list-0008"> <li> <p>Low risk of bias: missing data were unlikely to make treatment effects depart from plausible values. Sufficient methods, such as multiple imputation, were employed to handle missing data. </p> </li> <li> <p>Unclear risk of bias: there was insufficient information to assess whether missing data in combination with the method used to handle missing data were likely to induce bias on the results. </p> </li> <li> <p>High risk of bias: the results were likely to be biased due to missing data.</p> </li> </ul> </p> </section> <section id="CD001939-sec-0049"> <h5 class="title">Selective outcome reporting</h5> <p> <ul id="CD001939-list-0009"> <li> <p>Low risk: the trial reported mortality and hepatic encephalopathy. If the original trial protocol was available, the outcomes should have been those called for in that protocol. </p> </li> <li> <p>Unclear risk: it was unclear whether data on the pre‐defined outcomes were recorded or not. </p> </li> <li> <p>High risk: one or more of the pre‐defined outcomes were not reported.</p> </li> </ul> </p> </section> <section id="CD001939-sec-0050"> <h5 class="title">For‐profit bias</h5> <p> <ul id="CD001939-list-0010"> <li> <p>Low risk of bias: the trial appeared to be free of industry sponsorship or other type of for‐profit support that may manipulate the trial design, conductance, or results of the trial. </p> </li> <li> <p>Unclear risk of bias: the trial may or may not be free of for‐profit bias as no information on clinical trial support or sponsorship was provided. </p> </li> <li> <p>High risk of bias: the trial was sponsored by industry or received other type of for‐profit support. </p> </li> </ul> </p> </section> <section id="CD001939-sec-0051"> <h5 class="title">Other bias</h5> <p> <ul id="CD001939-list-0011"> <li> <p>Low risk of bias: the trial appeared to be free of other bias including vested interests and medicinal dosing problems that could put it at risk of bias. </p> </li> <li> <p>Unclear risk of bias: there was insufficient information to determine if the trial was free of other biases. </p> </li> <li> <p>High risk of bias: there were factors in the trial that could put it at risk of bias: for example, funding from a for‐profit organisation or the administration of inappropriate treatment was given to the controls (such as an inappropriate dose). </p> </li> </ul> </p> </section> </section> <section id="CD001939-sec-0052"> <h4 class="title">Measures of treatment effect</h4> <p>We used risk ratio (RR) for dichotomous outcomes and standardised mean differences (SMD) for continuous outcomes, both with 95% confidence intervals (CI). </p> </section> <section id="CD001939-sec-0053"> <h4 class="title">Unit of analysis issues</h4> <p>For cross‐over trials, we only used data from the first treatment period. For trials with more than one control group (e.g., trials with two different control diets), we combined data from the two control groups. </p> </section> <section id="CD001939-sec-0054"> <h4 class="title">Dealing with missing data</h4> <p>We gathered data to allow intention‐to‐treat analyses. Our analyses included data on all participants randomised, irrespective of compliance, protocol violations, or follow‐up. We used simple imputation to evaluate the potential influence of missing data (<a href="./references#CD001939-bbs2-0048" title="HigginsJP , WhiteIR , WoodAM . Imputation methods for missing outcome data in meta‐analysis of clinical trials. Clinical Trials2008;5:225‐39. ">Higgins 2008</a>). The analyses included missing values counted as failures or successes using the following strategies: </p> <p> <ul id="CD001939-list-0012"> <li> <p>all participants with missing data counted as failures;</p> </li> <li> <p>participants with missing outcome data in the BCAA arm counted as failures and in the control arm as successes. </p> </li> </ul> </p> </section> <section id="CD001939-sec-0055"> <h4 class="title">Assessment of heterogeneity</h4> <p>We expressed heterogeneity as I<sup>2</sup> values using the thresholds: 0% to 40% (unimportant), 40% to 60% (moderate), 60% to 80% (substantial), and greater than 80% (considerable). </p> </section> <section id="CD001939-sec-0056"> <h4 class="title">Assessment of reporting biases</h4> <p>For meta‐analyses with at least 10 trials, we assessed reporting biases and other dissemination biases based on analyses of small‐study effects (<a href="./references#CD001939-bbs2-0050" title="HigginsJP , WhiteheadA , SimmondsM . Sequential methods for random‐effects meta‐analysis. Statistics in Medicine2011;30(9):903‐21. [PUBMED: 21472757] ">Higgins 2011b</a>) using the Harbord modified test for dichotomous outcomes and Egger tests for continuous outcomes (<a href="./references#CD001939-bbs2-0035" title="EggerM , Davey SmithG , SchneiderM , MinderC . Bias in meta‐analysis detected by a simple, graphical test. BMJ (Clinical Research Ed.)1997;315(7109):629‐34. [PUBMED: 9310563] ">Egger 1997</a>; <a href="./references#CD001939-bbs2-0047" title="HarbordRM , EggerM , SterneJA . A modified test for small‐study effects in meta‐analyses of controlled trials with binary endpoints. Statistics in Medicine2006;25(20):3443‐57. [PUBMED: 16345038] ">Harbord 2006</a>). We also attempted to obtain trial protocols to compare reported outcome measures in the protocol and published trial. The Harbord test regresses Z/sqrt(V) against sqrt(V), where Z was the efficient score and V was Fisher's information (the variance of Z under the null hypothesis). The Egger test performs a linear regression of the intervention effect estimates on their standard errors, weighing by 1/(variance of the intervention effect estimate). We reported the result as P values. </p> </section> <section id="CD001939-sec-0057"> <h4 class="title">Data synthesis</h4> <p>We performed our analyses using Review Manager 5 (<a href="./references#CD001939-bbs2-0068" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>), STATA (<a href="./references#CD001939-bbs2-0072" title="Stata Corp. Stata 13. Texas: Stata Corp, 2007. ">Stata 13</a>), and trial sequential analysis (<a href="./references#CD001939-bbs2-0074" title="ThorlundK , EngstrømJ , WetterslevJ , BrokJ , ImbergerG , GluudC . User manual for Trial Sequential Analysis (TSA). ctu.dk/tsa/files/tsa_manual.pdf 2011 (accessed 23 April 2013). ">Thorlund 2011</a>; <a href="./references#CD001939-bbs2-0075" title="Copenhagen Trial Unit. TSA ‐ Trial Sequential Analysis. Version 0.9 Beta. Copenhagen: Copenhagen Trial Unit, 2011. ">TSA 2011</a>). </p> <section id="CD001939-sec-0058"> <h5 class="title">Meta‐analysis</h5> <p>We performed random‐effects and fixed‐effect meta‐analyses, but only reported the results of the fixed‐effect meta‐analyses if the result of the two models differed. </p> </section> <section id="CD001939-sec-0059"> <h5 class="title">Trial sequential analysis</h5> <p>We performed a trial sequential analysis for the outcome measures mortality and hepatic encephalopathy using random‐effects models with alpha set to 5%, power to 80%, and model‐based heterogeneity (<a href="./references#CD001939-bbs2-0080" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology2008;61(1):64‐75. [PUBMED: 18083463] ">Wetterslev 2008</a>; <a href="./references#CD001939-bbs2-0050" title="HigginsJP , WhiteheadA , SimmondsM . Sequential methods for random‐effects meta‐analysis. Statistics in Medicine2011;30(9):903‐21. [PUBMED: 21472757] ">Higgins 2011b</a>). We defined the required information size as the number of participants needed to detect or reject an intervention effect estimate based on the event proportion in the control group, the observed relative risk reduction (RRR), and the diversity of the meta‐analysis (<a href="./references#CD001939-bbs2-0081" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Estimating required information size by quantifying diversity in a random‐effects meta‐analysis. BMC Medical Research Methodology2009;9:86. ">Wetterslev 2009</a>). We constructed trial sequential monitoring boundaries (the inward sloping red lines) based on the required information size and defined firm evidence as being established if the Z‐curve (the result of the cumulative meta‐analysis) crossed the monitoring boundary and the required information size (the vertical red line at the end of the graph). In the analysis of mortality, we set alpha to 5%, power to 80%, control group event rate to 25%, RRR to 5%, and heterogeneity correction to 17%. In the analysis of hepatic encephalopathy, we set alpha to 5%, power to 80%, control group event rate to 63%, RRR to 45%, and heterogeneity correction to 47%. To account for the risk of overestimation of intervention effects due to bias (<a href="./references#CD001939-bbs2-0071" title="SavovicJ , JonesHE , AltmanDG , HarrisRJ , JuniP , PildalJ , et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Annals of Internal Medicine2012;157(6):429‐38. [PUBMED: 22945832] ">Savovic 2012</a>), we also conducted the analysis with the control group event rate set to 45% and RRR set to 35% for hepatic encephalopathy. </p> </section> </section> <section id="CD001939-sec-0060"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Subgroup analyses (reported using the P value based on test for subgroup differences):</p> <p> <ul id="CD001939-list-0013"> <li> <p>type of hepatic encephalopathy (overt or minimal);</p> </li> <li> <p>mode of administration (oral or intravenous);</p> </li> <li> <p>type of control group (e.g., placebo/no intervention, diets, non‐absorbable disaccharides or antibiotics). </p> </li> </ul> </p> <p>We used univariable meta‐regression analyses to evaluate the potential influence of continuous trial characteristics (e.g., the dose of BCAA and the duration of therapy) for meta‐analyses with at least 10 trials. </p> </section> <section id="CD001939-sec-0061"> <h4 class="title">Sensitivity analysis</h4> <p>To evaluate the robustness of the overall results, we repeated our analyses:</p> <p> <ul id="CD001939-list-0014"> <li> <p>including only trials with a low risk of bias based on individual domains;</p> </li> <li> <p>comparing trials published in abstract form or as full‐paper article;</p> </li> <li> <p>comparing the re‐calculated outcomes based on individual participant data or published data. </p> </li> </ul> </p> <section id="CD001939-sec-0062"> <h5 class="title">Exploratory (post‐hoc) analyses</h5> <p>Based on peer‐review comments, we performed sensitivity analysis in which we excluded:</p> <p> <ul id="CD001939-list-0015"> <li> <p>trials that included people with or without cirrhosis;</p> </li> <li> <p>trials with a lactulose or neomycin control group;</p> </li> <li> <p>trials with a placebo/no intervention or diet control group (i.e., only included trials with a lactulose or neomycin control group). </p> </li> </ul> </p> <p>We also performed univariable and multivariable random‐effects meta‐regression analyses to evaluate predictors of heterogeneity including characteristics of the experimental intervention (the dose, duration, and mode of administration), the control intervention (type of control group), and participant characteristics (proportion of men, mean age, proportion of participants with cirrhosis, and type of hepatic encephalopathy). </p> </section> <section id="CD001939-sec-0063"> <h5 class="title">'Summary of findings' tables</h5> <p>We included a <a href="./full#CD001939-tbl-0001">summary of findings Table for the main comparison</a> (<a href="./references#CD001939-bbs2-0046" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck‐YtterY , Alonso‐CoelloP , et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ (Clinical Research Ed.)2008;336(7650):924‐6. [PUBMED: 18436948] ">Guyatt 2008</a>) prepared using GRADE software (<a href="./references#CD001939-bbs2-0044" title="BrozekJ , OxmanA , SchünemannH . GRADEpro. Version 3.2 for Windows. Grade Working Group 2004‐2007, 2008. ">GRADEpro</a>) with information on the results of our primary outcomes in relation to the quality of the evidence based on the risk of heterogeneity, indirectness, imprecision, risk of bias, and publication bias. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD001939-sec-0064" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD001939-sec-0064"></div> <section id="CD001939-sec-0065"> <h3 class="title">Description of studies</h3> <p>See: <a href="./references#CD001939-sec-0111" title="">Characteristics of included studies</a>; <a href="./references#CD001939-sec-0112" title="">Characteristics of excluded studies</a>. </p> <p>We include 16 randomised clinical trials in the qualitative and quantitative analyses (<a href="./references#CD001939-bbs2-0004" title="FiaccadoriF . Branched chain amino acid enriched solutions in the treatment of hepatic encephalopathy: a controlled trial. Italian Journal of Gastroenterology (additional information from author November 2012). FiaccadoriF , GhinelliF , PedrettiG . Branched chain amino acid enriched solutions in the treatment of hepatic encephalopathy: a controlled trial. Italian Journal of Gastroenterology1985;17:5‐10. FiaccadoriF , GhinelliF , PedrettiG , ManciaD . Mental state course and biochemical findings in HE treated by BCAA‐enriched mixtures. In: HolmE , KasperH editor(s). Metabolism and Nutrition in Liver Disease Freiburg 1984: Proceedings of the 41st Falk Symposium. Lancaster: MTP Press, 1985:281‐5. FiaccadoriF , GhinelliF , PedrettiG , PelosiG , SacchiniD , ZeneroliML , et al. Branched chain amino acid enriched solutions in the treatment of hepatic encephalopathy: a controlled trial. In: CapocacciaL , FischerJE , Rossi‐FanelliF editor(s). Hepatic Encephalopathy in Chronic Liver Failure. New York: Plenum Press, 1984:323‐33. FiaccadoriF , GhinelliF , PelosiG , SacchiniD , VaonaG , ZeneroliML , et al. Selective amino acid solutions in hepatic encephalopathy treatment (a preliminary report). La Ricerca in Clinica e in Laboratorio1980;10:411‐22. [MEDLINE: 81102770] ">Fiaccadori 1984</a>; <a href="./references#CD001939-bbs2-0006" title="HorstD , GraceN , ConnHO , SchiffE , SchenkerS , ViteriA , et al. A double‐blind randomized comparison of dietary protein and an oral branched chain amino acid (BCAA) solution in cirrhotic patients with chronic portal‐systemic encephalopathy (PSE) [IASL abstract]. Hepatology (Baltimore, Md.)1982;2:184. HorstD , GraceND , ConnHO , SchiffE , SchenkerS , ViteriA , et al. Comparison of dietary protein with an oral, branched chain‐enriched amino acid supplement in chronic portal‐systemic encephalopathy: a randomized controlled trial. Hepatology (Baltimore, Md.)1984;4:279‐87. ">Horst 1984</a>; <a href="./references#CD001939-bbs2-0001" title="CalveyH , DavisM , WilliamsR . Controlled trial of nutritional supplementation, with and without branched chain amino acid enrichment, in treatment of acute alcoholic hepatitis. Journal of Hepatology1985;1:141‐51. CalveyH , DavisM , WilliamsR . Prospective study of nasogastric feeding via East Grinstead or Viomedex tubes compared with oral dietary supplementation in patients with cirrhosis. Clinical Nutrition1984;3:63‐6. WilliamsR , CalveyH , DavisM . Controlled trial of nutritional supplementation in acute alcoholic hepatitis. In: HolmEKH editor(s). Metabolism and Nutrition in Liver Disease. Lancaster, UK: MTP Press, Ltd, 1985:361‐8. ">Calvey 1985</a>; <a href="./references#CD001939-bbs2-0002" title="CerraFB . Disease‐specific amino acid infusion (F080) in hepatic encephalopathy: a prospective, randomized, double‐blind, controlled trial [personal communication]. Correspondence with authorsSeptember 2002. CerraFB , CheungNK , FischerJE , KaplowitzN , SchiffE‐R , DienstagJL , et al. Disease‐specific amino acid infusion (F080) in hepatic encephalopathy: a prospective, randomized, double‐blind, controlled trial. JPEN. Journal of Parenteral and Enteral Nutrition1985;9:288‐95. CerraFB , CheungNK , FischerJE , KaplowitzN , SchiffER , DienstagJL , et al. A multicenter trial of branched chain enriched amino acid infusion (F080) in hepatic encephalopathy (HE). Hepatology (Baltimore, Md.)1982;2:699. CerraFB , McMillenM , AngelicoR , ClineB , LyonsJ , FaulkenbachL , et al. Cirrhosis, encephalopathy, and improved results with metabolic support. Surgery1983;94:612‐9. ">Cerra 1985</a>; <a href="./references#CD001939-bbs2-0003" title="EgbertsEH , HamsterW , SchomeerusH , JürgensP . Effect of branched chain amino acids on latent porto‐systemic‐encephalopathy (PSE). JPEN. Journal of Parenteral and Enteral Nutrition1981;5:5. EgbertsEH , SchomeerusH , HamsterW , JürgensP . Effective treatment of latens porto‐systemic encephalopathy with oral branched chain amino acids. In: CapocacciaL , FischerJE , Rossi‐FanelliF editor(s). Hepatic Encephalopathy in Chronic Liver Failure. New York: Plenum Press, 1984:351‐7. EgbertsEH , SchomerusH , HamsterW , JurgensP . Branched chain amino acids in the treatment of latent portosystemic encephalopathy. A double‐blind placebo‐controlled crossover study. Gastroenterology1985;88:887‐95. EgbertsEH , SchomerusH , HamsterW , JürgensP . Branched‐chain amino acids in the treatment of latent porto‐systemic encephalopathy. A placebo‐controlled double‐blind cross‐over study [Verzweigtkettige Aminosäuren bei der behandlung der latenten portosystemischen enzephalopathie. Eine placebokontrollierte doppelblind‐cross‐over‐studie]. Zeitschrift für Ernährungswissenschaft1986;25:9‐28. HamsterW , EgbertsEH , HamsterH . Treatment with branched‐chain amino acids and effect on psycho‐physical capacity functions in latent porto‐systemic encephalopathy [Behandlung mit verzweigtkettigen aminosäuren und ihre auswirkung auf psychophysische leistungsfunktionen bei latenter portosystemischer enzephalopathie]. Arzneimittelforschung1982;32:901‐2. ">Egberts 1985</a>; <a href="./references#CD001939-bbs2-0011" title="MichelH , BoriesP , AubinJP , Pomier‐LayrarguesG , BauretP , Bellet‐HermanH . Treatment of acute hepatic encephalopathy in cirrhotics with a branched‐chain amino acids enriched versus a conventional amino acids mixture. A controlled study of 70 patients. Liver1985;5:282‐9. MichelH , Pomier‐LayrarguesG , AubinJP , BoriesP , MirouzeD , Bellet‐HermanH . Treatment of hepatic encephalopathy by infusion of a modified amino acid solution: results of a controlled study in 47 cirrhotic patients. In: CapocacciaL , FischerJE , Rossi‐FanelliF editor(s). Hepatic Encephalopathy in Chronic Liver Failure. New York: Plenum Press, 1984:301‐10. MichelH , Pomier‐LayrarguesG , DuhamelO , LacombeB , CuilleretG , Bellet‐HermannH . Intravenous infusion of ordinary and modified amino‐acid solutions in the management of hepatic encephalopathy (controlled study, 30 patients). Gastroenterology1980;79:1038. Pomier‐LayrarguesG , DuhamelO , LacombeB , CuilleretG , BelletH , MichelH . Intravenous infusion of ordinary and modified amino‐acid solutions in the management of hepatic encephalopathy. Liver1981;1:140. ">Michel 1985</a>; <a href="./references#CD001939-bbs2-0014" title="RiggioO , CangianoC , CascinoA , MerliM , StortoniM , Rossi‐FanelliF , et al. Long term dietary supplement with branched chain amino acids: a new approach in the prevention of hepatic encephalopathy: results of a controlled study in cirrhotics with porto‐caval anastomosis. In: Associazione Italiana per Lo Studio del Fegato. Congress, editor(s). Hepatic Encephalopathy in Chronic Liver Failure. New York: Plenum Press, 1984:183‐92. Rossi‐FanelliF , CangianoC , CapocacciaL , CascinoA , CeciF , MuscaritoliM , et al. Use of branched chain amino acids for treating hepatic encephalopathy: clinical experiences. Gut1986;27:111‐5. Rossi‐FanelliF , CangianoC , CascinoA , MerliM , RiggioO , StortoniM , et al. Branched‐chain amino acids in the treatment of severe hepatic encephalopathy. In: CapocacciaL , FischerJE , Rossi‐FanelliF editor(s). Hepatic Encephalopathy in Chronic Liver Failure. New York: Plenum Press, 1984:335‐44. Rossi‐FanelliF , RiggioO , CangianoC , CascinoA , DeConciliisD , MerliM , et al. Branched‐chain amino acids vs lactulose in the treatment of hepatic coma: a controlled study. Digestive Diseases and Sciences1982;27:929‐35. ">Rossi‐Fanelli 1986</a>; <a href="./references#CD001939-bbs2-0015" title="StraussE , Cartapatti Da SilvaE , LacetCM , CapacciMLL , BernardiniAP . Treatment of hepatic encephalopathy: a randomized clinical trial comparing a branched chain enriched amino acid solution to oral neomycin. Nutritional Support Services1986;6:18‐21. StraussE , SantosWR , DaSilvaEC , LacetCM , CapacciLL , BernardiniAP . A randomized controlled clinical trial for the evaluation of the efficacy of an enriched branched‐chain amino‐acid solution compared to neomycin in hepatic encephalopathy. Hepatology (Baltimore, Md.)1983;3:862. ">Strauss 1986</a>; <a href="./references#CD001939-bbs2-0007" title="HwangSJ , ChanCY , WuJC , LeeSD , HuanYS , TsaiYT , et al. A randomized controlled trial for the evaluation of the efficacy of branched chain amino acid‐enriched amino acid solution in the treatment of patients with hepatic encephalopathy. Chinese Journal of Gastroenterology1988;5:185‐92. ">Hwang 1988</a>; <a href="./references#CD001939-bbs2-0009" title="BianchiGP , MarchesiniG , ZoliM , AbbiatiR , FerrarioE , FabbriA , et al. Oral BCAA supplementation in cirrhosis with chronic encephalopathy: effects on prolactin and estradiol levels. Hepato‐gastroenterology1992;39:443‐6. MarchesiniG , BianchiG , MerliM , AmodioP , PanellaC , LoguercioC , et al. Nutritional supplementation with branched‐chain amino acids in advanced cirrhosis: a double‐blind, randomized trial. Gastroenterology2003;124:1792‐801. MarchesiniG , DioguardiFS , BianchiGP , ZoliM , BellatiG , RoffiL , et al. Long‐term oral branched‐chain amino acid treatment in chronic hepatic encephalopathy. A randomized double‐blind casein controlled trial. The Italian Multicenter Study Group. Journal of Hepatology1990;11:92‐101. ">Marchesini 1990</a>; <a href="./references#CD001939-bbs2-0016" title="GluudC , DejgaardA , HardtF , KristensenM , KøhlerO , MelgaardB , et al. Preliminary treatment results with balanced amino acid infusion to patients with hepatic encephalopathy. Scandinavian Journal of Gastroenterology1983;18:19. VilstrupH , GluudC , HardtF , KristensenM , KøhlerO , MelgaardB , et al. Branched chain enriched amino acid versus glucose treatment of hepatic encephalopathy. A double‐blind study of 65 patients with cirrhosis. Hepatology (Baltimore, Md.)1990;10:291‐6. VilstrupH , GluudC , HardtF , KristensenM , MelgaardB , KøhlerO , et al. Branched chain enriched amino acid nutrition does not change the outcome of hepatic coma in patients with cirrhosis of the liver. Journal of Hepatology1985;1:S347. ">Vilstrup 1990</a>; <a href="./references#CD001939-bbs2-0005" title="HayashiS , AoyagiY , FujiwaraK , OkaH , OdaT . A randomized controlled trial of branched‐chain amino acid (BCAA)‐enriched elemental diet (ED‐H) for hepatic encephalopathy. Journal of Gastroenterology and Hepatology1991;6:191. ">Hayashi 1991</a>; <a href="./references#CD001939-bbs2-0013" title="PlauthM , EgbertsE‐H , HamsterW , TörökM , MüllerP , BrandO , et al. Long‐term treatment with branched‐chain amino acids (BCA) improves the portosystemic encephalopathy (PSE) in ambulant patients. Results of a double blind, placebo controlled crossover study. Klinische Wochenschrift1992;69:126. PlauthM , EgbertsEH , HamsterW , TörökM , MüllerPH , BrandO , et al. Long‐term treatment of latent portosystemic encephalopathy with branched‐chain amino acids. A double‐blind placebo‐crossover study. Journal of Hepatology1993;17:308‐14. ">Plauth 1993</a>; <a href="./references#CD001939-bbs2-0010" title="MarchesiniG , BianchiG , MerliM , AmodioP , PanellaC , LoguercioC , et al. Nutritional supplementation with branched‐chain amino acids in advanced cirrhosis: a double‐blind, randomized trial. Gastroenterology2003;124:1980‐2. ">Marchesini 2003</a>; <a href="./references#CD001939-bbs2-0012" title="Horie‐TakashiI . Effects of oral branched‐chain amino acid granules on event‐free survival in patients with liver cirrhosis. Clinical Gastroenterology and Hepatology2005; Vol. 3:705‐13 (additional information and data received November 2011). MutoY , SatoS , WatanabeA , MoriwakiH , SuzukiK , KatoA , et al. Effects of oral branched‐chain amino acid granules on event‐free survival in patients with liver cirrhosis. Clinical Gastroenterology and Hepatology2005;3:705‐13. SatoS , WatanabeA , MutoY , SuzukiK , KatoA , MoriwakiH , et al. Clinical comparison of branched‐chain amino acid (l‐Leucine, l‐Isoleucine, l‐Valine) granules and oral nutrition for hepatic insufficiency in patients with decompensated liver cirrhosis (LIV‐EN study). Hepatology Research2005;31:232‐40. ">Muto 2005</a>; <a href="./references#CD001939-bbs2-0008" title="LesI , DovalE , Garcia‐MartinezR , PlanasM , CardenasG , GomezP , et al. Effects of branched‐chain amino acids supplementation in patients with cirrhosis and a previous episode of hepatic encephalopathy: a randomized study. American Journal of Gastroenterology2011;106:1081‐8. ">Les 2011</a>). The trials included 827 participants with hepatic encephalopathy (97% had cirrhosis). The type of hepatic encephalopathy was minimal in four trials (<a href="./references#CD001939-bbs2-0003" title="EgbertsEH , HamsterW , SchomeerusH , JürgensP . Effect of branched chain amino acids on latent porto‐systemic‐encephalopathy (PSE). JPEN. Journal of Parenteral and Enteral Nutrition1981;5:5. EgbertsEH , SchomeerusH , HamsterW , JürgensP . Effective treatment of latens porto‐systemic encephalopathy with oral branched chain amino acids. In: CapocacciaL , FischerJE , Rossi‐FanelliF editor(s). Hepatic Encephalopathy in Chronic Liver Failure. New York: Plenum Press, 1984:351‐7. EgbertsEH , SchomerusH , HamsterW , JurgensP . Branched chain amino acids in the treatment of latent portosystemic encephalopathy. A double‐blind placebo‐controlled crossover study. Gastroenterology1985;88:887‐95. EgbertsEH , SchomerusH , HamsterW , JürgensP . Branched‐chain amino acids in the treatment of latent porto‐systemic encephalopathy. A placebo‐controlled double‐blind cross‐over study [Verzweigtkettige Aminosäuren bei der behandlung der latenten portosystemischen enzephalopathie. Eine placebokontrollierte doppelblind‐cross‐over‐studie]. Zeitschrift für Ernährungswissenschaft1986;25:9‐28. HamsterW , EgbertsEH , HamsterH . Treatment with branched‐chain amino acids and effect on psycho‐physical capacity functions in latent porto‐systemic encephalopathy [Behandlung mit verzweigtkettigen aminosäuren und ihre auswirkung auf psychophysische leistungsfunktionen bei latenter portosystemischer enzephalopathie]. Arzneimittelforschung1982;32:901‐2. ">Egberts 1985</a>; <a href="./references#CD001939-bbs2-0013" title="PlauthM , EgbertsE‐H , HamsterW , TörökM , MüllerP , BrandO , et al. Long‐term treatment with branched‐chain amino acids (BCA) improves the portosystemic encephalopathy (PSE) in ambulant patients. Results of a double blind, placebo controlled crossover study. Klinische Wochenschrift1992;69:126. PlauthM , EgbertsEH , HamsterW , TörökM , MüllerPH , BrandO , et al. Long‐term treatment of latent portosystemic encephalopathy with branched‐chain amino acids. A double‐blind placebo‐crossover study. Journal of Hepatology1993;17:308‐14. ">Plauth 1993</a>; <a href="./references#CD001939-bbs2-0010" title="MarchesiniG , BianchiG , MerliM , AmodioP , PanellaC , LoguercioC , et al. Nutritional supplementation with branched‐chain amino acids in advanced cirrhosis: a double‐blind, randomized trial. Gastroenterology2003;124:1980‐2. ">Marchesini 2003</a>; <a href="./references#CD001939-bbs2-0008" title="LesI , DovalE , Garcia‐MartinezR , PlanasM , CardenasG , GomezP , et al. Effects of branched‐chain amino acids supplementation in patients with cirrhosis and a previous episode of hepatic encephalopathy: a randomized study. American Journal of Gastroenterology2011;106:1081‐8. ">Les 2011</a>), and overt in the remaining 12 trials. Eight trials assessed oral BCAA for minimal or overt hepatic encephalopathy (<a href="./references#CD001939-bbs2-0006" title="HorstD , GraceN , ConnHO , SchiffE , SchenkerS , ViteriA , et al. A double‐blind randomized comparison of dietary protein and an oral branched chain amino acid (BCAA) solution in cirrhotic patients with chronic portal‐systemic encephalopathy (PSE) [IASL abstract]. Hepatology (Baltimore, Md.)1982;2:184. HorstD , GraceND , ConnHO , SchiffE , SchenkerS , ViteriA , et al. Comparison of dietary protein with an oral, branched chain‐enriched amino acid supplement in chronic portal‐systemic encephalopathy: a randomized controlled trial. Hepatology (Baltimore, Md.)1984;4:279‐87. ">Horst 1984</a>; <a href="./references#CD001939-bbs2-0003" title="EgbertsEH , HamsterW , SchomeerusH , JürgensP . Effect of branched chain amino acids on latent porto‐systemic‐encephalopathy (PSE). JPEN. Journal of Parenteral and Enteral Nutrition1981;5:5. EgbertsEH , SchomeerusH , HamsterW , JürgensP . Effective treatment of latens porto‐systemic encephalopathy with oral branched chain amino acids. In: CapocacciaL , FischerJE , Rossi‐FanelliF editor(s). Hepatic Encephalopathy in Chronic Liver Failure. New York: Plenum Press, 1984:351‐7. EgbertsEH , SchomerusH , HamsterW , JurgensP . Branched chain amino acids in the treatment of latent portosystemic encephalopathy. A double‐blind placebo‐controlled crossover study. Gastroenterology1985;88:887‐95. EgbertsEH , SchomerusH , HamsterW , JürgensP . Branched‐chain amino acids in the treatment of latent porto‐systemic encephalopathy. A placebo‐controlled double‐blind cross‐over study [Verzweigtkettige Aminosäuren bei der behandlung der latenten portosystemischen enzephalopathie. Eine placebokontrollierte doppelblind‐cross‐over‐studie]. Zeitschrift für Ernährungswissenschaft1986;25:9‐28. HamsterW , EgbertsEH , HamsterH . Treatment with branched‐chain amino acids and effect on psycho‐physical capacity functions in latent porto‐systemic encephalopathy [Behandlung mit verzweigtkettigen aminosäuren und ihre auswirkung auf psychophysische leistungsfunktionen bei latenter portosystemischer enzephalopathie]. Arzneimittelforschung1982;32:901‐2. ">Egberts 1985</a>; <a href="./references#CD001939-bbs2-0009" title="BianchiGP , MarchesiniG , ZoliM , AbbiatiR , FerrarioE , FabbriA , et al. Oral BCAA supplementation in cirrhosis with chronic encephalopathy: effects on prolactin and estradiol levels. Hepato‐gastroenterology1992;39:443‐6. MarchesiniG , BianchiG , MerliM , AmodioP , PanellaC , LoguercioC , et al. Nutritional supplementation with branched‐chain amino acids in advanced cirrhosis: a double‐blind, randomized trial. Gastroenterology2003;124:1792‐801. MarchesiniG , DioguardiFS , BianchiGP , ZoliM , BellatiG , RoffiL , et al. Long‐term oral branched‐chain amino acid treatment in chronic hepatic encephalopathy. A randomized double‐blind casein controlled trial. The Italian Multicenter Study Group. Journal of Hepatology1990;11:92‐101. ">Marchesini 1990</a>; <a href="./references#CD001939-bbs2-0005" title="HayashiS , AoyagiY , FujiwaraK , OkaH , OdaT . A randomized controlled trial of branched‐chain amino acid (BCAA)‐enriched elemental diet (ED‐H) for hepatic encephalopathy. Journal of Gastroenterology and Hepatology1991;6:191. ">Hayashi 1991</a>; <a href="./references#CD001939-bbs2-0013" title="PlauthM , EgbertsE‐H , HamsterW , TörökM , MüllerP , BrandO , et al. Long‐term treatment with branched‐chain amino acids (BCA) improves the portosystemic encephalopathy (PSE) in ambulant patients. Results of a double blind, placebo controlled crossover study. Klinische Wochenschrift1992;69:126. PlauthM , EgbertsEH , HamsterW , TörökM , MüllerPH , BrandO , et al. Long‐term treatment of latent portosystemic encephalopathy with branched‐chain amino acids. A double‐blind placebo‐crossover study. Journal of Hepatology1993;17:308‐14. ">Plauth 1993</a>; <a href="./references#CD001939-bbs2-0010" title="MarchesiniG , BianchiG , MerliM , AmodioP , PanellaC , LoguercioC , et al. Nutritional supplementation with branched‐chain amino acids in advanced cirrhosis: a double‐blind, randomized trial. Gastroenterology2003;124:1980‐2. ">Marchesini 2003</a>; <a href="./references#CD001939-bbs2-0012" title="Horie‐TakashiI . Effects of oral branched‐chain amino acid granules on event‐free survival in patients with liver cirrhosis. Clinical Gastroenterology and Hepatology2005; Vol. 3:705‐13 (additional information and data received November 2011). MutoY , SatoS , WatanabeA , MoriwakiH , SuzukiK , KatoA , et al. Effects of oral branched‐chain amino acid granules on event‐free survival in patients with liver cirrhosis. Clinical Gastroenterology and Hepatology2005;3:705‐13. SatoS , WatanabeA , MutoY , SuzukiK , KatoA , MoriwakiH , et al. Clinical comparison of branched‐chain amino acid (l‐Leucine, l‐Isoleucine, l‐Valine) granules and oral nutrition for hepatic insufficiency in patients with decompensated liver cirrhosis (LIV‐EN study). Hepatology Research2005;31:232‐40. ">Muto 2005</a>; <a href="./references#CD001939-bbs2-0008" title="LesI , DovalE , Garcia‐MartinezR , PlanasM , CardenasG , GomezP , et al. Effects of branched‐chain amino acids supplementation in patients with cirrhosis and a previous episode of hepatic encephalopathy: a randomized study. American Journal of Gastroenterology2011;106:1081‐8. ">Les 2011</a>). Seven trials assessed intravenous BCAA for overt hepatic encephalopathy (<a href="./references#CD001939-bbs2-0004" title="FiaccadoriF . Branched chain amino acid enriched solutions in the treatment of hepatic encephalopathy: a controlled trial. Italian Journal of Gastroenterology (additional information from author November 2012). FiaccadoriF , GhinelliF , PedrettiG . Branched chain amino acid enriched solutions in the treatment of hepatic encephalopathy: a controlled trial. Italian Journal of Gastroenterology1985;17:5‐10. FiaccadoriF , GhinelliF , PedrettiG , ManciaD . Mental state course and biochemical findings in HE treated by BCAA‐enriched mixtures. In: HolmE , KasperH editor(s). Metabolism and Nutrition in Liver Disease Freiburg 1984: Proceedings of the 41st Falk Symposium. Lancaster: MTP Press, 1985:281‐5. FiaccadoriF , GhinelliF , PedrettiG , PelosiG , SacchiniD , ZeneroliML , et al. Branched chain amino acid enriched solutions in the treatment of hepatic encephalopathy: a controlled trial. In: CapocacciaL , FischerJE , Rossi‐FanelliF editor(s). Hepatic Encephalopathy in Chronic Liver Failure. New York: Plenum Press, 1984:323‐33. FiaccadoriF , GhinelliF , PelosiG , SacchiniD , VaonaG , ZeneroliML , et al. Selective amino acid solutions in hepatic encephalopathy treatment (a preliminary report). La Ricerca in Clinica e in Laboratorio1980;10:411‐22. [MEDLINE: 81102770] ">Fiaccadori 1984</a>; <a href="./references#CD001939-bbs2-0002" title="CerraFB . Disease‐specific amino acid infusion (F080) in hepatic encephalopathy: a prospective, randomized, double‐blind, controlled trial [personal communication]. Correspondence with authorsSeptember 2002. CerraFB , CheungNK , FischerJE , KaplowitzN , SchiffE‐R , DienstagJL , et al. Disease‐specific amino acid infusion (F080) in hepatic encephalopathy: a prospective, randomized, double‐blind, controlled trial. JPEN. Journal of Parenteral and Enteral Nutrition1985;9:288‐95. CerraFB , CheungNK , FischerJE , KaplowitzN , SchiffER , DienstagJL , et al. A multicenter trial of branched chain enriched amino acid infusion (F080) in hepatic encephalopathy (HE). Hepatology (Baltimore, Md.)1982;2:699. CerraFB , McMillenM , AngelicoR , ClineB , LyonsJ , FaulkenbachL , et al. Cirrhosis, encephalopathy, and improved results with metabolic support. Surgery1983;94:612‐9. ">Cerra 1985</a>; <a href="./references#CD001939-bbs2-0011" title="MichelH , BoriesP , AubinJP , Pomier‐LayrarguesG , BauretP , Bellet‐HermanH . Treatment of acute hepatic encephalopathy in cirrhotics with a branched‐chain amino acids enriched versus a conventional amino acids mixture. A controlled study of 70 patients. Liver1985;5:282‐9. MichelH , Pomier‐LayrarguesG , AubinJP , BoriesP , MirouzeD , Bellet‐HermanH . Treatment of hepatic encephalopathy by infusion of a modified amino acid solution: results of a controlled study in 47 cirrhotic patients. In: CapocacciaL , FischerJE , Rossi‐FanelliF editor(s). Hepatic Encephalopathy in Chronic Liver Failure. New York: Plenum Press, 1984:301‐10. MichelH , Pomier‐LayrarguesG , DuhamelO , LacombeB , CuilleretG , Bellet‐HermannH . Intravenous infusion of ordinary and modified amino‐acid solutions in the management of hepatic encephalopathy (controlled study, 30 patients). Gastroenterology1980;79:1038. Pomier‐LayrarguesG , DuhamelO , LacombeB , CuilleretG , BelletH , MichelH . Intravenous infusion of ordinary and modified amino‐acid solutions in the management of hepatic encephalopathy. Liver1981;1:140. ">Michel 1985</a>; <a href="./references#CD001939-bbs2-0014" title="RiggioO , CangianoC , CascinoA , MerliM , StortoniM , Rossi‐FanelliF , et al. Long term dietary supplement with branched chain amino acids: a new approach in the prevention of hepatic encephalopathy: results of a controlled study in cirrhotics with porto‐caval anastomosis. In: Associazione Italiana per Lo Studio del Fegato. Congress, editor(s). Hepatic Encephalopathy in Chronic Liver Failure. New York: Plenum Press, 1984:183‐92. Rossi‐FanelliF , CangianoC , CapocacciaL , CascinoA , CeciF , MuscaritoliM , et al. Use of branched chain amino acids for treating hepatic encephalopathy: clinical experiences. Gut1986;27:111‐5. Rossi‐FanelliF , CangianoC , CascinoA , MerliM , RiggioO , StortoniM , et al. Branched‐chain amino acids in the treatment of severe hepatic encephalopathy. In: CapocacciaL , FischerJE , Rossi‐FanelliF editor(s). Hepatic Encephalopathy in Chronic Liver Failure. New York: Plenum Press, 1984:335‐44. Rossi‐FanelliF , RiggioO , CangianoC , CascinoA , DeConciliisD , MerliM , et al. Branched‐chain amino acids vs lactulose in the treatment of hepatic coma: a controlled study. Digestive Diseases and Sciences1982;27:929‐35. ">Rossi‐Fanelli 1986</a>; <a href="./references#CD001939-bbs2-0015" title="StraussE , Cartapatti Da SilvaE , LacetCM , CapacciMLL , BernardiniAP . Treatment of hepatic encephalopathy: a randomized clinical trial comparing a branched chain enriched amino acid solution to oral neomycin. Nutritional Support Services1986;6:18‐21. StraussE , SantosWR , DaSilvaEC , LacetCM , CapacciLL , BernardiniAP . A randomized controlled clinical trial for the evaluation of the efficacy of an enriched branched‐chain amino‐acid solution compared to neomycin in hepatic encephalopathy. Hepatology (Baltimore, Md.)1983;3:862. ">Strauss 1986</a>; <a href="./references#CD001939-bbs2-0007" title="HwangSJ , ChanCY , WuJC , LeeSD , HuanYS , TsaiYT , et al. A randomized controlled trial for the evaluation of the efficacy of branched chain amino acid‐enriched amino acid solution in the treatment of patients with hepatic encephalopathy. Chinese Journal of Gastroenterology1988;5:185‐92. ">Hwang 1988</a>; <a href="./references#CD001939-bbs2-0016" title="GluudC , DejgaardA , HardtF , KristensenM , KøhlerO , MelgaardB , et al. Preliminary treatment results with balanced amino acid infusion to patients with hepatic encephalopathy. Scandinavian Journal of Gastroenterology1983;18:19. VilstrupH , GluudC , HardtF , KristensenM , KøhlerO , MelgaardB , et al. Branched chain enriched amino acid versus glucose treatment of hepatic encephalopathy. A double‐blind study of 65 patients with cirrhosis. Hepatology (Baltimore, Md.)1990;10:291‐6. VilstrupH , GluudC , HardtF , KristensenM , MelgaardB , KøhlerO , et al. Branched chain enriched amino acid nutrition does not change the outcome of hepatic coma in patients with cirrhosis of the liver. Journal of Hepatology1985;1:S347. ">Vilstrup 1990</a>). One trial assessed oral or intravenous BCAA versus a control diet for overt hepatic encephalopathy (<a href="./references#CD001939-bbs2-0002" title="CerraFB . Disease‐specific amino acid infusion (F080) in hepatic encephalopathy: a prospective, randomized, double‐blind, controlled trial [personal communication]. Correspondence with authorsSeptember 2002. CerraFB , CheungNK , FischerJE , KaplowitzN , SchiffE‐R , DienstagJL , et al. Disease‐specific amino acid infusion (F080) in hepatic encephalopathy: a prospective, randomized, double‐blind, controlled trial. JPEN. Journal of Parenteral and Enteral Nutrition1985;9:288‐95. CerraFB , CheungNK , FischerJE , KaplowitzN , SchiffER , DienstagJL , et al. A multicenter trial of branched chain enriched amino acid infusion (F080) in hepatic encephalopathy (HE). Hepatology (Baltimore, Md.)1982;2:699. CerraFB , McMillenM , AngelicoR , ClineB , LyonsJ , FaulkenbachL , et al. Cirrhosis, encephalopathy, and improved results with metabolic support. Surgery1983;94:612‐9. ">Cerra 1985</a>). In the eight trials studying oral BCAA, people in the control group received placebo/no intervention or diets. In the seven trials studying intravenous BCAA, people in the control groups received placebo/no intervention or diets (<a href="./references#CD001939-bbs2-0011" title="MichelH , BoriesP , AubinJP , Pomier‐LayrarguesG , BauretP , Bellet‐HermanH . Treatment of acute hepatic encephalopathy in cirrhotics with a branched‐chain amino acids enriched versus a conventional amino acids mixture. A controlled study of 70 patients. Liver1985;5:282‐9. MichelH , Pomier‐LayrarguesG , AubinJP , BoriesP , MirouzeD , Bellet‐HermanH . Treatment of hepatic encephalopathy by infusion of a modified amino acid solution: results of a controlled study in 47 cirrhotic patients. In: CapocacciaL , FischerJE , Rossi‐FanelliF editor(s). Hepatic Encephalopathy in Chronic Liver Failure. New York: Plenum Press, 1984:301‐10. MichelH , Pomier‐LayrarguesG , DuhamelO , LacombeB , CuilleretG , Bellet‐HermannH . Intravenous infusion of ordinary and modified amino‐acid solutions in the management of hepatic encephalopathy (controlled study, 30 patients). Gastroenterology1980;79:1038. Pomier‐LayrarguesG , DuhamelO , LacombeB , CuilleretG , BelletH , MichelH . Intravenous infusion of ordinary and modified amino‐acid solutions in the management of hepatic encephalopathy. Liver1981;1:140. ">Michel 1985</a>; <a href="./references#CD001939-bbs2-0007" title="HwangSJ , ChanCY , WuJC , LeeSD , HuanYS , TsaiYT , et al. A randomized controlled trial for the evaluation of the efficacy of branched chain amino acid‐enriched amino acid solution in the treatment of patients with hepatic encephalopathy. Chinese Journal of Gastroenterology1988;5:185‐92. ">Hwang 1988</a>; <a href="./references#CD001939-bbs2-0016" title="GluudC , DejgaardA , HardtF , KristensenM , KøhlerO , MelgaardB , et al. Preliminary treatment results with balanced amino acid infusion to patients with hepatic encephalopathy. Scandinavian Journal of Gastroenterology1983;18:19. VilstrupH , GluudC , HardtF , KristensenM , KøhlerO , MelgaardB , et al. Branched chain enriched amino acid versus glucose treatment of hepatic encephalopathy. A double‐blind study of 65 patients with cirrhosis. Hepatology (Baltimore, Md.)1990;10:291‐6. VilstrupH , GluudC , HardtF , KristensenM , MelgaardB , KøhlerO , et al. Branched chain enriched amino acid nutrition does not change the outcome of hepatic coma in patients with cirrhosis of the liver. Journal of Hepatology1985;1:S347. ">Vilstrup 1990</a>), neomycin (<a href="./references#CD001939-bbs2-0002" title="CerraFB . Disease‐specific amino acid infusion (F080) in hepatic encephalopathy: a prospective, randomized, double‐blind, controlled trial [personal communication]. Correspondence with authorsSeptember 2002. CerraFB , CheungNK , FischerJE , KaplowitzN , SchiffE‐R , DienstagJL , et al. Disease‐specific amino acid infusion (F080) in hepatic encephalopathy: a prospective, randomized, double‐blind, controlled trial. JPEN. Journal of Parenteral and Enteral Nutrition1985;9:288‐95. CerraFB , CheungNK , FischerJE , KaplowitzN , SchiffER , DienstagJL , et al. A multicenter trial of branched chain enriched amino acid infusion (F080) in hepatic encephalopathy (HE). Hepatology (Baltimore, Md.)1982;2:699. CerraFB , McMillenM , AngelicoR , ClineB , LyonsJ , FaulkenbachL , et al. Cirrhosis, encephalopathy, and improved results with metabolic support. Surgery1983;94:612‐9. ">Cerra 1985</a>; <a href="./references#CD001939-bbs2-0015" title="StraussE , Cartapatti Da SilvaE , LacetCM , CapacciMLL , BernardiniAP . Treatment of hepatic encephalopathy: a randomized clinical trial comparing a branched chain enriched amino acid solution to oral neomycin. Nutritional Support Services1986;6:18‐21. StraussE , SantosWR , DaSilvaEC , LacetCM , CapacciLL , BernardiniAP . A randomized controlled clinical trial for the evaluation of the efficacy of an enriched branched‐chain amino‐acid solution compared to neomycin in hepatic encephalopathy. Hepatology (Baltimore, Md.)1983;3:862. ">Strauss 1986</a>), or lactulose (<a href="./references#CD001939-bbs2-0004" title="FiaccadoriF . Branched chain amino acid enriched solutions in the treatment of hepatic encephalopathy: a controlled trial. Italian Journal of Gastroenterology (additional information from author November 2012). FiaccadoriF , GhinelliF , PedrettiG . Branched chain amino acid enriched solutions in the treatment of hepatic encephalopathy: a controlled trial. Italian Journal of Gastroenterology1985;17:5‐10. FiaccadoriF , GhinelliF , PedrettiG , ManciaD . Mental state course and biochemical findings in HE treated by BCAA‐enriched mixtures. In: HolmE , KasperH editor(s). Metabolism and Nutrition in Liver Disease Freiburg 1984: Proceedings of the 41st Falk Symposium. Lancaster: MTP Press, 1985:281‐5. FiaccadoriF , GhinelliF , PedrettiG , PelosiG , SacchiniD , ZeneroliML , et al. Branched chain amino acid enriched solutions in the treatment of hepatic encephalopathy: a controlled trial. In: CapocacciaL , FischerJE , Rossi‐FanelliF editor(s). Hepatic Encephalopathy in Chronic Liver Failure. New York: Plenum Press, 1984:323‐33. FiaccadoriF , GhinelliF , PelosiG , SacchiniD , VaonaG , ZeneroliML , et al. Selective amino acid solutions in hepatic encephalopathy treatment (a preliminary report). La Ricerca in Clinica e in Laboratorio1980;10:411‐22. [MEDLINE: 81102770] ">Fiaccadori 1984</a>; <a href="./references#CD001939-bbs2-0014" title="RiggioO , CangianoC , CascinoA , MerliM , StortoniM , Rossi‐FanelliF , et al. Long term dietary supplement with branched chain amino acids: a new approach in the prevention of hepatic encephalopathy: results of a controlled study in cirrhotics with porto‐caval anastomosis. In: Associazione Italiana per Lo Studio del Fegato. Congress, editor(s). Hepatic Encephalopathy in Chronic Liver Failure. New York: Plenum Press, 1984:183‐92. Rossi‐FanelliF , CangianoC , CapocacciaL , CascinoA , CeciF , MuscaritoliM , et al. Use of branched chain amino acids for treating hepatic encephalopathy: clinical experiences. Gut1986;27:111‐5. Rossi‐FanelliF , CangianoC , CascinoA , MerliM , RiggioO , StortoniM , et al. Branched‐chain amino acids in the treatment of severe hepatic encephalopathy. In: CapocacciaL , FischerJE , Rossi‐FanelliF editor(s). Hepatic Encephalopathy in Chronic Liver Failure. New York: Plenum Press, 1984:335‐44. Rossi‐FanelliF , RiggioO , CangianoC , CascinoA , DeConciliisD , MerliM , et al. Branched‐chain amino acids vs lactulose in the treatment of hepatic coma: a controlled study. Digestive Diseases and Sciences1982;27:929‐35. ">Rossi‐Fanelli 1986</a>). </p> <section id="CD001939-sec-0066"> <h4 class="title">Results of the search</h4> <p>We identified 1196 potentially relevant records in the electronic searches and 20 additional records in the manual searches (<a href="#CD001939-fig-0001">Figure 1</a>). Of these, 40 records that referred to 16 randomised clinical trials fulfilled our inclusion criteria. We found one trial published in abstract form (<a href="./references#CD001939-bbs2-0005" title="HayashiS , AoyagiY , FujiwaraK , OkaH , OdaT . A randomized controlled trial of branched‐chain amino acid (BCAA)‐enriched elemental diet (ED‐H) for hepatic encephalopathy. Journal of Gastroenterology and Hepatology1991;6:191. ">Hayashi 1991</a>), and 15 trials described in full paper articles (<a href="./references#CD001939-bbs2-0004" title="FiaccadoriF . Branched chain amino acid enriched solutions in the treatment of hepatic encephalopathy: a controlled trial. Italian Journal of Gastroenterology (additional information from author November 2012). FiaccadoriF , GhinelliF , PedrettiG . Branched chain amino acid enriched solutions in the treatment of hepatic encephalopathy: a controlled trial. Italian Journal of Gastroenterology1985;17:5‐10. FiaccadoriF , GhinelliF , PedrettiG , ManciaD . Mental state course and biochemical findings in HE treated by BCAA‐enriched mixtures. In: HolmE , KasperH editor(s). Metabolism and Nutrition in Liver Disease Freiburg 1984: Proceedings of the 41st Falk Symposium. Lancaster: MTP Press, 1985:281‐5. FiaccadoriF , GhinelliF , PedrettiG , PelosiG , SacchiniD , ZeneroliML , et al. Branched chain amino acid enriched solutions in the treatment of hepatic encephalopathy: a controlled trial. In: CapocacciaL , FischerJE , Rossi‐FanelliF editor(s). Hepatic Encephalopathy in Chronic Liver Failure. New York: Plenum Press, 1984:323‐33. FiaccadoriF , GhinelliF , PelosiG , SacchiniD , VaonaG , ZeneroliML , et al. Selective amino acid solutions in hepatic encephalopathy treatment (a preliminary report). La Ricerca in Clinica e in Laboratorio1980;10:411‐22. [MEDLINE: 81102770] ">Fiaccadori 1984</a>; <a href="./references#CD001939-bbs2-0006" title="HorstD , GraceN , ConnHO , SchiffE , SchenkerS , ViteriA , et al. A double‐blind randomized comparison of dietary protein and an oral branched chain amino acid (BCAA) solution in cirrhotic patients with chronic portal‐systemic encephalopathy (PSE) [IASL abstract]. Hepatology (Baltimore, Md.)1982;2:184. HorstD , GraceND , ConnHO , SchiffE , SchenkerS , ViteriA , et al. Comparison of dietary protein with an oral, branched chain‐enriched amino acid supplement in chronic portal‐systemic encephalopathy: a randomized controlled trial. Hepatology (Baltimore, Md.)1984;4:279‐87. ">Horst 1984</a>; <a href="./references#CD001939-bbs2-0001" title="CalveyH , DavisM , WilliamsR . Controlled trial of nutritional supplementation, with and without branched chain amino acid enrichment, in treatment of acute alcoholic hepatitis. Journal of Hepatology1985;1:141‐51. CalveyH , DavisM , WilliamsR . Prospective study of nasogastric feeding via East Grinstead or Viomedex tubes compared with oral dietary supplementation in patients with cirrhosis. Clinical Nutrition1984;3:63‐6. WilliamsR , CalveyH , DavisM . Controlled trial of nutritional supplementation in acute alcoholic hepatitis. In: HolmEKH editor(s). Metabolism and Nutrition in Liver Disease. Lancaster, UK: MTP Press, Ltd, 1985:361‐8. ">Calvey 1985</a>; <a href="./references#CD001939-bbs2-0002" title="CerraFB . Disease‐specific amino acid infusion (F080) in hepatic encephalopathy: a prospective, randomized, double‐blind, controlled trial [personal communication]. Correspondence with authorsSeptember 2002. CerraFB , CheungNK , FischerJE , KaplowitzN , SchiffE‐R , DienstagJL , et al. Disease‐specific amino acid infusion (F080) in hepatic encephalopathy: a prospective, randomized, double‐blind, controlled trial. JPEN. Journal of Parenteral and Enteral Nutrition1985;9:288‐95. CerraFB , CheungNK , FischerJE , KaplowitzN , SchiffER , DienstagJL , et al. A multicenter trial of branched chain enriched amino acid infusion (F080) in hepatic encephalopathy (HE). Hepatology (Baltimore, Md.)1982;2:699. CerraFB , McMillenM , AngelicoR , ClineB , LyonsJ , FaulkenbachL , et al. Cirrhosis, encephalopathy, and improved results with metabolic support. Surgery1983;94:612‐9. ">Cerra 1985</a>; <a href="./references#CD001939-bbs2-0003" title="EgbertsEH , HamsterW , SchomeerusH , JürgensP . Effect of branched chain amino acids on latent porto‐systemic‐encephalopathy (PSE). JPEN. Journal of Parenteral and Enteral Nutrition1981;5:5. EgbertsEH , SchomeerusH , HamsterW , JürgensP . Effective treatment of latens porto‐systemic encephalopathy with oral branched chain amino acids. In: CapocacciaL , FischerJE , Rossi‐FanelliF editor(s). Hepatic Encephalopathy in Chronic Liver Failure. New York: Plenum Press, 1984:351‐7. EgbertsEH , SchomerusH , HamsterW , JurgensP . Branched chain amino acids in the treatment of latent portosystemic encephalopathy. A double‐blind placebo‐controlled crossover study. Gastroenterology1985;88:887‐95. EgbertsEH , SchomerusH , HamsterW , JürgensP . Branched‐chain amino acids in the treatment of latent porto‐systemic encephalopathy. A placebo‐controlled double‐blind cross‐over study [Verzweigtkettige Aminosäuren bei der behandlung der latenten portosystemischen enzephalopathie. Eine placebokontrollierte doppelblind‐cross‐over‐studie]. Zeitschrift für Ernährungswissenschaft1986;25:9‐28. HamsterW , EgbertsEH , HamsterH . Treatment with branched‐chain amino acids and effect on psycho‐physical capacity functions in latent porto‐systemic encephalopathy [Behandlung mit verzweigtkettigen aminosäuren und ihre auswirkung auf psychophysische leistungsfunktionen bei latenter portosystemischer enzephalopathie]. Arzneimittelforschung1982;32:901‐2. ">Egberts 1985</a>; <a href="./references#CD001939-bbs2-0011" title="MichelH , BoriesP , AubinJP , Pomier‐LayrarguesG , BauretP , Bellet‐HermanH . Treatment of acute hepatic encephalopathy in cirrhotics with a branched‐chain amino acids enriched versus a conventional amino acids mixture. A controlled study of 70 patients. Liver1985;5:282‐9. MichelH , Pomier‐LayrarguesG , AubinJP , BoriesP , MirouzeD , Bellet‐HermanH . Treatment of hepatic encephalopathy by infusion of a modified amino acid solution: results of a controlled study in 47 cirrhotic patients. In: CapocacciaL , FischerJE , Rossi‐FanelliF editor(s). Hepatic Encephalopathy in Chronic Liver Failure. New York: Plenum Press, 1984:301‐10. MichelH , Pomier‐LayrarguesG , DuhamelO , LacombeB , CuilleretG , Bellet‐HermannH . Intravenous infusion of ordinary and modified amino‐acid solutions in the management of hepatic encephalopathy (controlled study, 30 patients). Gastroenterology1980;79:1038. Pomier‐LayrarguesG , DuhamelO , LacombeB , CuilleretG , BelletH , MichelH . Intravenous infusion of ordinary and modified amino‐acid solutions in the management of hepatic encephalopathy. Liver1981;1:140. ">Michel 1985</a>; <a href="./references#CD001939-bbs2-0014" title="RiggioO , CangianoC , CascinoA , MerliM , StortoniM , Rossi‐FanelliF , et al. Long term dietary supplement with branched chain amino acids: a new approach in the prevention of hepatic encephalopathy: results of a controlled study in cirrhotics with porto‐caval anastomosis. In: Associazione Italiana per Lo Studio del Fegato. Congress, editor(s). Hepatic Encephalopathy in Chronic Liver Failure. New York: Plenum Press, 1984:183‐92. Rossi‐FanelliF , CangianoC , CapocacciaL , CascinoA , CeciF , MuscaritoliM , et al. Use of branched chain amino acids for treating hepatic encephalopathy: clinical experiences. Gut1986;27:111‐5. Rossi‐FanelliF , CangianoC , CascinoA , MerliM , RiggioO , StortoniM , et al. Branched‐chain amino acids in the treatment of severe hepatic encephalopathy. In: CapocacciaL , FischerJE , Rossi‐FanelliF editor(s). Hepatic Encephalopathy in Chronic Liver Failure. New York: Plenum Press, 1984:335‐44. Rossi‐FanelliF , RiggioO , CangianoC , CascinoA , DeConciliisD , MerliM , et al. Branched‐chain amino acids vs lactulose in the treatment of hepatic coma: a controlled study. Digestive Diseases and Sciences1982;27:929‐35. ">Rossi‐Fanelli 1986</a>; <a href="./references#CD001939-bbs2-0015" title="StraussE , Cartapatti Da SilvaE , LacetCM , CapacciMLL , BernardiniAP . Treatment of hepatic encephalopathy: a randomized clinical trial comparing a branched chain enriched amino acid solution to oral neomycin. Nutritional Support Services1986;6:18‐21. StraussE , SantosWR , DaSilvaEC , LacetCM , CapacciLL , BernardiniAP . A randomized controlled clinical trial for the evaluation of the efficacy of an enriched branched‐chain amino‐acid solution compared to neomycin in hepatic encephalopathy. Hepatology (Baltimore, Md.)1983;3:862. ">Strauss 1986</a>; <a href="./references#CD001939-bbs2-0007" title="HwangSJ , ChanCY , WuJC , LeeSD , HuanYS , TsaiYT , et al. A randomized controlled trial for the evaluation of the efficacy of branched chain amino acid‐enriched amino acid solution in the treatment of patients with hepatic encephalopathy. Chinese Journal of Gastroenterology1988;5:185‐92. ">Hwang 1988</a>; <a href="./references#CD001939-bbs2-0009" title="BianchiGP , MarchesiniG , ZoliM , AbbiatiR , FerrarioE , FabbriA , et al. Oral BCAA supplementation in cirrhosis with chronic encephalopathy: effects on prolactin and estradiol levels. Hepato‐gastroenterology1992;39:443‐6. MarchesiniG , BianchiG , MerliM , AmodioP , PanellaC , LoguercioC , et al. Nutritional supplementation with branched‐chain amino acids in advanced cirrhosis: a double‐blind, randomized trial. Gastroenterology2003;124:1792‐801. MarchesiniG , DioguardiFS , BianchiGP , ZoliM , BellatiG , RoffiL , et al. Long‐term oral branched‐chain amino acid treatment in chronic hepatic encephalopathy. A randomized double‐blind casein controlled trial. The Italian Multicenter Study Group. Journal of Hepatology1990;11:92‐101. ">Marchesini 1990</a>; <a href="./references#CD001939-bbs2-0016" title="GluudC , DejgaardA , HardtF , KristensenM , KøhlerO , MelgaardB , et al. Preliminary treatment results with balanced amino acid infusion to patients with hepatic encephalopathy. Scandinavian Journal of Gastroenterology1983;18:19. VilstrupH , GluudC , HardtF , KristensenM , KøhlerO , MelgaardB , et al. Branched chain enriched amino acid versus glucose treatment of hepatic encephalopathy. A double‐blind study of 65 patients with cirrhosis. Hepatology (Baltimore, Md.)1990;10:291‐6. VilstrupH , GluudC , HardtF , KristensenM , MelgaardB , KøhlerO , et al. Branched chain enriched amino acid nutrition does not change the outcome of hepatic coma in patients with cirrhosis of the liver. Journal of Hepatology1985;1:S347. ">Vilstrup 1990</a>; <a href="./references#CD001939-bbs2-0013" title="PlauthM , EgbertsE‐H , HamsterW , TörökM , MüllerP , BrandO , et al. Long‐term treatment with branched‐chain amino acids (BCA) improves the portosystemic encephalopathy (PSE) in ambulant patients. Results of a double blind, placebo controlled crossover study. Klinische Wochenschrift1992;69:126. PlauthM , EgbertsEH , HamsterW , TörökM , MüllerPH , BrandO , et al. Long‐term treatment of latent portosystemic encephalopathy with branched‐chain amino acids. A double‐blind placebo‐crossover study. Journal of Hepatology1993;17:308‐14. ">Plauth 1993</a>; <a href="./references#CD001939-bbs2-0010" title="MarchesiniG , BianchiG , MerliM , AmodioP , PanellaC , LoguercioC , et al. Nutritional supplementation with branched‐chain amino acids in advanced cirrhosis: a double‐blind, randomized trial. Gastroenterology2003;124:1980‐2. ">Marchesini 2003</a>; <a href="./references#CD001939-bbs2-0012" title="Horie‐TakashiI . Effects of oral branched‐chain amino acid granules on event‐free survival in patients with liver cirrhosis. Clinical Gastroenterology and Hepatology2005; Vol. 3:705‐13 (additional information and data received November 2011). MutoY , SatoS , WatanabeA , MoriwakiH , SuzukiK , KatoA , et al. Effects of oral branched‐chain amino acid granules on event‐free survival in patients with liver cirrhosis. Clinical Gastroenterology and Hepatology2005;3:705‐13. SatoS , WatanabeA , MutoY , SuzukiK , KatoA , MoriwakiH , et al. Clinical comparison of branched‐chain amino acid (l‐Leucine, l‐Isoleucine, l‐Valine) granules and oral nutrition for hepatic insufficiency in patients with decompensated liver cirrhosis (LIV‐EN study). Hepatology Research2005;31:232‐40. ">Muto 2005</a>; <a href="./references#CD001939-bbs2-0008" title="LesI , DovalE , Garcia‐MartinezR , PlanasM , CardenasG , GomezP , et al. Effects of branched‐chain amino acids supplementation in patients with cirrhosis and a previous episode of hepatic encephalopathy: a randomized study. American Journal of Gastroenterology2011;106:1081‐8. ">Les 2011</a>). We were able to obtain unpublished information about the trial design (<a href="./references#CD001939-sec-0111" title="">Characteristics of included studies</a>) and data that allowed re‐calculation of outcomes based on the individual participant data for four trials (<a href="./references#CD001939-bbs2-0009" title="BianchiGP , MarchesiniG , ZoliM , AbbiatiR , FerrarioE , FabbriA , et al. Oral BCAA supplementation in cirrhosis with chronic encephalopathy: effects on prolactin and estradiol levels. Hepato‐gastroenterology1992;39:443‐6. MarchesiniG , BianchiG , MerliM , AmodioP , PanellaC , LoguercioC , et al. Nutritional supplementation with branched‐chain amino acids in advanced cirrhosis: a double‐blind, randomized trial. Gastroenterology2003;124:1792‐801. MarchesiniG , DioguardiFS , BianchiGP , ZoliM , BellatiG , RoffiL , et al. Long‐term oral branched‐chain amino acid treatment in chronic hepatic encephalopathy. A randomized double‐blind casein controlled trial. The Italian Multicenter Study Group. Journal of Hepatology1990;11:92‐101. ">Marchesini 1990</a>; <a href="./references#CD001939-bbs2-0010" title="MarchesiniG , BianchiG , MerliM , AmodioP , PanellaC , LoguercioC , et al. Nutritional supplementation with branched‐chain amino acids in advanced cirrhosis: a double‐blind, randomized trial. Gastroenterology2003;124:1980‐2. ">Marchesini 2003</a>; <a href="./references#CD001939-bbs2-0012" title="Horie‐TakashiI . Effects of oral branched‐chain amino acid granules on event‐free survival in patients with liver cirrhosis. Clinical Gastroenterology and Hepatology2005; Vol. 3:705‐13 (additional information and data received November 2011). MutoY , SatoS , WatanabeA , MoriwakiH , SuzukiK , KatoA , et al. Effects of oral branched‐chain amino acid granules on event‐free survival in patients with liver cirrhosis. Clinical Gastroenterology and Hepatology2005;3:705‐13. SatoS , WatanabeA , MutoY , SuzukiK , KatoA , MoriwakiH , et al. Clinical comparison of branched‐chain amino acid (l‐Leucine, l‐Isoleucine, l‐Valine) granules and oral nutrition for hepatic insufficiency in patients with decompensated liver cirrhosis (LIV‐EN study). Hepatology Research2005;31:232‐40. ">Muto 2005</a>; <a href="./references#CD001939-bbs2-0008" title="LesI , DovalE , Garcia‐MartinezR , PlanasM , CardenasG , GomezP , et al. Effects of branched‐chain amino acids supplementation in patients with cirrhosis and a previous episode of hepatic encephalopathy: a randomized study. American Journal of Gastroenterology2011;106:1081‐8. ">Les 2011</a>). Four authors of the present review (IL, JC, GM, and HV) were investigators on included randomised clinical trials (<a href="./references#CD001939-bbs2-0009" title="BianchiGP , MarchesiniG , ZoliM , AbbiatiR , FerrarioE , FabbriA , et al. Oral BCAA supplementation in cirrhosis with chronic encephalopathy: effects on prolactin and estradiol levels. Hepato‐gastroenterology1992;39:443‐6. MarchesiniG , BianchiG , MerliM , AmodioP , PanellaC , LoguercioC , et al. Nutritional supplementation with branched‐chain amino acids in advanced cirrhosis: a double‐blind, randomized trial. Gastroenterology2003;124:1792‐801. MarchesiniG , DioguardiFS , BianchiGP , ZoliM , BellatiG , RoffiL , et al. Long‐term oral branched‐chain amino acid treatment in chronic hepatic encephalopathy. A randomized double‐blind casein controlled trial. The Italian Multicenter Study Group. Journal of Hepatology1990;11:92‐101. ">Marchesini 1990</a>; <a href="./references#CD001939-bbs2-0016" title="GluudC , DejgaardA , HardtF , KristensenM , KøhlerO , MelgaardB , et al. Preliminary treatment results with balanced amino acid infusion to patients with hepatic encephalopathy. Scandinavian Journal of Gastroenterology1983;18:19. VilstrupH , GluudC , HardtF , KristensenM , KøhlerO , MelgaardB , et al. Branched chain enriched amino acid versus glucose treatment of hepatic encephalopathy. A double‐blind study of 65 patients with cirrhosis. Hepatology (Baltimore, Md.)1990;10:291‐6. VilstrupH , GluudC , HardtF , KristensenM , MelgaardB , KøhlerO , et al. Branched chain enriched amino acid nutrition does not change the outcome of hepatic coma in patients with cirrhosis of the liver. Journal of Hepatology1985;1:S347. ">Vilstrup 1990</a>; <a href="./references#CD001939-bbs2-0010" title="MarchesiniG , BianchiG , MerliM , AmodioP , PanellaC , LoguercioC , et al. Nutritional supplementation with branched‐chain amino acids in advanced cirrhosis: a double‐blind, randomized trial. Gastroenterology2003;124:1980‐2. ">Marchesini 2003</a>; <a href="./references#CD001939-bbs2-0008" title="LesI , DovalE , Garcia‐MartinezR , PlanasM , CardenasG , GomezP , et al. Effects of branched‐chain amino acids supplementation in patients with cirrhosis and a previous episode of hepatic encephalopathy: a randomized study. American Journal of Gastroenterology2011;106:1081‐8. ">Les 2011</a>). </p> <div class="figure" id="CD001939-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram. BCAA: branched‐chain amino acids." data-id="CD001939-fig-0001" src="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/image_n/nCD001939-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram. BCAA: branched‐chain amino acids.</p> </div> </div> </div> </section> <section id="CD001939-sec-0067"> <h4 class="title">Included studies</h4> <p><b>Participants</b> </p> <p>The trials included 827 participants with hepatic encephalopathy. None used BCAA deficiency in their inclusion or exclusion criteria. Most participants (97%) had cirrhosis. The proportion of men ranged from 47% to 90%, the proportion of people with alcoholic liver disease ranged from 8% to 100%, and the proportion of people with viral hepatitis ranged from 0% to 81%. The mean age ranged from 47 to 64 years. In four trials, 6% to 74% of people had hepatic encephalopathy at baseline (we only included data on the people with hepatic encephalopathy in our analyses) (<a href="./references#CD001939-bbs2-0006" title="HorstD , GraceN , ConnHO , SchiffE , SchenkerS , ViteriA , et al. A double‐blind randomized comparison of dietary protein and an oral branched chain amino acid (BCAA) solution in cirrhotic patients with chronic portal‐systemic encephalopathy (PSE) [IASL abstract]. Hepatology (Baltimore, Md.)1982;2:184. HorstD , GraceND , ConnHO , SchiffE , SchenkerS , ViteriA , et al. Comparison of dietary protein with an oral, branched chain‐enriched amino acid supplement in chronic portal‐systemic encephalopathy: a randomized controlled trial. Hepatology (Baltimore, Md.)1984;4:279‐87. ">Horst 1984</a>; <a href="./references#CD001939-bbs2-0010" title="MarchesiniG , BianchiG , MerliM , AmodioP , PanellaC , LoguercioC , et al. Nutritional supplementation with branched‐chain amino acids in advanced cirrhosis: a double‐blind, randomized trial. Gastroenterology2003;124:1980‐2. ">Marchesini 2003</a>; <a href="./references#CD001939-bbs2-0012" title="Horie‐TakashiI . Effects of oral branched‐chain amino acid granules on event‐free survival in patients with liver cirrhosis. Clinical Gastroenterology and Hepatology2005; Vol. 3:705‐13 (additional information and data received November 2011). MutoY , SatoS , WatanabeA , MoriwakiH , SuzukiK , KatoA , et al. Effects of oral branched‐chain amino acid granules on event‐free survival in patients with liver cirrhosis. Clinical Gastroenterology and Hepatology2005;3:705‐13. SatoS , WatanabeA , MutoY , SuzukiK , KatoA , MoriwakiH , et al. Clinical comparison of branched‐chain amino acid (l‐Leucine, l‐Isoleucine, l‐Valine) granules and oral nutrition for hepatic insufficiency in patients with decompensated liver cirrhosis (LIV‐EN study). Hepatology Research2005;31:232‐40. ">Muto 2005</a>; <a href="./references#CD001939-bbs2-0008" title="LesI , DovalE , Garcia‐MartinezR , PlanasM , CardenasG , GomezP , et al. Effects of branched‐chain amino acids supplementation in patients with cirrhosis and a previous episode of hepatic encephalopathy: a randomized study. American Journal of Gastroenterology2011;106:1081‐8. ">Les 2011</a>). The type of hepatic encephalopathy was minimal in four trials (<a href="./references#CD001939-bbs2-0003" title="EgbertsEH , HamsterW , SchomeerusH , JürgensP . Effect of branched chain amino acids on latent porto‐systemic‐encephalopathy (PSE). JPEN. Journal of Parenteral and Enteral Nutrition1981;5:5. EgbertsEH , SchomeerusH , HamsterW , JürgensP . Effective treatment of latens porto‐systemic encephalopathy with oral branched chain amino acids. In: CapocacciaL , FischerJE , Rossi‐FanelliF editor(s). Hepatic Encephalopathy in Chronic Liver Failure. New York: Plenum Press, 1984:351‐7. EgbertsEH , SchomerusH , HamsterW , JurgensP . Branched chain amino acids in the treatment of latent portosystemic encephalopathy. A double‐blind placebo‐controlled crossover study. Gastroenterology1985;88:887‐95. EgbertsEH , SchomerusH , HamsterW , JürgensP . Branched‐chain amino acids in the treatment of latent porto‐systemic encephalopathy. A placebo‐controlled double‐blind cross‐over study [Verzweigtkettige Aminosäuren bei der behandlung der latenten portosystemischen enzephalopathie. Eine placebokontrollierte doppelblind‐cross‐over‐studie]. Zeitschrift für Ernährungswissenschaft1986;25:9‐28. HamsterW , EgbertsEH , HamsterH . Treatment with branched‐chain amino acids and effect on psycho‐physical capacity functions in latent porto‐systemic encephalopathy [Behandlung mit verzweigtkettigen aminosäuren und ihre auswirkung auf psychophysische leistungsfunktionen bei latenter portosystemischer enzephalopathie]. Arzneimittelforschung1982;32:901‐2. ">Egberts 1985</a>; <a href="./references#CD001939-bbs2-0013" title="PlauthM , EgbertsE‐H , HamsterW , TörökM , MüllerP , BrandO , et al. Long‐term treatment with branched‐chain amino acids (BCA) improves the portosystemic encephalopathy (PSE) in ambulant patients. Results of a double blind, placebo controlled crossover study. Klinische Wochenschrift1992;69:126. PlauthM , EgbertsEH , HamsterW , TörökM , MüllerPH , BrandO , et al. Long‐term treatment of latent portosystemic encephalopathy with branched‐chain amino acids. A double‐blind placebo‐crossover study. Journal of Hepatology1993;17:308‐14. ">Plauth 1993</a>; <a href="./references#CD001939-bbs2-0010" title="MarchesiniG , BianchiG , MerliM , AmodioP , PanellaC , LoguercioC , et al. Nutritional supplementation with branched‐chain amino acids in advanced cirrhosis: a double‐blind, randomized trial. Gastroenterology2003;124:1980‐2. ">Marchesini 2003</a>; <a href="./references#CD001939-bbs2-0008" title="LesI , DovalE , Garcia‐MartinezR , PlanasM , CardenasG , GomezP , et al. Effects of branched‐chain amino acids supplementation in patients with cirrhosis and a previous episode of hepatic encephalopathy: a randomized study. American Journal of Gastroenterology2011;106:1081‐8. ">Les 2011</a>), and overt in the remaining 11 trials (<a href="./references#CD001939-bbs2-0004" title="FiaccadoriF . Branched chain amino acid enriched solutions in the treatment of hepatic encephalopathy: a controlled trial. Italian Journal of Gastroenterology (additional information from author November 2012). FiaccadoriF , GhinelliF , PedrettiG . Branched chain amino acid enriched solutions in the treatment of hepatic encephalopathy: a controlled trial. Italian Journal of Gastroenterology1985;17:5‐10. FiaccadoriF , GhinelliF , PedrettiG , ManciaD . Mental state course and biochemical findings in HE treated by BCAA‐enriched mixtures. In: HolmE , KasperH editor(s). Metabolism and Nutrition in Liver Disease Freiburg 1984: Proceedings of the 41st Falk Symposium. Lancaster: MTP Press, 1985:281‐5. FiaccadoriF , GhinelliF , PedrettiG , PelosiG , SacchiniD , ZeneroliML , et al. Branched chain amino acid enriched solutions in the treatment of hepatic encephalopathy: a controlled trial. In: CapocacciaL , FischerJE , Rossi‐FanelliF editor(s). Hepatic Encephalopathy in Chronic Liver Failure. New York: Plenum Press, 1984:323‐33. FiaccadoriF , GhinelliF , PelosiG , SacchiniD , VaonaG , ZeneroliML , et al. Selective amino acid solutions in hepatic encephalopathy treatment (a preliminary report). La Ricerca in Clinica e in Laboratorio1980;10:411‐22. [MEDLINE: 81102770] ">Fiaccadori 1984</a>; <a href="./references#CD001939-bbs2-0006" title="HorstD , GraceN , ConnHO , SchiffE , SchenkerS , ViteriA , et al. A double‐blind randomized comparison of dietary protein and an oral branched chain amino acid (BCAA) solution in cirrhotic patients with chronic portal‐systemic encephalopathy (PSE) [IASL abstract]. Hepatology (Baltimore, Md.)1982;2:184. HorstD , GraceND , ConnHO , SchiffE , SchenkerS , ViteriA , et al. Comparison of dietary protein with an oral, branched chain‐enriched amino acid supplement in chronic portal‐systemic encephalopathy: a randomized controlled trial. Hepatology (Baltimore, Md.)1984;4:279‐87. ">Horst 1984</a>; <a href="./references#CD001939-bbs2-0001" title="CalveyH , DavisM , WilliamsR . Controlled trial of nutritional supplementation, with and without branched chain amino acid enrichment, in treatment of acute alcoholic hepatitis. Journal of Hepatology1985;1:141‐51. CalveyH , DavisM , WilliamsR . Prospective study of nasogastric feeding via East Grinstead or Viomedex tubes compared with oral dietary supplementation in patients with cirrhosis. Clinical Nutrition1984;3:63‐6. WilliamsR , CalveyH , DavisM . Controlled trial of nutritional supplementation in acute alcoholic hepatitis. In: HolmEKH editor(s). Metabolism and Nutrition in Liver Disease. Lancaster, UK: MTP Press, Ltd, 1985:361‐8. ">Calvey 1985</a>; <a href="./references#CD001939-bbs2-0002" title="CerraFB . Disease‐specific amino acid infusion (F080) in hepatic encephalopathy: a prospective, randomized, double‐blind, controlled trial [personal communication]. Correspondence with authorsSeptember 2002. CerraFB , CheungNK , FischerJE , KaplowitzN , SchiffE‐R , DienstagJL , et al. Disease‐specific amino acid infusion (F080) in hepatic encephalopathy: a prospective, randomized, double‐blind, controlled trial. JPEN. Journal of Parenteral and Enteral Nutrition1985;9:288‐95. CerraFB , CheungNK , FischerJE , KaplowitzN , SchiffER , DienstagJL , et al. A multicenter trial of branched chain enriched amino acid infusion (F080) in hepatic encephalopathy (HE). Hepatology (Baltimore, Md.)1982;2:699. CerraFB , McMillenM , AngelicoR , ClineB , LyonsJ , FaulkenbachL , et al. Cirrhosis, encephalopathy, and improved results with metabolic support. Surgery1983;94:612‐9. ">Cerra 1985</a>; <a href="./references#CD001939-bbs2-0011" title="MichelH , BoriesP , AubinJP , Pomier‐LayrarguesG , BauretP , Bellet‐HermanH . Treatment of acute hepatic encephalopathy in cirrhotics with a branched‐chain amino acids enriched versus a conventional amino acids mixture. A controlled study of 70 patients. Liver1985;5:282‐9. MichelH , Pomier‐LayrarguesG , AubinJP , BoriesP , MirouzeD , Bellet‐HermanH . Treatment of hepatic encephalopathy by infusion of a modified amino acid solution: results of a controlled study in 47 cirrhotic patients. In: CapocacciaL , FischerJE , Rossi‐FanelliF editor(s). Hepatic Encephalopathy in Chronic Liver Failure. New York: Plenum Press, 1984:301‐10. MichelH , Pomier‐LayrarguesG , DuhamelO , LacombeB , CuilleretG , Bellet‐HermannH . Intravenous infusion of ordinary and modified amino‐acid solutions in the management of hepatic encephalopathy (controlled study, 30 patients). Gastroenterology1980;79:1038. Pomier‐LayrarguesG , DuhamelO , LacombeB , CuilleretG , BelletH , MichelH . Intravenous infusion of ordinary and modified amino‐acid solutions in the management of hepatic encephalopathy. Liver1981;1:140. ">Michel 1985</a>; <a href="./references#CD001939-bbs2-0014" title="RiggioO , CangianoC , CascinoA , MerliM , StortoniM , Rossi‐FanelliF , et al. Long term dietary supplement with branched chain amino acids: a new approach in the prevention of hepatic encephalopathy: results of a controlled study in cirrhotics with porto‐caval anastomosis. In: Associazione Italiana per Lo Studio del Fegato. Congress, editor(s). Hepatic Encephalopathy in Chronic Liver Failure. New York: Plenum Press, 1984:183‐92. Rossi‐FanelliF , CangianoC , CapocacciaL , CascinoA , CeciF , MuscaritoliM , et al. Use of branched chain amino acids for treating hepatic encephalopathy: clinical experiences. Gut1986;27:111‐5. Rossi‐FanelliF , CangianoC , CascinoA , MerliM , RiggioO , StortoniM , et al. Branched‐chain amino acids in the treatment of severe hepatic encephalopathy. In: CapocacciaL , FischerJE , Rossi‐FanelliF editor(s). Hepatic Encephalopathy in Chronic Liver Failure. New York: Plenum Press, 1984:335‐44. Rossi‐FanelliF , RiggioO , CangianoC , CascinoA , DeConciliisD , MerliM , et al. Branched‐chain amino acids vs lactulose in the treatment of hepatic coma: a controlled study. Digestive Diseases and Sciences1982;27:929‐35. ">Rossi‐Fanelli 1986</a>; <a href="./references#CD001939-bbs2-0015" title="StraussE , Cartapatti Da SilvaE , LacetCM , CapacciMLL , BernardiniAP . Treatment of hepatic encephalopathy: a randomized clinical trial comparing a branched chain enriched amino acid solution to oral neomycin. Nutritional Support Services1986;6:18‐21. StraussE , SantosWR , DaSilvaEC , LacetCM , CapacciLL , BernardiniAP . A randomized controlled clinical trial for the evaluation of the efficacy of an enriched branched‐chain amino‐acid solution compared to neomycin in hepatic encephalopathy. Hepatology (Baltimore, Md.)1983;3:862. ">Strauss 1986</a>; <a href="./references#CD001939-bbs2-0007" title="HwangSJ , ChanCY , WuJC , LeeSD , HuanYS , TsaiYT , et al. A randomized controlled trial for the evaluation of the efficacy of branched chain amino acid‐enriched amino acid solution in the treatment of patients with hepatic encephalopathy. Chinese Journal of Gastroenterology1988;5:185‐92. ">Hwang 1988</a>; <a href="./references#CD001939-bbs2-0009" title="BianchiGP , MarchesiniG , ZoliM , AbbiatiR , FerrarioE , FabbriA , et al. Oral BCAA supplementation in cirrhosis with chronic encephalopathy: effects on prolactin and estradiol levels. Hepato‐gastroenterology1992;39:443‐6. MarchesiniG , BianchiG , MerliM , AmodioP , PanellaC , LoguercioC , et al. Nutritional supplementation with branched‐chain amino acids in advanced cirrhosis: a double‐blind, randomized trial. Gastroenterology2003;124:1792‐801. MarchesiniG , DioguardiFS , BianchiGP , ZoliM , BellatiG , RoffiL , et al. Long‐term oral branched‐chain amino acid treatment in chronic hepatic encephalopathy. A randomized double‐blind casein controlled trial. The Italian Multicenter Study Group. Journal of Hepatology1990;11:92‐101. ">Marchesini 1990</a>; <a href="./references#CD001939-bbs2-0016" title="GluudC , DejgaardA , HardtF , KristensenM , KøhlerO , MelgaardB , et al. Preliminary treatment results with balanced amino acid infusion to patients with hepatic encephalopathy. Scandinavian Journal of Gastroenterology1983;18:19. VilstrupH , GluudC , HardtF , KristensenM , KøhlerO , MelgaardB , et al. Branched chain enriched amino acid versus glucose treatment of hepatic encephalopathy. A double‐blind study of 65 patients with cirrhosis. Hepatology (Baltimore, Md.)1990;10:291‐6. VilstrupH , GluudC , HardtF , KristensenM , MelgaardB , KøhlerO , et al. Branched chain enriched amino acid nutrition does not change the outcome of hepatic coma in patients with cirrhosis of the liver. Journal of Hepatology1985;1:S347. ">Vilstrup 1990</a>; <a href="./references#CD001939-bbs2-0012" title="Horie‐TakashiI . Effects of oral branched‐chain amino acid granules on event‐free survival in patients with liver cirrhosis. Clinical Gastroenterology and Hepatology2005; Vol. 3:705‐13 (additional information and data received November 2011). MutoY , SatoS , WatanabeA , MoriwakiH , SuzukiK , KatoA , et al. Effects of oral branched‐chain amino acid granules on event‐free survival in patients with liver cirrhosis. Clinical Gastroenterology and Hepatology2005;3:705‐13. SatoS , WatanabeA , MutoY , SuzukiK , KatoA , MoriwakiH , et al. Clinical comparison of branched‐chain amino acid (l‐Leucine, l‐Isoleucine, l‐Valine) granules and oral nutrition for hepatic insufficiency in patients with decompensated liver cirrhosis (LIV‐EN study). Hepatology Research2005;31:232‐40. ">Muto 2005</a>). </p> <p><b>Interventions</b> </p> <p>In one trial, most participants received oral BCAA and people who deteriorated received intravenous BCAA (<a href="./references#CD001939-bbs2-0001" title="CalveyH , DavisM , WilliamsR . Controlled trial of nutritional supplementation, with and without branched chain amino acid enrichment, in treatment of acute alcoholic hepatitis. Journal of Hepatology1985;1:141‐51. CalveyH , DavisM , WilliamsR . Prospective study of nasogastric feeding via East Grinstead or Viomedex tubes compared with oral dietary supplementation in patients with cirrhosis. Clinical Nutrition1984;3:63‐6. WilliamsR , CalveyH , DavisM . Controlled trial of nutritional supplementation in acute alcoholic hepatitis. In: HolmEKH editor(s). Metabolism and Nutrition in Liver Disease. Lancaster, UK: MTP Press, Ltd, 1985:361‐8. ">Calvey 1985</a>). Seven trials assessed oral BCAA (<a href="./references#CD001939-bbs2-0006" title="HorstD , GraceN , ConnHO , SchiffE , SchenkerS , ViteriA , et al. A double‐blind randomized comparison of dietary protein and an oral branched chain amino acid (BCAA) solution in cirrhotic patients with chronic portal‐systemic encephalopathy (PSE) [IASL abstract]. Hepatology (Baltimore, Md.)1982;2:184. HorstD , GraceND , ConnHO , SchiffE , SchenkerS , ViteriA , et al. Comparison of dietary protein with an oral, branched chain‐enriched amino acid supplement in chronic portal‐systemic encephalopathy: a randomized controlled trial. Hepatology (Baltimore, Md.)1984;4:279‐87. ">Horst 1984</a>; <a href="./references#CD001939-bbs2-0003" title="EgbertsEH , HamsterW , SchomeerusH , JürgensP . Effect of branched chain amino acids on latent porto‐systemic‐encephalopathy (PSE). JPEN. Journal of Parenteral and Enteral Nutrition1981;5:5. EgbertsEH , SchomeerusH , HamsterW , JürgensP . Effective treatment of latens porto‐systemic encephalopathy with oral branched chain amino acids. In: CapocacciaL , FischerJE , Rossi‐FanelliF editor(s). Hepatic Encephalopathy in Chronic Liver Failure. New York: Plenum Press, 1984:351‐7. EgbertsEH , SchomerusH , HamsterW , JurgensP . Branched chain amino acids in the treatment of latent portosystemic encephalopathy. A double‐blind placebo‐controlled crossover study. Gastroenterology1985;88:887‐95. EgbertsEH , SchomerusH , HamsterW , JürgensP . Branched‐chain amino acids in the treatment of latent porto‐systemic encephalopathy. A placebo‐controlled double‐blind cross‐over study [Verzweigtkettige Aminosäuren bei der behandlung der latenten portosystemischen enzephalopathie. Eine placebokontrollierte doppelblind‐cross‐over‐studie]. Zeitschrift für Ernährungswissenschaft1986;25:9‐28. HamsterW , EgbertsEH , HamsterH . Treatment with branched‐chain amino acids and effect on psycho‐physical capacity functions in latent porto‐systemic encephalopathy [Behandlung mit verzweigtkettigen aminosäuren und ihre auswirkung auf psychophysische leistungsfunktionen bei latenter portosystemischer enzephalopathie]. Arzneimittelforschung1982;32:901‐2. ">Egberts 1985</a>; <a href="./references#CD001939-bbs2-0009" title="BianchiGP , MarchesiniG , ZoliM , AbbiatiR , FerrarioE , FabbriA , et al. Oral BCAA supplementation in cirrhosis with chronic encephalopathy: effects on prolactin and estradiol levels. Hepato‐gastroenterology1992;39:443‐6. MarchesiniG , BianchiG , MerliM , AmodioP , PanellaC , LoguercioC , et al. Nutritional supplementation with branched‐chain amino acids in advanced cirrhosis: a double‐blind, randomized trial. Gastroenterology2003;124:1792‐801. MarchesiniG , DioguardiFS , BianchiGP , ZoliM , BellatiG , RoffiL , et al. Long‐term oral branched‐chain amino acid treatment in chronic hepatic encephalopathy. A randomized double‐blind casein controlled trial. The Italian Multicenter Study Group. Journal of Hepatology1990;11:92‐101. ">Marchesini 1990</a>; <a href="./references#CD001939-bbs2-0005" title="HayashiS , AoyagiY , FujiwaraK , OkaH , OdaT . A randomized controlled trial of branched‐chain amino acid (BCAA)‐enriched elemental diet (ED‐H) for hepatic encephalopathy. Journal of Gastroenterology and Hepatology1991;6:191. ">Hayashi 1991</a>; <a href="./references#CD001939-bbs2-0013" title="PlauthM , EgbertsE‐H , HamsterW , TörökM , MüllerP , BrandO , et al. Long‐term treatment with branched‐chain amino acids (BCA) improves the portosystemic encephalopathy (PSE) in ambulant patients. Results of a double blind, placebo controlled crossover study. Klinische Wochenschrift1992;69:126. PlauthM , EgbertsEH , HamsterW , TörökM , MüllerPH , BrandO , et al. Long‐term treatment of latent portosystemic encephalopathy with branched‐chain amino acids. A double‐blind placebo‐crossover study. Journal of Hepatology1993;17:308‐14. ">Plauth 1993</a>; <a href="./references#CD001939-bbs2-0010" title="MarchesiniG , BianchiG , MerliM , AmodioP , PanellaC , LoguercioC , et al. Nutritional supplementation with branched‐chain amino acids in advanced cirrhosis: a double‐blind, randomized trial. Gastroenterology2003;124:1980‐2. ">Marchesini 2003</a>; <a href="./references#CD001939-bbs2-0012" title="Horie‐TakashiI . Effects of oral branched‐chain amino acid granules on event‐free survival in patients with liver cirrhosis. Clinical Gastroenterology and Hepatology2005; Vol. 3:705‐13 (additional information and data received November 2011). MutoY , SatoS , WatanabeA , MoriwakiH , SuzukiK , KatoA , et al. Effects of oral branched‐chain amino acid granules on event‐free survival in patients with liver cirrhosis. Clinical Gastroenterology and Hepatology2005;3:705‐13. SatoS , WatanabeA , MutoY , SuzukiK , KatoA , MoriwakiH , et al. Clinical comparison of branched‐chain amino acid (l‐Leucine, l‐Isoleucine, l‐Valine) granules and oral nutrition for hepatic insufficiency in patients with decompensated liver cirrhosis (LIV‐EN study). Hepatology Research2005;31:232‐40. ">Muto 2005</a>; <a href="./references#CD001939-bbs2-0008" title="LesI , DovalE , Garcia‐MartinezR , PlanasM , CardenasG , GomezP , et al. Effects of branched‐chain amino acids supplementation in patients with cirrhosis and a previous episode of hepatic encephalopathy: a randomized study. American Journal of Gastroenterology2011;106:1081‐8. ">Les 2011</a>), or intravenous BCAA (<a href="./references#CD001939-bbs2-0004" title="FiaccadoriF . Branched chain amino acid enriched solutions in the treatment of hepatic encephalopathy: a controlled trial. Italian Journal of Gastroenterology (additional information from author November 2012). FiaccadoriF , GhinelliF , PedrettiG . Branched chain amino acid enriched solutions in the treatment of hepatic encephalopathy: a controlled trial. Italian Journal of Gastroenterology1985;17:5‐10. FiaccadoriF , GhinelliF , PedrettiG , ManciaD . Mental state course and biochemical findings in HE treated by BCAA‐enriched mixtures. In: HolmE , KasperH editor(s). Metabolism and Nutrition in Liver Disease Freiburg 1984: Proceedings of the 41st Falk Symposium. Lancaster: MTP Press, 1985:281‐5. FiaccadoriF , GhinelliF , PedrettiG , PelosiG , SacchiniD , ZeneroliML , et al. Branched chain amino acid enriched solutions in the treatment of hepatic encephalopathy: a controlled trial. In: CapocacciaL , FischerJE , Rossi‐FanelliF editor(s). Hepatic Encephalopathy in Chronic Liver Failure. New York: Plenum Press, 1984:323‐33. FiaccadoriF , GhinelliF , PelosiG , SacchiniD , VaonaG , ZeneroliML , et al. Selective amino acid solutions in hepatic encephalopathy treatment (a preliminary report). La Ricerca in Clinica e in Laboratorio1980;10:411‐22. [MEDLINE: 81102770] ">Fiaccadori 1984</a>; <a href="./references#CD001939-bbs2-0002" title="CerraFB . Disease‐specific amino acid infusion (F080) in hepatic encephalopathy: a prospective, randomized, double‐blind, controlled trial [personal communication]. Correspondence with authorsSeptember 2002. CerraFB , CheungNK , FischerJE , KaplowitzN , SchiffE‐R , DienstagJL , et al. Disease‐specific amino acid infusion (F080) in hepatic encephalopathy: a prospective, randomized, double‐blind, controlled trial. JPEN. Journal of Parenteral and Enteral Nutrition1985;9:288‐95. CerraFB , CheungNK , FischerJE , KaplowitzN , SchiffER , DienstagJL , et al. A multicenter trial of branched chain enriched amino acid infusion (F080) in hepatic encephalopathy (HE). Hepatology (Baltimore, Md.)1982;2:699. CerraFB , McMillenM , AngelicoR , ClineB , LyonsJ , FaulkenbachL , et al. Cirrhosis, encephalopathy, and improved results with metabolic support. Surgery1983;94:612‐9. ">Cerra 1985</a>; <a href="./references#CD001939-bbs2-0011" title="MichelH , BoriesP , AubinJP , Pomier‐LayrarguesG , BauretP , Bellet‐HermanH . Treatment of acute hepatic encephalopathy in cirrhotics with a branched‐chain amino acids enriched versus a conventional amino acids mixture. A controlled study of 70 patients. Liver1985;5:282‐9. MichelH , Pomier‐LayrarguesG , AubinJP , BoriesP , MirouzeD , Bellet‐HermanH . Treatment of hepatic encephalopathy by infusion of a modified amino acid solution: results of a controlled study in 47 cirrhotic patients. In: CapocacciaL , FischerJE , Rossi‐FanelliF editor(s). Hepatic Encephalopathy in Chronic Liver Failure. New York: Plenum Press, 1984:301‐10. MichelH , Pomier‐LayrarguesG , DuhamelO , LacombeB , CuilleretG , Bellet‐HermannH . Intravenous infusion of ordinary and modified amino‐acid solutions in the management of hepatic encephalopathy (controlled study, 30 patients). Gastroenterology1980;79:1038. Pomier‐LayrarguesG , DuhamelO , LacombeB , CuilleretG , BelletH , MichelH . Intravenous infusion of ordinary and modified amino‐acid solutions in the management of hepatic encephalopathy. Liver1981;1:140. ">Michel 1985</a>; <a href="./references#CD001939-bbs2-0014" title="RiggioO , CangianoC , CascinoA , MerliM , StortoniM , Rossi‐FanelliF , et al. Long term dietary supplement with branched chain amino acids: a new approach in the prevention of hepatic encephalopathy: results of a controlled study in cirrhotics with porto‐caval anastomosis. In: Associazione Italiana per Lo Studio del Fegato. Congress, editor(s). Hepatic Encephalopathy in Chronic Liver Failure. New York: Plenum Press, 1984:183‐92. Rossi‐FanelliF , CangianoC , CapocacciaL , CascinoA , CeciF , MuscaritoliM , et al. Use of branched chain amino acids for treating hepatic encephalopathy: clinical experiences. Gut1986;27:111‐5. Rossi‐FanelliF , CangianoC , CascinoA , MerliM , RiggioO , StortoniM , et al. Branched‐chain amino acids in the treatment of severe hepatic encephalopathy. In: CapocacciaL , FischerJE , Rossi‐FanelliF editor(s). Hepatic Encephalopathy in Chronic Liver Failure. New York: Plenum Press, 1984:335‐44. Rossi‐FanelliF , RiggioO , CangianoC , CascinoA , DeConciliisD , MerliM , et al. Branched‐chain amino acids vs lactulose in the treatment of hepatic coma: a controlled study. Digestive Diseases and Sciences1982;27:929‐35. ">Rossi‐Fanelli 1986</a>; <a href="./references#CD001939-bbs2-0015" title="StraussE , Cartapatti Da SilvaE , LacetCM , CapacciMLL , BernardiniAP . Treatment of hepatic encephalopathy: a randomized clinical trial comparing a branched chain enriched amino acid solution to oral neomycin. Nutritional Support Services1986;6:18‐21. StraussE , SantosWR , DaSilvaEC , LacetCM , CapacciLL , BernardiniAP . A randomized controlled clinical trial for the evaluation of the efficacy of an enriched branched‐chain amino‐acid solution compared to neomycin in hepatic encephalopathy. Hepatology (Baltimore, Md.)1983;3:862. ">Strauss 1986</a>; <a href="./references#CD001939-bbs2-0007" title="HwangSJ , ChanCY , WuJC , LeeSD , HuanYS , TsaiYT , et al. A randomized controlled trial for the evaluation of the efficacy of branched chain amino acid‐enriched amino acid solution in the treatment of patients with hepatic encephalopathy. Chinese Journal of Gastroenterology1988;5:185‐92. ">Hwang 1988</a>; <a href="./references#CD001939-bbs2-0016" title="GluudC , DejgaardA , HardtF , KristensenM , KøhlerO , MelgaardB , et al. Preliminary treatment results with balanced amino acid infusion to patients with hepatic encephalopathy. Scandinavian Journal of Gastroenterology1983;18:19. VilstrupH , GluudC , HardtF , KristensenM , KøhlerO , MelgaardB , et al. Branched chain enriched amino acid versus glucose treatment of hepatic encephalopathy. A double‐blind study of 65 patients with cirrhosis. Hepatology (Baltimore, Md.)1990;10:291‐6. VilstrupH , GluudC , HardtF , KristensenM , MelgaardB , KøhlerO , et al. Branched chain enriched amino acid nutrition does not change the outcome of hepatic coma in patients with cirrhosis of the liver. Journal of Hepatology1985;1:S347. ">Vilstrup 1990</a>). Trials studying intravenous BCAA treated people in hospital and the remainder on an outpatient basis. The dose of BCAA ranged from 11 g/day to 57 g/day (median 20 g/day) and treatment duration from one to 104 weeks (median four weeks). </p> <p><b>Comparisons</b> </p> <p>The control groups received placebo/no intervention in two trials (<a href="./references#CD001939-bbs2-0007" title="HwangSJ , ChanCY , WuJC , LeeSD , HuanYS , TsaiYT , et al. A randomized controlled trial for the evaluation of the efficacy of branched chain amino acid‐enriched amino acid solution in the treatment of patients with hepatic encephalopathy. Chinese Journal of Gastroenterology1988;5:185‐92. ">Hwang 1988</a>; <a href="./references#CD001939-bbs2-0013" title="PlauthM , EgbertsE‐H , HamsterW , TörökM , MüllerP , BrandO , et al. Long‐term treatment with branched‐chain amino acids (BCA) improves the portosystemic encephalopathy (PSE) in ambulant patients. Results of a double blind, placebo controlled crossover study. Klinische Wochenschrift1992;69:126. PlauthM , EgbertsEH , HamsterW , TörökM , MüllerPH , BrandO , et al. Long‐term treatment of latent portosystemic encephalopathy with branched‐chain amino acids. A double‐blind placebo‐crossover study. Journal of Hepatology1993;17:308‐14. ">Plauth 1993</a>). The type of BCAA in these two trials was oral (<a href="./references#CD001939-bbs2-0013" title="PlauthM , EgbertsE‐H , HamsterW , TörökM , MüllerP , BrandO , et al. Long‐term treatment with branched‐chain amino acids (BCA) improves the portosystemic encephalopathy (PSE) in ambulant patients. Results of a double blind, placebo controlled crossover study. Klinische Wochenschrift1992;69:126. PlauthM , EgbertsEH , HamsterW , TörökM , MüllerPH , BrandO , et al. Long‐term treatment of latent portosystemic encephalopathy with branched‐chain amino acids. A double‐blind placebo‐crossover study. Journal of Hepatology1993;17:308‐14. ">Plauth 1993</a>), or intravenous (<a href="./references#CD001939-bbs2-0007" title="HwangSJ , ChanCY , WuJC , LeeSD , HuanYS , TsaiYT , et al. A randomized controlled trial for the evaluation of the efficacy of branched chain amino acid‐enriched amino acid solution in the treatment of patients with hepatic encephalopathy. Chinese Journal of Gastroenterology1988;5:185‐92. ">Hwang 1988</a>). In 10 trials, participants were allocated to BCAA versus diets (<a href="./references#CD001939-bbs2-0006" title="HorstD , GraceN , ConnHO , SchiffE , SchenkerS , ViteriA , et al. A double‐blind randomized comparison of dietary protein and an oral branched chain amino acid (BCAA) solution in cirrhotic patients with chronic portal‐systemic encephalopathy (PSE) [IASL abstract]. Hepatology (Baltimore, Md.)1982;2:184. HorstD , GraceND , ConnHO , SchiffE , SchenkerS , ViteriA , et al. Comparison of dietary protein with an oral, branched chain‐enriched amino acid supplement in chronic portal‐systemic encephalopathy: a randomized controlled trial. Hepatology (Baltimore, Md.)1984;4:279‐87. ">Horst 1984</a>; <a href="./references#CD001939-bbs2-0001" title="CalveyH , DavisM , WilliamsR . Controlled trial of nutritional supplementation, with and without branched chain amino acid enrichment, in treatment of acute alcoholic hepatitis. Journal of Hepatology1985;1:141‐51. CalveyH , DavisM , WilliamsR . Prospective study of nasogastric feeding via East Grinstead or Viomedex tubes compared with oral dietary supplementation in patients with cirrhosis. Clinical Nutrition1984;3:63‐6. WilliamsR , CalveyH , DavisM . Controlled trial of nutritional supplementation in acute alcoholic hepatitis. In: HolmEKH editor(s). Metabolism and Nutrition in Liver Disease. Lancaster, UK: MTP Press, Ltd, 1985:361‐8. ">Calvey 1985</a>; <a href="./references#CD001939-bbs2-0003" title="EgbertsEH , HamsterW , SchomeerusH , JürgensP . Effect of branched chain amino acids on latent porto‐systemic‐encephalopathy (PSE). JPEN. Journal of Parenteral and Enteral Nutrition1981;5:5. EgbertsEH , SchomeerusH , HamsterW , JürgensP . Effective treatment of latens porto‐systemic encephalopathy with oral branched chain amino acids. In: CapocacciaL , FischerJE , Rossi‐FanelliF editor(s). Hepatic Encephalopathy in Chronic Liver Failure. New York: Plenum Press, 1984:351‐7. EgbertsEH , SchomerusH , HamsterW , JurgensP . Branched chain amino acids in the treatment of latent portosystemic encephalopathy. A double‐blind placebo‐controlled crossover study. Gastroenterology1985;88:887‐95. EgbertsEH , SchomerusH , HamsterW , JürgensP . Branched‐chain amino acids in the treatment of latent porto‐systemic encephalopathy. A placebo‐controlled double‐blind cross‐over study [Verzweigtkettige Aminosäuren bei der behandlung der latenten portosystemischen enzephalopathie. Eine placebokontrollierte doppelblind‐cross‐over‐studie]. Zeitschrift für Ernährungswissenschaft1986;25:9‐28. HamsterW , EgbertsEH , HamsterH . Treatment with branched‐chain amino acids and effect on psycho‐physical capacity functions in latent porto‐systemic encephalopathy [Behandlung mit verzweigtkettigen aminosäuren und ihre auswirkung auf psychophysische leistungsfunktionen bei latenter portosystemischer enzephalopathie]. Arzneimittelforschung1982;32:901‐2. ">Egberts 1985</a>; <a href="./references#CD001939-bbs2-0011" title="MichelH , BoriesP , AubinJP , Pomier‐LayrarguesG , BauretP , Bellet‐HermanH . Treatment of acute hepatic encephalopathy in cirrhotics with a branched‐chain amino acids enriched versus a conventional amino acids mixture. A controlled study of 70 patients. Liver1985;5:282‐9. MichelH , Pomier‐LayrarguesG , AubinJP , BoriesP , MirouzeD , Bellet‐HermanH . Treatment of hepatic encephalopathy by infusion of a modified amino acid solution: results of a controlled study in 47 cirrhotic patients. In: CapocacciaL , FischerJE , Rossi‐FanelliF editor(s). Hepatic Encephalopathy in Chronic Liver Failure. New York: Plenum Press, 1984:301‐10. MichelH , Pomier‐LayrarguesG , DuhamelO , LacombeB , CuilleretG , Bellet‐HermannH . Intravenous infusion of ordinary and modified amino‐acid solutions in the management of hepatic encephalopathy (controlled study, 30 patients). Gastroenterology1980;79:1038. Pomier‐LayrarguesG , DuhamelO , LacombeB , CuilleretG , BelletH , MichelH . Intravenous infusion of ordinary and modified amino‐acid solutions in the management of hepatic encephalopathy. Liver1981;1:140. ">Michel 1985</a>; <a href="./references#CD001939-bbs2-0009" title="BianchiGP , MarchesiniG , ZoliM , AbbiatiR , FerrarioE , FabbriA , et al. Oral BCAA supplementation in cirrhosis with chronic encephalopathy: effects on prolactin and estradiol levels. Hepato‐gastroenterology1992;39:443‐6. MarchesiniG , BianchiG , MerliM , AmodioP , PanellaC , LoguercioC , et al. Nutritional supplementation with branched‐chain amino acids in advanced cirrhosis: a double‐blind, randomized trial. Gastroenterology2003;124:1792‐801. MarchesiniG , DioguardiFS , BianchiGP , ZoliM , BellatiG , RoffiL , et al. Long‐term oral branched‐chain amino acid treatment in chronic hepatic encephalopathy. A randomized double‐blind casein controlled trial. The Italian Multicenter Study Group. Journal of Hepatology1990;11:92‐101. ">Marchesini 1990</a>; <a href="./references#CD001939-bbs2-0016" title="GluudC , DejgaardA , HardtF , KristensenM , KøhlerO , MelgaardB , et al. Preliminary treatment results with balanced amino acid infusion to patients with hepatic encephalopathy. Scandinavian Journal of Gastroenterology1983;18:19. VilstrupH , GluudC , HardtF , KristensenM , KøhlerO , MelgaardB , et al. Branched chain enriched amino acid versus glucose treatment of hepatic encephalopathy. A double‐blind study of 65 patients with cirrhosis. Hepatology (Baltimore, Md.)1990;10:291‐6. VilstrupH , GluudC , HardtF , KristensenM , MelgaardB , KøhlerO , et al. Branched chain enriched amino acid nutrition does not change the outcome of hepatic coma in patients with cirrhosis of the liver. Journal of Hepatology1985;1:S347. ">Vilstrup 1990</a>; <a href="./references#CD001939-bbs2-0005" title="HayashiS , AoyagiY , FujiwaraK , OkaH , OdaT . A randomized controlled trial of branched‐chain amino acid (BCAA)‐enriched elemental diet (ED‐H) for hepatic encephalopathy. Journal of Gastroenterology and Hepatology1991;6:191. ">Hayashi 1991</a>; <a href="./references#CD001939-bbs2-0010" title="MarchesiniG , BianchiG , MerliM , AmodioP , PanellaC , LoguercioC , et al. Nutritional supplementation with branched‐chain amino acids in advanced cirrhosis: a double‐blind, randomized trial. Gastroenterology2003;124:1980‐2. ">Marchesini 2003</a>; <a href="./references#CD001939-bbs2-0012" title="Horie‐TakashiI . Effects of oral branched‐chain amino acid granules on event‐free survival in patients with liver cirrhosis. Clinical Gastroenterology and Hepatology2005; Vol. 3:705‐13 (additional information and data received November 2011). MutoY , SatoS , WatanabeA , MoriwakiH , SuzukiK , KatoA , et al. Effects of oral branched‐chain amino acid granules on event‐free survival in patients with liver cirrhosis. Clinical Gastroenterology and Hepatology2005;3:705‐13. SatoS , WatanabeA , MutoY , SuzukiK , KatoA , MoriwakiH , et al. Clinical comparison of branched‐chain amino acid (l‐Leucine, l‐Isoleucine, l‐Valine) granules and oral nutrition for hepatic insufficiency in patients with decompensated liver cirrhosis (LIV‐EN study). Hepatology Research2005;31:232‐40. ">Muto 2005</a>; <a href="./references#CD001939-bbs2-0008" title="LesI , DovalE , Garcia‐MartinezR , PlanasM , CardenasG , GomezP , et al. Effects of branched‐chain amino acids supplementation in patients with cirrhosis and a previous episode of hepatic encephalopathy: a randomized study. American Journal of Gastroenterology2011;106:1081‐8. ">Les 2011</a>). The experimental intervention in these trials was oral BCAA (<a href="./references#CD001939-bbs2-0006" title="HorstD , GraceN , ConnHO , SchiffE , SchenkerS , ViteriA , et al. A double‐blind randomized comparison of dietary protein and an oral branched chain amino acid (BCAA) solution in cirrhotic patients with chronic portal‐systemic encephalopathy (PSE) [IASL abstract]. Hepatology (Baltimore, Md.)1982;2:184. HorstD , GraceND , ConnHO , SchiffE , SchenkerS , ViteriA , et al. Comparison of dietary protein with an oral, branched chain‐enriched amino acid supplement in chronic portal‐systemic encephalopathy: a randomized controlled trial. Hepatology (Baltimore, Md.)1984;4:279‐87. ">Horst 1984</a>; <a href="./references#CD001939-bbs2-0001" title="CalveyH , DavisM , WilliamsR . Controlled trial of nutritional supplementation, with and without branched chain amino acid enrichment, in treatment of acute alcoholic hepatitis. Journal of Hepatology1985;1:141‐51. CalveyH , DavisM , WilliamsR . Prospective study of nasogastric feeding via East Grinstead or Viomedex tubes compared with oral dietary supplementation in patients with cirrhosis. Clinical Nutrition1984;3:63‐6. WilliamsR , CalveyH , DavisM . Controlled trial of nutritional supplementation in acute alcoholic hepatitis. In: HolmEKH editor(s). Metabolism and Nutrition in Liver Disease. Lancaster, UK: MTP Press, Ltd, 1985:361‐8. ">Calvey 1985</a>; <a href="./references#CD001939-bbs2-0003" title="EgbertsEH , HamsterW , SchomeerusH , JürgensP . Effect of branched chain amino acids on latent porto‐systemic‐encephalopathy (PSE). JPEN. Journal of Parenteral and Enteral Nutrition1981;5:5. EgbertsEH , SchomeerusH , HamsterW , JürgensP . Effective treatment of latens porto‐systemic encephalopathy with oral branched chain amino acids. In: CapocacciaL , FischerJE , Rossi‐FanelliF editor(s). Hepatic Encephalopathy in Chronic Liver Failure. New York: Plenum Press, 1984:351‐7. EgbertsEH , SchomerusH , HamsterW , JurgensP . Branched chain amino acids in the treatment of latent portosystemic encephalopathy. A double‐blind placebo‐controlled crossover study. Gastroenterology1985;88:887‐95. EgbertsEH , SchomerusH , HamsterW , JürgensP . Branched‐chain amino acids in the treatment of latent porto‐systemic encephalopathy. A placebo‐controlled double‐blind cross‐over study [Verzweigtkettige Aminosäuren bei der behandlung der latenten portosystemischen enzephalopathie. Eine placebokontrollierte doppelblind‐cross‐over‐studie]. Zeitschrift für Ernährungswissenschaft1986;25:9‐28. HamsterW , EgbertsEH , HamsterH . Treatment with branched‐chain amino acids and effect on psycho‐physical capacity functions in latent porto‐systemic encephalopathy [Behandlung mit verzweigtkettigen aminosäuren und ihre auswirkung auf psychophysische leistungsfunktionen bei latenter portosystemischer enzephalopathie]. Arzneimittelforschung1982;32:901‐2. ">Egberts 1985</a>; <a href="./references#CD001939-bbs2-0009" title="BianchiGP , MarchesiniG , ZoliM , AbbiatiR , FerrarioE , FabbriA , et al. Oral BCAA supplementation in cirrhosis with chronic encephalopathy: effects on prolactin and estradiol levels. Hepato‐gastroenterology1992;39:443‐6. MarchesiniG , BianchiG , MerliM , AmodioP , PanellaC , LoguercioC , et al. Nutritional supplementation with branched‐chain amino acids in advanced cirrhosis: a double‐blind, randomized trial. Gastroenterology2003;124:1792‐801. MarchesiniG , DioguardiFS , BianchiGP , ZoliM , BellatiG , RoffiL , et al. Long‐term oral branched‐chain amino acid treatment in chronic hepatic encephalopathy. A randomized double‐blind casein controlled trial. The Italian Multicenter Study Group. Journal of Hepatology1990;11:92‐101. ">Marchesini 1990</a>; <a href="./references#CD001939-bbs2-0005" title="HayashiS , AoyagiY , FujiwaraK , OkaH , OdaT . A randomized controlled trial of branched‐chain amino acid (BCAA)‐enriched elemental diet (ED‐H) for hepatic encephalopathy. Journal of Gastroenterology and Hepatology1991;6:191. ">Hayashi 1991</a>; <a href="./references#CD001939-bbs2-0010" title="MarchesiniG , BianchiG , MerliM , AmodioP , PanellaC , LoguercioC , et al. Nutritional supplementation with branched‐chain amino acids in advanced cirrhosis: a double‐blind, randomized trial. Gastroenterology2003;124:1980‐2. ">Marchesini 2003</a>; <a href="./references#CD001939-bbs2-0012" title="Horie‐TakashiI . Effects of oral branched‐chain amino acid granules on event‐free survival in patients with liver cirrhosis. Clinical Gastroenterology and Hepatology2005; Vol. 3:705‐13 (additional information and data received November 2011). MutoY , SatoS , WatanabeA , MoriwakiH , SuzukiK , KatoA , et al. Effects of oral branched‐chain amino acid granules on event‐free survival in patients with liver cirrhosis. Clinical Gastroenterology and Hepatology2005;3:705‐13. SatoS , WatanabeA , MutoY , SuzukiK , KatoA , MoriwakiH , et al. Clinical comparison of branched‐chain amino acid (l‐Leucine, l‐Isoleucine, l‐Valine) granules and oral nutrition for hepatic insufficiency in patients with decompensated liver cirrhosis (LIV‐EN study). Hepatology Research2005;31:232‐40. ">Muto 2005</a>; <a href="./references#CD001939-bbs2-0008" title="LesI , DovalE , Garcia‐MartinezR , PlanasM , CardenasG , GomezP , et al. Effects of branched‐chain amino acids supplementation in patients with cirrhosis and a previous episode of hepatic encephalopathy: a randomized study. American Journal of Gastroenterology2011;106:1081‐8. ">Les 2011</a>), or intravenous BCAA (<a href="./references#CD001939-bbs2-0011" title="MichelH , BoriesP , AubinJP , Pomier‐LayrarguesG , BauretP , Bellet‐HermanH . Treatment of acute hepatic encephalopathy in cirrhotics with a branched‐chain amino acids enriched versus a conventional amino acids mixture. A controlled study of 70 patients. Liver1985;5:282‐9. MichelH , Pomier‐LayrarguesG , AubinJP , BoriesP , MirouzeD , Bellet‐HermanH . Treatment of hepatic encephalopathy by infusion of a modified amino acid solution: results of a controlled study in 47 cirrhotic patients. In: CapocacciaL , FischerJE , Rossi‐FanelliF editor(s). Hepatic Encephalopathy in Chronic Liver Failure. New York: Plenum Press, 1984:301‐10. MichelH , Pomier‐LayrarguesG , DuhamelO , LacombeB , CuilleretG , Bellet‐HermannH . Intravenous infusion of ordinary and modified amino‐acid solutions in the management of hepatic encephalopathy (controlled study, 30 patients). Gastroenterology1980;79:1038. Pomier‐LayrarguesG , DuhamelO , LacombeB , CuilleretG , BelletH , MichelH . Intravenous infusion of ordinary and modified amino‐acid solutions in the management of hepatic encephalopathy. Liver1981;1:140. ">Michel 1985</a>; <a href="./references#CD001939-bbs2-0016" title="GluudC , DejgaardA , HardtF , KristensenM , KøhlerO , MelgaardB , et al. Preliminary treatment results with balanced amino acid infusion to patients with hepatic encephalopathy. Scandinavian Journal of Gastroenterology1983;18:19. VilstrupH , GluudC , HardtF , KristensenM , KøhlerO , MelgaardB , et al. Branched chain enriched amino acid versus glucose treatment of hepatic encephalopathy. A double‐blind study of 65 patients with cirrhosis. Hepatology (Baltimore, Md.)1990;10:291‐6. VilstrupH , GluudC , HardtF , KristensenM , MelgaardB , KøhlerO , et al. Branched chain enriched amino acid nutrition does not change the outcome of hepatic coma in patients with cirrhosis of the liver. Journal of Hepatology1985;1:S347. ">Vilstrup 1990</a>). Four trials compared intravenous BCAA versus lactulose (<a href="./references#CD001939-bbs2-0004" title="FiaccadoriF . Branched chain amino acid enriched solutions in the treatment of hepatic encephalopathy: a controlled trial. Italian Journal of Gastroenterology (additional information from author November 2012). FiaccadoriF , GhinelliF , PedrettiG . Branched chain amino acid enriched solutions in the treatment of hepatic encephalopathy: a controlled trial. Italian Journal of Gastroenterology1985;17:5‐10. FiaccadoriF , GhinelliF , PedrettiG , ManciaD . Mental state course and biochemical findings in HE treated by BCAA‐enriched mixtures. In: HolmE , KasperH editor(s). Metabolism and Nutrition in Liver Disease Freiburg 1984: Proceedings of the 41st Falk Symposium. Lancaster: MTP Press, 1985:281‐5. FiaccadoriF , GhinelliF , PedrettiG , PelosiG , SacchiniD , ZeneroliML , et al. Branched chain amino acid enriched solutions in the treatment of hepatic encephalopathy: a controlled trial. In: CapocacciaL , FischerJE , Rossi‐FanelliF editor(s). Hepatic Encephalopathy in Chronic Liver Failure. New York: Plenum Press, 1984:323‐33. FiaccadoriF , GhinelliF , PelosiG , SacchiniD , VaonaG , ZeneroliML , et al. Selective amino acid solutions in hepatic encephalopathy treatment (a preliminary report). La Ricerca in Clinica e in Laboratorio1980;10:411‐22. [MEDLINE: 81102770] ">Fiaccadori 1984</a>; <a href="./references#CD001939-bbs2-0014" title="RiggioO , CangianoC , CascinoA , MerliM , StortoniM , Rossi‐FanelliF , et al. Long term dietary supplement with branched chain amino acids: a new approach in the prevention of hepatic encephalopathy: results of a controlled study in cirrhotics with porto‐caval anastomosis. In: Associazione Italiana per Lo Studio del Fegato. Congress, editor(s). Hepatic Encephalopathy in Chronic Liver Failure. New York: Plenum Press, 1984:183‐92. Rossi‐FanelliF , CangianoC , CapocacciaL , CascinoA , CeciF , MuscaritoliM , et al. Use of branched chain amino acids for treating hepatic encephalopathy: clinical experiences. Gut1986;27:111‐5. Rossi‐FanelliF , CangianoC , CascinoA , MerliM , RiggioO , StortoniM , et al. Branched‐chain amino acids in the treatment of severe hepatic encephalopathy. In: CapocacciaL , FischerJE , Rossi‐FanelliF editor(s). Hepatic Encephalopathy in Chronic Liver Failure. New York: Plenum Press, 1984:335‐44. Rossi‐FanelliF , RiggioO , CangianoC , CascinoA , DeConciliisD , MerliM , et al. Branched‐chain amino acids vs lactulose in the treatment of hepatic coma: a controlled study. Digestive Diseases and Sciences1982;27:929‐35. ">Rossi‐Fanelli 1986</a>), or neomycin (<a href="./references#CD001939-bbs2-0002" title="CerraFB . Disease‐specific amino acid infusion (F080) in hepatic encephalopathy: a prospective, randomized, double‐blind, controlled trial [personal communication]. Correspondence with authorsSeptember 2002. CerraFB , CheungNK , FischerJE , KaplowitzN , SchiffE‐R , DienstagJL , et al. Disease‐specific amino acid infusion (F080) in hepatic encephalopathy: a prospective, randomized, double‐blind, controlled trial. JPEN. Journal of Parenteral and Enteral Nutrition1985;9:288‐95. CerraFB , CheungNK , FischerJE , KaplowitzN , SchiffER , DienstagJL , et al. A multicenter trial of branched chain enriched amino acid infusion (F080) in hepatic encephalopathy (HE). Hepatology (Baltimore, Md.)1982;2:699. CerraFB , McMillenM , AngelicoR , ClineB , LyonsJ , FaulkenbachL , et al. Cirrhosis, encephalopathy, and improved results with metabolic support. Surgery1983;94:612‐9. ">Cerra 1985</a>; <a href="./references#CD001939-bbs2-0015" title="StraussE , Cartapatti Da SilvaE , LacetCM , CapacciMLL , BernardiniAP . Treatment of hepatic encephalopathy: a randomized clinical trial comparing a branched chain enriched amino acid solution to oral neomycin. Nutritional Support Services1986;6:18‐21. StraussE , SantosWR , DaSilvaEC , LacetCM , CapacciLL , BernardiniAP . A randomized controlled clinical trial for the evaluation of the efficacy of an enriched branched‐chain amino‐acid solution compared to neomycin in hepatic encephalopathy. Hepatology (Baltimore, Md.)1983;3:862. ">Strauss 1986</a>). </p> <p><b>Outcomes</b> </p> <p>One trial did not report mortality (<a href="./references#CD001939-bbs2-0005" title="HayashiS , AoyagiY , FujiwaraK , OkaH , OdaT . A randomized controlled trial of branched‐chain amino acid (BCAA)‐enriched elemental diet (ED‐H) for hepatic encephalopathy. Journal of Gastroenterology and Hepatology1991;6:191. ">Hayashi 1991</a>). The remaining trials reported mortality at the end of treatment. All trials reported the effect of BCAA on hepatic encephalopathy. Twelve trials assessed the effect of BCAA on manifestations of overt hepatic encephalopathy (<a href="./references#CD001939-bbs2-0004" title="FiaccadoriF . Branched chain amino acid enriched solutions in the treatment of hepatic encephalopathy: a controlled trial. Italian Journal of Gastroenterology (additional information from author November 2012). FiaccadoriF , GhinelliF , PedrettiG . Branched chain amino acid enriched solutions in the treatment of hepatic encephalopathy: a controlled trial. Italian Journal of Gastroenterology1985;17:5‐10. FiaccadoriF , GhinelliF , PedrettiG , ManciaD . Mental state course and biochemical findings in HE treated by BCAA‐enriched mixtures. In: HolmE , KasperH editor(s). Metabolism and Nutrition in Liver Disease Freiburg 1984: Proceedings of the 41st Falk Symposium. Lancaster: MTP Press, 1985:281‐5. FiaccadoriF , GhinelliF , PedrettiG , PelosiG , SacchiniD , ZeneroliML , et al. Branched chain amino acid enriched solutions in the treatment of hepatic encephalopathy: a controlled trial. In: CapocacciaL , FischerJE , Rossi‐FanelliF editor(s). Hepatic Encephalopathy in Chronic Liver Failure. New York: Plenum Press, 1984:323‐33. FiaccadoriF , GhinelliF , PelosiG , SacchiniD , VaonaG , ZeneroliML , et al. Selective amino acid solutions in hepatic encephalopathy treatment (a preliminary report). La Ricerca in Clinica e in Laboratorio1980;10:411‐22. [MEDLINE: 81102770] ">Fiaccadori 1984</a>; <a href="./references#CD001939-bbs2-0006" title="HorstD , GraceN , ConnHO , SchiffE , SchenkerS , ViteriA , et al. A double‐blind randomized comparison of dietary protein and an oral branched chain amino acid (BCAA) solution in cirrhotic patients with chronic portal‐systemic encephalopathy (PSE) [IASL abstract]. Hepatology (Baltimore, Md.)1982;2:184. HorstD , GraceND , ConnHO , SchiffE , SchenkerS , ViteriA , et al. Comparison of dietary protein with an oral, branched chain‐enriched amino acid supplement in chronic portal‐systemic encephalopathy: a randomized controlled trial. Hepatology (Baltimore, Md.)1984;4:279‐87. ">Horst 1984</a>; <a href="./references#CD001939-bbs2-0001" title="CalveyH , DavisM , WilliamsR . Controlled trial of nutritional supplementation, with and without branched chain amino acid enrichment, in treatment of acute alcoholic hepatitis. Journal of Hepatology1985;1:141‐51. CalveyH , DavisM , WilliamsR . Prospective study of nasogastric feeding via East Grinstead or Viomedex tubes compared with oral dietary supplementation in patients with cirrhosis. Clinical Nutrition1984;3:63‐6. WilliamsR , CalveyH , DavisM . Controlled trial of nutritional supplementation in acute alcoholic hepatitis. In: HolmEKH editor(s). Metabolism and Nutrition in Liver Disease. Lancaster, UK: MTP Press, Ltd, 1985:361‐8. ">Calvey 1985</a>; <a href="./references#CD001939-bbs2-0002" title="CerraFB . Disease‐specific amino acid infusion (F080) in hepatic encephalopathy: a prospective, randomized, double‐blind, controlled trial [personal communication]. Correspondence with authorsSeptember 2002. CerraFB , CheungNK , FischerJE , KaplowitzN , SchiffE‐R , DienstagJL , et al. Disease‐specific amino acid infusion (F080) in hepatic encephalopathy: a prospective, randomized, double‐blind, controlled trial. JPEN. Journal of Parenteral and Enteral Nutrition1985;9:288‐95. CerraFB , CheungNK , FischerJE , KaplowitzN , SchiffER , DienstagJL , et al. A multicenter trial of branched chain enriched amino acid infusion (F080) in hepatic encephalopathy (HE). Hepatology (Baltimore, Md.)1982;2:699. CerraFB , McMillenM , AngelicoR , ClineB , LyonsJ , FaulkenbachL , et al. Cirrhosis, encephalopathy, and improved results with metabolic support. Surgery1983;94:612‐9. ">Cerra 1985</a>; <a href="./references#CD001939-bbs2-0011" title="MichelH , BoriesP , AubinJP , Pomier‐LayrarguesG , BauretP , Bellet‐HermanH . Treatment of acute hepatic encephalopathy in cirrhotics with a branched‐chain amino acids enriched versus a conventional amino acids mixture. A controlled study of 70 patients. Liver1985;5:282‐9. MichelH , Pomier‐LayrarguesG , AubinJP , BoriesP , MirouzeD , Bellet‐HermanH . Treatment of hepatic encephalopathy by infusion of a modified amino acid solution: results of a controlled study in 47 cirrhotic patients. In: CapocacciaL , FischerJE , Rossi‐FanelliF editor(s). Hepatic Encephalopathy in Chronic Liver Failure. New York: Plenum Press, 1984:301‐10. MichelH , Pomier‐LayrarguesG , DuhamelO , LacombeB , CuilleretG , Bellet‐HermannH . Intravenous infusion of ordinary and modified amino‐acid solutions in the management of hepatic encephalopathy (controlled study, 30 patients). Gastroenterology1980;79:1038. Pomier‐LayrarguesG , DuhamelO , LacombeB , CuilleretG , BelletH , MichelH . Intravenous infusion of ordinary and modified amino‐acid solutions in the management of hepatic encephalopathy. Liver1981;1:140. ">Michel 1985</a>; <a href="./references#CD001939-bbs2-0014" title="RiggioO , CangianoC , CascinoA , MerliM , StortoniM , Rossi‐FanelliF , et al. Long term dietary supplement with branched chain amino acids: a new approach in the prevention of hepatic encephalopathy: results of a controlled study in cirrhotics with porto‐caval anastomosis. In: Associazione Italiana per Lo Studio del Fegato. Congress, editor(s). Hepatic Encephalopathy in Chronic Liver Failure. New York: Plenum Press, 1984:183‐92. Rossi‐FanelliF , CangianoC , CapocacciaL , CascinoA , CeciF , MuscaritoliM , et al. Use of branched chain amino acids for treating hepatic encephalopathy: clinical experiences. Gut1986;27:111‐5. Rossi‐FanelliF , CangianoC , CascinoA , MerliM , RiggioO , StortoniM , et al. Branched‐chain amino acids in the treatment of severe hepatic encephalopathy. In: CapocacciaL , FischerJE , Rossi‐FanelliF editor(s). Hepatic Encephalopathy in Chronic Liver Failure. New York: Plenum Press, 1984:335‐44. Rossi‐FanelliF , RiggioO , CangianoC , CascinoA , DeConciliisD , MerliM , et al. Branched‐chain amino acids vs lactulose in the treatment of hepatic coma: a controlled study. Digestive Diseases and Sciences1982;27:929‐35. ">Rossi‐Fanelli 1986</a>; <a href="./references#CD001939-bbs2-0015" title="StraussE , Cartapatti Da SilvaE , LacetCM , CapacciMLL , BernardiniAP . Treatment of hepatic encephalopathy: a randomized clinical trial comparing a branched chain enriched amino acid solution to oral neomycin. Nutritional Support Services1986;6:18‐21. StraussE , SantosWR , DaSilvaEC , LacetCM , CapacciLL , BernardiniAP . A randomized controlled clinical trial for the evaluation of the efficacy of an enriched branched‐chain amino‐acid solution compared to neomycin in hepatic encephalopathy. Hepatology (Baltimore, Md.)1983;3:862. ">Strauss 1986</a>; <a href="./references#CD001939-bbs2-0007" title="HwangSJ , ChanCY , WuJC , LeeSD , HuanYS , TsaiYT , et al. A randomized controlled trial for the evaluation of the efficacy of branched chain amino acid‐enriched amino acid solution in the treatment of patients with hepatic encephalopathy. Chinese Journal of Gastroenterology1988;5:185‐92. ">Hwang 1988</a>; <a href="./references#CD001939-bbs2-0009" title="BianchiGP , MarchesiniG , ZoliM , AbbiatiR , FerrarioE , FabbriA , et al. Oral BCAA supplementation in cirrhosis with chronic encephalopathy: effects on prolactin and estradiol levels. Hepato‐gastroenterology1992;39:443‐6. MarchesiniG , BianchiG , MerliM , AmodioP , PanellaC , LoguercioC , et al. Nutritional supplementation with branched‐chain amino acids in advanced cirrhosis: a double‐blind, randomized trial. Gastroenterology2003;124:1792‐801. MarchesiniG , DioguardiFS , BianchiGP , ZoliM , BellatiG , RoffiL , et al. Long‐term oral branched‐chain amino acid treatment in chronic hepatic encephalopathy. A randomized double‐blind casein controlled trial. The Italian Multicenter Study Group. Journal of Hepatology1990;11:92‐101. ">Marchesini 1990</a>; <a href="./references#CD001939-bbs2-0016" title="GluudC , DejgaardA , HardtF , KristensenM , KøhlerO , MelgaardB , et al. Preliminary treatment results with balanced amino acid infusion to patients with hepatic encephalopathy. Scandinavian Journal of Gastroenterology1983;18:19. VilstrupH , GluudC , HardtF , KristensenM , KøhlerO , MelgaardB , et al. Branched chain enriched amino acid versus glucose treatment of hepatic encephalopathy. A double‐blind study of 65 patients with cirrhosis. Hepatology (Baltimore, Md.)1990;10:291‐6. VilstrupH , GluudC , HardtF , KristensenM , MelgaardB , KøhlerO , et al. Branched chain enriched amino acid nutrition does not change the outcome of hepatic coma in patients with cirrhosis of the liver. Journal of Hepatology1985;1:S347. ">Vilstrup 1990</a>; <a href="./references#CD001939-bbs2-0005" title="HayashiS , AoyagiY , FujiwaraK , OkaH , OdaT . A randomized controlled trial of branched‐chain amino acid (BCAA)‐enriched elemental diet (ED‐H) for hepatic encephalopathy. Journal of Gastroenterology and Hepatology1991;6:191. ">Hayashi 1991</a>; <a href="./references#CD001939-bbs2-0012" title="Horie‐TakashiI . Effects of oral branched‐chain amino acid granules on event‐free survival in patients with liver cirrhosis. Clinical Gastroenterology and Hepatology2005; Vol. 3:705‐13 (additional information and data received November 2011). MutoY , SatoS , WatanabeA , MoriwakiH , SuzukiK , KatoA , et al. Effects of oral branched‐chain amino acid granules on event‐free survival in patients with liver cirrhosis. Clinical Gastroenterology and Hepatology2005;3:705‐13. SatoS , WatanabeA , MutoY , SuzukiK , KatoA , MoriwakiH , et al. Clinical comparison of branched‐chain amino acid (l‐Leucine, l‐Isoleucine, l‐Valine) granules and oral nutrition for hepatic insufficiency in patients with decompensated liver cirrhosis (LIV‐EN study). Hepatology Research2005;31:232‐40. ">Muto 2005</a>), and four trials of minimal hepatic encephalopathy (<a href="./references#CD001939-bbs2-0003" title="EgbertsEH , HamsterW , SchomeerusH , JürgensP . Effect of branched chain amino acids on latent porto‐systemic‐encephalopathy (PSE). JPEN. Journal of Parenteral and Enteral Nutrition1981;5:5. EgbertsEH , SchomeerusH , HamsterW , JürgensP . Effective treatment of latens porto‐systemic encephalopathy with oral branched chain amino acids. In: CapocacciaL , FischerJE , Rossi‐FanelliF editor(s). Hepatic Encephalopathy in Chronic Liver Failure. New York: Plenum Press, 1984:351‐7. EgbertsEH , SchomerusH , HamsterW , JurgensP . Branched chain amino acids in the treatment of latent portosystemic encephalopathy. A double‐blind placebo‐controlled crossover study. Gastroenterology1985;88:887‐95. EgbertsEH , SchomerusH , HamsterW , JürgensP . Branched‐chain amino acids in the treatment of latent porto‐systemic encephalopathy. A placebo‐controlled double‐blind cross‐over study [Verzweigtkettige Aminosäuren bei der behandlung der latenten portosystemischen enzephalopathie. Eine placebokontrollierte doppelblind‐cross‐over‐studie]. Zeitschrift für Ernährungswissenschaft1986;25:9‐28. HamsterW , EgbertsEH , HamsterH . Treatment with branched‐chain amino acids and effect on psycho‐physical capacity functions in latent porto‐systemic encephalopathy [Behandlung mit verzweigtkettigen aminosäuren und ihre auswirkung auf psychophysische leistungsfunktionen bei latenter portosystemischer enzephalopathie]. Arzneimittelforschung1982;32:901‐2. ">Egberts 1985</a>; <a href="./references#CD001939-bbs2-0013" title="PlauthM , EgbertsE‐H , HamsterW , TörökM , MüllerP , BrandO , et al. Long‐term treatment with branched‐chain amino acids (BCA) improves the portosystemic encephalopathy (PSE) in ambulant patients. Results of a double blind, placebo controlled crossover study. Klinische Wochenschrift1992;69:126. PlauthM , EgbertsEH , HamsterW , TörökM , MüllerPH , BrandO , et al. Long‐term treatment of latent portosystemic encephalopathy with branched‐chain amino acids. A double‐blind placebo‐crossover study. Journal of Hepatology1993;17:308‐14. ">Plauth 1993</a>; <a href="./references#CD001939-bbs2-0010" title="MarchesiniG , BianchiG , MerliM , AmodioP , PanellaC , LoguercioC , et al. Nutritional supplementation with branched‐chain amino acids in advanced cirrhosis: a double‐blind, randomized trial. Gastroenterology2003;124:1980‐2. ">Marchesini 2003</a>; <a href="./references#CD001939-bbs2-0008" title="LesI , DovalE , Garcia‐MartinezR , PlanasM , CardenasG , GomezP , et al. Effects of branched‐chain amino acids supplementation in patients with cirrhosis and a previous episode of hepatic encephalopathy: a randomized study. American Journal of Gastroenterology2011;106:1081‐8. ">Les 2011</a>). </p> </section> <section id="CD001939-sec-0068"> <h4 class="title">Excluded studies</h4> <p>The excluded trials were quasi‐randomised studies in which different BCAA regimens were compared, or people without hepatic encephalopathy were assessed (<a href="./references#CD001939-sec-0112" title="">Characteristics of excluded studies</a>). We were unable to gather data on adverse events from these studies. We did not identify any ongoing trials. </p> </section> </section> <section id="CD001939-sec-0069"> <h3 class="title">Risk of bias in included studies</h3> <p>The assessment of bias (<a href="#CD001939-fig-0002">Figure 2</a>; <a href="#CD001939-fig-0003">Figure 3</a>) included information retrieved from the published trial reports as well as information obtained from the primary investigators (<a href="./references#CD001939-sec-0111" title="">Characteristics of included studies</a>). </p> <div class="figure" id="CD001939-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Methodological quality summary: review authors' judgements about each methodological quality item for each included study. CHBG: Cochrane Hepato‐Biliary Group." data-id="CD001939-fig-0002" src="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/image_n/nCD001939-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Methodological quality summary: review authors' judgements about each methodological quality item for each included study. CHBG: Cochrane Hepato‐Biliary Group. </p> </div> </div> </div> <div class="figure" id="CD001939-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. CHBG: Cochrane Hepato‐Biliary Group." data-id="CD001939-fig-0003" src="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/image_n/nCD001939-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. CHBG: Cochrane Hepato‐Biliary Group. </p> </div> </div> </div> <section id="CD001939-sec-0070"> <h4 class="title">Allocation</h4> <section id="CD001939-sec-0071"> <h5 class="title">Sequence generation and allocation concealment</h5> <p>Based on the information that we collected from the published reports and information from authors, we classed the allocation sequence generation and allocation concealment as low risk of bias in 10 trials (<a href="./references#CD001939-bbs2-0006" title="HorstD , GraceN , ConnHO , SchiffE , SchenkerS , ViteriA , et al. A double‐blind randomized comparison of dietary protein and an oral branched chain amino acid (BCAA) solution in cirrhotic patients with chronic portal‐systemic encephalopathy (PSE) [IASL abstract]. Hepatology (Baltimore, Md.)1982;2:184. HorstD , GraceND , ConnHO , SchiffE , SchenkerS , ViteriA , et al. Comparison of dietary protein with an oral, branched chain‐enriched amino acid supplement in chronic portal‐systemic encephalopathy: a randomized controlled trial. Hepatology (Baltimore, Md.)1984;4:279‐87. ">Horst 1984</a>; <a href="./references#CD001939-bbs2-0002" title="CerraFB . Disease‐specific amino acid infusion (F080) in hepatic encephalopathy: a prospective, randomized, double‐blind, controlled trial [personal communication]. Correspondence with authorsSeptember 2002. CerraFB , CheungNK , FischerJE , KaplowitzN , SchiffE‐R , DienstagJL , et al. Disease‐specific amino acid infusion (F080) in hepatic encephalopathy: a prospective, randomized, double‐blind, controlled trial. JPEN. Journal of Parenteral and Enteral Nutrition1985;9:288‐95. CerraFB , CheungNK , FischerJE , KaplowitzN , SchiffER , DienstagJL , et al. A multicenter trial of branched chain enriched amino acid infusion (F080) in hepatic encephalopathy (HE). Hepatology (Baltimore, Md.)1982;2:699. CerraFB , McMillenM , AngelicoR , ClineB , LyonsJ , FaulkenbachL , et al. Cirrhosis, encephalopathy, and improved results with metabolic support. Surgery1983;94:612‐9. ">Cerra 1985</a>; <a href="./references#CD001939-bbs2-0003" title="EgbertsEH , HamsterW , SchomeerusH , JürgensP . Effect of branched chain amino acids on latent porto‐systemic‐encephalopathy (PSE). JPEN. Journal of Parenteral and Enteral Nutrition1981;5:5. EgbertsEH , SchomeerusH , HamsterW , JürgensP . Effective treatment of latens porto‐systemic encephalopathy with oral branched chain amino acids. In: CapocacciaL , FischerJE , Rossi‐FanelliF editor(s). Hepatic Encephalopathy in Chronic Liver Failure. New York: Plenum Press, 1984:351‐7. EgbertsEH , SchomerusH , HamsterW , JurgensP . Branched chain amino acids in the treatment of latent portosystemic encephalopathy. A double‐blind placebo‐controlled crossover study. Gastroenterology1985;88:887‐95. EgbertsEH , SchomerusH , HamsterW , JürgensP . Branched‐chain amino acids in the treatment of latent porto‐systemic encephalopathy. A placebo‐controlled double‐blind cross‐over study [Verzweigtkettige Aminosäuren bei der behandlung der latenten portosystemischen enzephalopathie. Eine placebokontrollierte doppelblind‐cross‐over‐studie]. Zeitschrift für Ernährungswissenschaft1986;25:9‐28. HamsterW , EgbertsEH , HamsterH . Treatment with branched‐chain amino acids and effect on psycho‐physical capacity functions in latent porto‐systemic encephalopathy [Behandlung mit verzweigtkettigen aminosäuren und ihre auswirkung auf psychophysische leistungsfunktionen bei latenter portosystemischer enzephalopathie]. Arzneimittelforschung1982;32:901‐2. ">Egberts 1985</a>; <a href="./references#CD001939-bbs2-0015" title="StraussE , Cartapatti Da SilvaE , LacetCM , CapacciMLL , BernardiniAP . Treatment of hepatic encephalopathy: a randomized clinical trial comparing a branched chain enriched amino acid solution to oral neomycin. Nutritional Support Services1986;6:18‐21. StraussE , SantosWR , DaSilvaEC , LacetCM , CapacciLL , BernardiniAP . A randomized controlled clinical trial for the evaluation of the efficacy of an enriched branched‐chain amino‐acid solution compared to neomycin in hepatic encephalopathy. Hepatology (Baltimore, Md.)1983;3:862. ">Strauss 1986</a>; <a href="./references#CD001939-bbs2-0009" title="BianchiGP , MarchesiniG , ZoliM , AbbiatiR , FerrarioE , FabbriA , et al. Oral BCAA supplementation in cirrhosis with chronic encephalopathy: effects on prolactin and estradiol levels. Hepato‐gastroenterology1992;39:443‐6. MarchesiniG , BianchiG , MerliM , AmodioP , PanellaC , LoguercioC , et al. Nutritional supplementation with branched‐chain amino acids in advanced cirrhosis: a double‐blind, randomized trial. Gastroenterology2003;124:1792‐801. MarchesiniG , DioguardiFS , BianchiGP , ZoliM , BellatiG , RoffiL , et al. Long‐term oral branched‐chain amino acid treatment in chronic hepatic encephalopathy. A randomized double‐blind casein controlled trial. The Italian Multicenter Study Group. Journal of Hepatology1990;11:92‐101. ">Marchesini 1990</a>; <a href="./references#CD001939-bbs2-0016" title="GluudC , DejgaardA , HardtF , KristensenM , KøhlerO , MelgaardB , et al. Preliminary treatment results with balanced amino acid infusion to patients with hepatic encephalopathy. Scandinavian Journal of Gastroenterology1983;18:19. VilstrupH , GluudC , HardtF , KristensenM , KøhlerO , MelgaardB , et al. Branched chain enriched amino acid versus glucose treatment of hepatic encephalopathy. A double‐blind study of 65 patients with cirrhosis. Hepatology (Baltimore, Md.)1990;10:291‐6. VilstrupH , GluudC , HardtF , KristensenM , MelgaardB , KøhlerO , et al. Branched chain enriched amino acid nutrition does not change the outcome of hepatic coma in patients with cirrhosis of the liver. Journal of Hepatology1985;1:S347. ">Vilstrup 1990</a>; <a href="./references#CD001939-bbs2-0013" title="PlauthM , EgbertsE‐H , HamsterW , TörökM , MüllerP , BrandO , et al. Long‐term treatment with branched‐chain amino acids (BCA) improves the portosystemic encephalopathy (PSE) in ambulant patients. Results of a double blind, placebo controlled crossover study. Klinische Wochenschrift1992;69:126. PlauthM , EgbertsEH , HamsterW , TörökM , MüllerPH , BrandO , et al. Long‐term treatment of latent portosystemic encephalopathy with branched‐chain amino acids. A double‐blind placebo‐crossover study. Journal of Hepatology1993;17:308‐14. ">Plauth 1993</a>; <a href="./references#CD001939-bbs2-0010" title="MarchesiniG , BianchiG , MerliM , AmodioP , PanellaC , LoguercioC , et al. Nutritional supplementation with branched‐chain amino acids in advanced cirrhosis: a double‐blind, randomized trial. Gastroenterology2003;124:1980‐2. ">Marchesini 2003</a>; <a href="./references#CD001939-bbs2-0012" title="Horie‐TakashiI . Effects of oral branched‐chain amino acid granules on event‐free survival in patients with liver cirrhosis. Clinical Gastroenterology and Hepatology2005; Vol. 3:705‐13 (additional information and data received November 2011). MutoY , SatoS , WatanabeA , MoriwakiH , SuzukiK , KatoA , et al. Effects of oral branched‐chain amino acid granules on event‐free survival in patients with liver cirrhosis. Clinical Gastroenterology and Hepatology2005;3:705‐13. SatoS , WatanabeA , MutoY , SuzukiK , KatoA , MoriwakiH , et al. Clinical comparison of branched‐chain amino acid (l‐Leucine, l‐Isoleucine, l‐Valine) granules and oral nutrition for hepatic insufficiency in patients with decompensated liver cirrhosis (LIV‐EN study). Hepatology Research2005;31:232‐40. ">Muto 2005</a>; <a href="./references#CD001939-bbs2-0008" title="LesI , DovalE , Garcia‐MartinezR , PlanasM , CardenasG , GomezP , et al. Effects of branched‐chain amino acids supplementation in patients with cirrhosis and a previous episode of hepatic encephalopathy: a randomized study. American Journal of Gastroenterology2011;106:1081‐8. ">Les 2011</a>). We classed the sequence generation and/or allocation concealment as unclear in the remaining six trials (<a href="./references#CD001939-bbs2-0004" title="FiaccadoriF . Branched chain amino acid enriched solutions in the treatment of hepatic encephalopathy: a controlled trial. Italian Journal of Gastroenterology (additional information from author November 2012). FiaccadoriF , GhinelliF , PedrettiG . Branched chain amino acid enriched solutions in the treatment of hepatic encephalopathy: a controlled trial. Italian Journal of Gastroenterology1985;17:5‐10. FiaccadoriF , GhinelliF , PedrettiG , ManciaD . Mental state course and biochemical findings in HE treated by BCAA‐enriched mixtures. In: HolmE , KasperH editor(s). Metabolism and Nutrition in Liver Disease Freiburg 1984: Proceedings of the 41st Falk Symposium. Lancaster: MTP Press, 1985:281‐5. FiaccadoriF , GhinelliF , PedrettiG , PelosiG , SacchiniD , ZeneroliML , et al. Branched chain amino acid enriched solutions in the treatment of hepatic encephalopathy: a controlled trial. In: CapocacciaL , FischerJE , Rossi‐FanelliF editor(s). Hepatic Encephalopathy in Chronic Liver Failure. New York: Plenum Press, 1984:323‐33. FiaccadoriF , GhinelliF , PelosiG , SacchiniD , VaonaG , ZeneroliML , et al. Selective amino acid solutions in hepatic encephalopathy treatment (a preliminary report). La Ricerca in Clinica e in Laboratorio1980;10:411‐22. [MEDLINE: 81102770] ">Fiaccadori 1984</a>; <a href="./references#CD001939-bbs2-0001" title="CalveyH , DavisM , WilliamsR . Controlled trial of nutritional supplementation, with and without branched chain amino acid enrichment, in treatment of acute alcoholic hepatitis. Journal of Hepatology1985;1:141‐51. CalveyH , DavisM , WilliamsR . Prospective study of nasogastric feeding via East Grinstead or Viomedex tubes compared with oral dietary supplementation in patients with cirrhosis. Clinical Nutrition1984;3:63‐6. WilliamsR , CalveyH , DavisM . Controlled trial of nutritional supplementation in acute alcoholic hepatitis. In: HolmEKH editor(s). Metabolism and Nutrition in Liver Disease. Lancaster, UK: MTP Press, Ltd, 1985:361‐8. ">Calvey 1985</a>; <a href="./references#CD001939-bbs2-0011" title="MichelH , BoriesP , AubinJP , Pomier‐LayrarguesG , BauretP , Bellet‐HermanH . Treatment of acute hepatic encephalopathy in cirrhotics with a branched‐chain amino acids enriched versus a conventional amino acids mixture. A controlled study of 70 patients. Liver1985;5:282‐9. MichelH , Pomier‐LayrarguesG , AubinJP , BoriesP , MirouzeD , Bellet‐HermanH . Treatment of hepatic encephalopathy by infusion of a modified amino acid solution: results of a controlled study in 47 cirrhotic patients. In: CapocacciaL , FischerJE , Rossi‐FanelliF editor(s). Hepatic Encephalopathy in Chronic Liver Failure. New York: Plenum Press, 1984:301‐10. MichelH , Pomier‐LayrarguesG , DuhamelO , LacombeB , CuilleretG , Bellet‐HermannH . Intravenous infusion of ordinary and modified amino‐acid solutions in the management of hepatic encephalopathy (controlled study, 30 patients). Gastroenterology1980;79:1038. Pomier‐LayrarguesG , DuhamelO , LacombeB , CuilleretG , BelletH , MichelH . Intravenous infusion of ordinary and modified amino‐acid solutions in the management of hepatic encephalopathy. Liver1981;1:140. ">Michel 1985</a>; <a href="./references#CD001939-bbs2-0014" title="RiggioO , CangianoC , CascinoA , MerliM , StortoniM , Rossi‐FanelliF , et al. Long term dietary supplement with branched chain amino acids: a new approach in the prevention of hepatic encephalopathy: results of a controlled study in cirrhotics with porto‐caval anastomosis. In: Associazione Italiana per Lo Studio del Fegato. Congress, editor(s). Hepatic Encephalopathy in Chronic Liver Failure. New York: Plenum Press, 1984:183‐92. Rossi‐FanelliF , CangianoC , CapocacciaL , CascinoA , CeciF , MuscaritoliM , et al. Use of branched chain amino acids for treating hepatic encephalopathy: clinical experiences. Gut1986;27:111‐5. Rossi‐FanelliF , CangianoC , CascinoA , MerliM , RiggioO , StortoniM , et al. Branched‐chain amino acids in the treatment of severe hepatic encephalopathy. In: CapocacciaL , FischerJE , Rossi‐FanelliF editor(s). Hepatic Encephalopathy in Chronic Liver Failure. New York: Plenum Press, 1984:335‐44. Rossi‐FanelliF , RiggioO , CangianoC , CascinoA , DeConciliisD , MerliM , et al. Branched‐chain amino acids vs lactulose in the treatment of hepatic coma: a controlled study. Digestive Diseases and Sciences1982;27:929‐35. ">Rossi‐Fanelli 1986</a>; <a href="./references#CD001939-bbs2-0007" title="HwangSJ , ChanCY , WuJC , LeeSD , HuanYS , TsaiYT , et al. A randomized controlled trial for the evaluation of the efficacy of branched chain amino acid‐enriched amino acid solution in the treatment of patients with hepatic encephalopathy. Chinese Journal of Gastroenterology1988;5:185‐92. ">Hwang 1988</a>; <a href="./references#CD001939-bbs2-0005" title="HayashiS , AoyagiY , FujiwaraK , OkaH , OdaT . A randomized controlled trial of branched‐chain amino acid (BCAA)‐enriched elemental diet (ED‐H) for hepatic encephalopathy. Journal of Gastroenterology and Hepatology1991;6:191. ">Hayashi 1991</a>). </p> </section> </section> <section id="CD001939-sec-0072"> <h4 class="title">Blinding</h4> <p>Seven trials were open without blinding of participants or investigators (<a href="./references#CD001939-bbs2-0004" title="FiaccadoriF . Branched chain amino acid enriched solutions in the treatment of hepatic encephalopathy: a controlled trial. Italian Journal of Gastroenterology (additional information from author November 2012). FiaccadoriF , GhinelliF , PedrettiG . Branched chain amino acid enriched solutions in the treatment of hepatic encephalopathy: a controlled trial. Italian Journal of Gastroenterology1985;17:5‐10. FiaccadoriF , GhinelliF , PedrettiG , ManciaD . Mental state course and biochemical findings in HE treated by BCAA‐enriched mixtures. In: HolmE , KasperH editor(s). Metabolism and Nutrition in Liver Disease Freiburg 1984: Proceedings of the 41st Falk Symposium. Lancaster: MTP Press, 1985:281‐5. FiaccadoriF , GhinelliF , PedrettiG , PelosiG , SacchiniD , ZeneroliML , et al. Branched chain amino acid enriched solutions in the treatment of hepatic encephalopathy: a controlled trial. In: CapocacciaL , FischerJE , Rossi‐FanelliF editor(s). Hepatic Encephalopathy in Chronic Liver Failure. New York: Plenum Press, 1984:323‐33. FiaccadoriF , GhinelliF , PelosiG , SacchiniD , VaonaG , ZeneroliML , et al. Selective amino acid solutions in hepatic encephalopathy treatment (a preliminary report). La Ricerca in Clinica e in Laboratorio1980;10:411‐22. [MEDLINE: 81102770] ">Fiaccadori 1984</a>; <a href="./references#CD001939-bbs2-0011" title="MichelH , BoriesP , AubinJP , Pomier‐LayrarguesG , BauretP , Bellet‐HermanH . Treatment of acute hepatic encephalopathy in cirrhotics with a branched‐chain amino acids enriched versus a conventional amino acids mixture. A controlled study of 70 patients. Liver1985;5:282‐9. MichelH , Pomier‐LayrarguesG , AubinJP , BoriesP , MirouzeD , Bellet‐HermanH . Treatment of hepatic encephalopathy by infusion of a modified amino acid solution: results of a controlled study in 47 cirrhotic patients. In: CapocacciaL , FischerJE , Rossi‐FanelliF editor(s). Hepatic Encephalopathy in Chronic Liver Failure. New York: Plenum Press, 1984:301‐10. MichelH , Pomier‐LayrarguesG , DuhamelO , LacombeB , CuilleretG , Bellet‐HermannH . Intravenous infusion of ordinary and modified amino‐acid solutions in the management of hepatic encephalopathy (controlled study, 30 patients). Gastroenterology1980;79:1038. Pomier‐LayrarguesG , DuhamelO , LacombeB , CuilleretG , BelletH , MichelH . Intravenous infusion of ordinary and modified amino‐acid solutions in the management of hepatic encephalopathy. Liver1981;1:140. ">Michel 1985</a>; <a href="./references#CD001939-bbs2-0014" title="RiggioO , CangianoC , CascinoA , MerliM , StortoniM , Rossi‐FanelliF , et al. Long term dietary supplement with branched chain amino acids: a new approach in the prevention of hepatic encephalopathy: results of a controlled study in cirrhotics with porto‐caval anastomosis. In: Associazione Italiana per Lo Studio del Fegato. Congress, editor(s). Hepatic Encephalopathy in Chronic Liver Failure. New York: Plenum Press, 1984:183‐92. Rossi‐FanelliF , CangianoC , CapocacciaL , CascinoA , CeciF , MuscaritoliM , et al. Use of branched chain amino acids for treating hepatic encephalopathy: clinical experiences. Gut1986;27:111‐5. Rossi‐FanelliF , CangianoC , CascinoA , MerliM , RiggioO , StortoniM , et al. Branched‐chain amino acids in the treatment of severe hepatic encephalopathy. In: CapocacciaL , FischerJE , Rossi‐FanelliF editor(s). Hepatic Encephalopathy in Chronic Liver Failure. New York: Plenum Press, 1984:335‐44. Rossi‐FanelliF , RiggioO , CangianoC , CascinoA , DeConciliisD , MerliM , et al. Branched‐chain amino acids vs lactulose in the treatment of hepatic coma: a controlled study. Digestive Diseases and Sciences1982;27:929‐35. ">Rossi‐Fanelli 1986</a>; <a href="./references#CD001939-bbs2-0015" title="StraussE , Cartapatti Da SilvaE , LacetCM , CapacciMLL , BernardiniAP . Treatment of hepatic encephalopathy: a randomized clinical trial comparing a branched chain enriched amino acid solution to oral neomycin. Nutritional Support Services1986;6:18‐21. StraussE , SantosWR , DaSilvaEC , LacetCM , CapacciLL , BernardiniAP . A randomized controlled clinical trial for the evaluation of the efficacy of an enriched branched‐chain amino‐acid solution compared to neomycin in hepatic encephalopathy. Hepatology (Baltimore, Md.)1983;3:862. ">Strauss 1986</a>; <a href="./references#CD001939-bbs2-0007" title="HwangSJ , ChanCY , WuJC , LeeSD , HuanYS , TsaiYT , et al. A randomized controlled trial for the evaluation of the efficacy of branched chain amino acid‐enriched amino acid solution in the treatment of patients with hepatic encephalopathy. Chinese Journal of Gastroenterology1988;5:185‐92. ">Hwang 1988</a>; <a href="./references#CD001939-bbs2-0005" title="HayashiS , AoyagiY , FujiwaraK , OkaH , OdaT . A randomized controlled trial of branched‐chain amino acid (BCAA)‐enriched elemental diet (ED‐H) for hepatic encephalopathy. Journal of Gastroenterology and Hepatology1991;6:191. ">Hayashi 1991</a>; <a href="./references#CD001939-bbs2-0012" title="Horie‐TakashiI . Effects of oral branched‐chain amino acid granules on event‐free survival in patients with liver cirrhosis. Clinical Gastroenterology and Hepatology2005; Vol. 3:705‐13 (additional information and data received November 2011). MutoY , SatoS , WatanabeA , MoriwakiH , SuzukiK , KatoA , et al. Effects of oral branched‐chain amino acid granules on event‐free survival in patients with liver cirrhosis. Clinical Gastroenterology and Hepatology2005;3:705‐13. SatoS , WatanabeA , MutoY , SuzukiK , KatoA , MoriwakiH , et al. Clinical comparison of branched‐chain amino acid (l‐Leucine, l‐Isoleucine, l‐Valine) granules and oral nutrition for hepatic insufficiency in patients with decompensated liver cirrhosis (LIV‐EN study). Hepatology Research2005;31:232‐40. ">Muto 2005</a>). We classed these trials as having a high risk of bias in the assessment of hepatic encephalopathy, adverse events, and quality of life. Nine trials were double blind with blinding of participants and personnel, and blinded outcome assessment. We classed them as low risk of performance and detection bias (<a href="./references#CD001939-bbs2-0006" title="HorstD , GraceN , ConnHO , SchiffE , SchenkerS , ViteriA , et al. A double‐blind randomized comparison of dietary protein and an oral branched chain amino acid (BCAA) solution in cirrhotic patients with chronic portal‐systemic encephalopathy (PSE) [IASL abstract]. Hepatology (Baltimore, Md.)1982;2:184. HorstD , GraceND , ConnHO , SchiffE , SchenkerS , ViteriA , et al. Comparison of dietary protein with an oral, branched chain‐enriched amino acid supplement in chronic portal‐systemic encephalopathy: a randomized controlled trial. Hepatology (Baltimore, Md.)1984;4:279‐87. ">Horst 1984</a>; <a href="./references#CD001939-bbs2-0001" title="CalveyH , DavisM , WilliamsR . Controlled trial of nutritional supplementation, with and without branched chain amino acid enrichment, in treatment of acute alcoholic hepatitis. Journal of Hepatology1985;1:141‐51. CalveyH , DavisM , WilliamsR . Prospective study of nasogastric feeding via East Grinstead or Viomedex tubes compared with oral dietary supplementation in patients with cirrhosis. Clinical Nutrition1984;3:63‐6. WilliamsR , CalveyH , DavisM . Controlled trial of nutritional supplementation in acute alcoholic hepatitis. In: HolmEKH editor(s). Metabolism and Nutrition in Liver Disease. Lancaster, UK: MTP Press, Ltd, 1985:361‐8. ">Calvey 1985</a>; <a href="./references#CD001939-bbs2-0002" title="CerraFB . Disease‐specific amino acid infusion (F080) in hepatic encephalopathy: a prospective, randomized, double‐blind, controlled trial [personal communication]. Correspondence with authorsSeptember 2002. CerraFB , CheungNK , FischerJE , KaplowitzN , SchiffE‐R , DienstagJL , et al. Disease‐specific amino acid infusion (F080) in hepatic encephalopathy: a prospective, randomized, double‐blind, controlled trial. JPEN. Journal of Parenteral and Enteral Nutrition1985;9:288‐95. CerraFB , CheungNK , FischerJE , KaplowitzN , SchiffER , DienstagJL , et al. A multicenter trial of branched chain enriched amino acid infusion (F080) in hepatic encephalopathy (HE). Hepatology (Baltimore, Md.)1982;2:699. CerraFB , McMillenM , AngelicoR , ClineB , LyonsJ , FaulkenbachL , et al. Cirrhosis, encephalopathy, and improved results with metabolic support. Surgery1983;94:612‐9. ">Cerra 1985</a>; <a href="./references#CD001939-bbs2-0003" title="EgbertsEH , HamsterW , SchomeerusH , JürgensP . Effect of branched chain amino acids on latent porto‐systemic‐encephalopathy (PSE). JPEN. Journal of Parenteral and Enteral Nutrition1981;5:5. EgbertsEH , SchomeerusH , HamsterW , JürgensP . Effective treatment of latens porto‐systemic encephalopathy with oral branched chain amino acids. In: CapocacciaL , FischerJE , Rossi‐FanelliF editor(s). Hepatic Encephalopathy in Chronic Liver Failure. New York: Plenum Press, 1984:351‐7. EgbertsEH , SchomerusH , HamsterW , JurgensP . Branched chain amino acids in the treatment of latent portosystemic encephalopathy. A double‐blind placebo‐controlled crossover study. Gastroenterology1985;88:887‐95. EgbertsEH , SchomerusH , HamsterW , JürgensP . Branched‐chain amino acids in the treatment of latent porto‐systemic encephalopathy. A placebo‐controlled double‐blind cross‐over study [Verzweigtkettige Aminosäuren bei der behandlung der latenten portosystemischen enzephalopathie. Eine placebokontrollierte doppelblind‐cross‐over‐studie]. Zeitschrift für Ernährungswissenschaft1986;25:9‐28. HamsterW , EgbertsEH , HamsterH . Treatment with branched‐chain amino acids and effect on psycho‐physical capacity functions in latent porto‐systemic encephalopathy [Behandlung mit verzweigtkettigen aminosäuren und ihre auswirkung auf psychophysische leistungsfunktionen bei latenter portosystemischer enzephalopathie]. Arzneimittelforschung1982;32:901‐2. ">Egberts 1985</a>; <a href="./references#CD001939-bbs2-0009" title="BianchiGP , MarchesiniG , ZoliM , AbbiatiR , FerrarioE , FabbriA , et al. Oral BCAA supplementation in cirrhosis with chronic encephalopathy: effects on prolactin and estradiol levels. Hepato‐gastroenterology1992;39:443‐6. MarchesiniG , BianchiG , MerliM , AmodioP , PanellaC , LoguercioC , et al. Nutritional supplementation with branched‐chain amino acids in advanced cirrhosis: a double‐blind, randomized trial. Gastroenterology2003;124:1792‐801. MarchesiniG , DioguardiFS , BianchiGP , ZoliM , BellatiG , RoffiL , et al. Long‐term oral branched‐chain amino acid treatment in chronic hepatic encephalopathy. A randomized double‐blind casein controlled trial. The Italian Multicenter Study Group. Journal of Hepatology1990;11:92‐101. ">Marchesini 1990</a>; <a href="./references#CD001939-bbs2-0016" title="GluudC , DejgaardA , HardtF , KristensenM , KøhlerO , MelgaardB , et al. Preliminary treatment results with balanced amino acid infusion to patients with hepatic encephalopathy. Scandinavian Journal of Gastroenterology1983;18:19. VilstrupH , GluudC , HardtF , KristensenM , KøhlerO , MelgaardB , et al. Branched chain enriched amino acid versus glucose treatment of hepatic encephalopathy. A double‐blind study of 65 patients with cirrhosis. Hepatology (Baltimore, Md.)1990;10:291‐6. VilstrupH , GluudC , HardtF , KristensenM , MelgaardB , KøhlerO , et al. Branched chain enriched amino acid nutrition does not change the outcome of hepatic coma in patients with cirrhosis of the liver. Journal of Hepatology1985;1:S347. ">Vilstrup 1990</a>; <a href="./references#CD001939-bbs2-0013" title="PlauthM , EgbertsE‐H , HamsterW , TörökM , MüllerP , BrandO , et al. Long‐term treatment with branched‐chain amino acids (BCA) improves the portosystemic encephalopathy (PSE) in ambulant patients. Results of a double blind, placebo controlled crossover study. Klinische Wochenschrift1992;69:126. PlauthM , EgbertsEH , HamsterW , TörökM , MüllerPH , BrandO , et al. Long‐term treatment of latent portosystemic encephalopathy with branched‐chain amino acids. A double‐blind placebo‐crossover study. Journal of Hepatology1993;17:308‐14. ">Plauth 1993</a>; <a href="./references#CD001939-bbs2-0010" title="MarchesiniG , BianchiG , MerliM , AmodioP , PanellaC , LoguercioC , et al. Nutritional supplementation with branched‐chain amino acids in advanced cirrhosis: a double‐blind, randomized trial. Gastroenterology2003;124:1980‐2. ">Marchesini 2003</a>; <a href="./references#CD001939-bbs2-0008" title="LesI , DovalE , Garcia‐MartinezR , PlanasM , CardenasG , GomezP , et al. Effects of branched‐chain amino acids supplementation in patients with cirrhosis and a previous episode of hepatic encephalopathy: a randomized study. American Journal of Gastroenterology2011;106:1081‐8. ">Les 2011</a>). </p> </section> <section id="CD001939-sec-0073"> <h4 class="title">Incomplete outcome data</h4> <p>We classed four trials as having a high risk of attrition bias because they did not account for participants with missing outcomes (<a href="./references#CD001939-bbs2-0004" title="FiaccadoriF . Branched chain amino acid enriched solutions in the treatment of hepatic encephalopathy: a controlled trial. Italian Journal of Gastroenterology (additional information from author November 2012). FiaccadoriF , GhinelliF , PedrettiG . Branched chain amino acid enriched solutions in the treatment of hepatic encephalopathy: a controlled trial. Italian Journal of Gastroenterology1985;17:5‐10. FiaccadoriF , GhinelliF , PedrettiG , ManciaD . Mental state course and biochemical findings in HE treated by BCAA‐enriched mixtures. In: HolmE , KasperH editor(s). Metabolism and Nutrition in Liver Disease Freiburg 1984: Proceedings of the 41st Falk Symposium. Lancaster: MTP Press, 1985:281‐5. FiaccadoriF , GhinelliF , PedrettiG , PelosiG , SacchiniD , ZeneroliML , et al. Branched chain amino acid enriched solutions in the treatment of hepatic encephalopathy: a controlled trial. In: CapocacciaL , FischerJE , Rossi‐FanelliF editor(s). Hepatic Encephalopathy in Chronic Liver Failure. New York: Plenum Press, 1984:323‐33. FiaccadoriF , GhinelliF , PelosiG , SacchiniD , VaonaG , ZeneroliML , et al. Selective amino acid solutions in hepatic encephalopathy treatment (a preliminary report). La Ricerca in Clinica e in Laboratorio1980;10:411‐22. [MEDLINE: 81102770] ">Fiaccadori 1984</a>; <a href="./references#CD001939-bbs2-0014" title="RiggioO , CangianoC , CascinoA , MerliM , StortoniM , Rossi‐FanelliF , et al. Long term dietary supplement with branched chain amino acids: a new approach in the prevention of hepatic encephalopathy: results of a controlled study in cirrhotics with porto‐caval anastomosis. In: Associazione Italiana per Lo Studio del Fegato. Congress, editor(s). Hepatic Encephalopathy in Chronic Liver Failure. New York: Plenum Press, 1984:183‐92. Rossi‐FanelliF , CangianoC , CapocacciaL , CascinoA , CeciF , MuscaritoliM , et al. Use of branched chain amino acids for treating hepatic encephalopathy: clinical experiences. Gut1986;27:111‐5. Rossi‐FanelliF , CangianoC , CascinoA , MerliM , RiggioO , StortoniM , et al. Branched‐chain amino acids in the treatment of severe hepatic encephalopathy. In: CapocacciaL , FischerJE , Rossi‐FanelliF editor(s). Hepatic Encephalopathy in Chronic Liver Failure. New York: Plenum Press, 1984:335‐44. Rossi‐FanelliF , RiggioO , CangianoC , CascinoA , DeConciliisD , MerliM , et al. Branched‐chain amino acids vs lactulose in the treatment of hepatic coma: a controlled study. Digestive Diseases and Sciences1982;27:929‐35. ">Rossi‐Fanelli 1986</a>; <a href="./references#CD001939-bbs2-0016" title="GluudC , DejgaardA , HardtF , KristensenM , KøhlerO , MelgaardB , et al. Preliminary treatment results with balanced amino acid infusion to patients with hepatic encephalopathy. Scandinavian Journal of Gastroenterology1983;18:19. VilstrupH , GluudC , HardtF , KristensenM , KøhlerO , MelgaardB , et al. Branched chain enriched amino acid versus glucose treatment of hepatic encephalopathy. A double‐blind study of 65 patients with cirrhosis. Hepatology (Baltimore, Md.)1990;10:291‐6. VilstrupH , GluudC , HardtF , KristensenM , MelgaardB , KøhlerO , et al. Branched chain enriched amino acid nutrition does not change the outcome of hepatic coma in patients with cirrhosis of the liver. Journal of Hepatology1985;1:S347. ">Vilstrup 1990</a>; <a href="./references#CD001939-bbs2-0005" title="HayashiS , AoyagiY , FujiwaraK , OkaH , OdaT . A randomized controlled trial of branched‐chain amino acid (BCAA)‐enriched elemental diet (ED‐H) for hepatic encephalopathy. Journal of Gastroenterology and Hepatology1991;6:191. ">Hayashi 1991</a>), and the remaining 12 trials as low risk of attrition bias (<a href="./references#CD001939-bbs2-0006" title="HorstD , GraceN , ConnHO , SchiffE , SchenkerS , ViteriA , et al. A double‐blind randomized comparison of dietary protein and an oral branched chain amino acid (BCAA) solution in cirrhotic patients with chronic portal‐systemic encephalopathy (PSE) [IASL abstract]. Hepatology (Baltimore, Md.)1982;2:184. HorstD , GraceND , ConnHO , SchiffE , SchenkerS , ViteriA , et al. Comparison of dietary protein with an oral, branched chain‐enriched amino acid supplement in chronic portal‐systemic encephalopathy: a randomized controlled trial. Hepatology (Baltimore, Md.)1984;4:279‐87. ">Horst 1984</a>; <a href="./references#CD001939-bbs2-0001" title="CalveyH , DavisM , WilliamsR . Controlled trial of nutritional supplementation, with and without branched chain amino acid enrichment, in treatment of acute alcoholic hepatitis. Journal of Hepatology1985;1:141‐51. CalveyH , DavisM , WilliamsR . Prospective study of nasogastric feeding via East Grinstead or Viomedex tubes compared with oral dietary supplementation in patients with cirrhosis. Clinical Nutrition1984;3:63‐6. WilliamsR , CalveyH , DavisM . Controlled trial of nutritional supplementation in acute alcoholic hepatitis. In: HolmEKH editor(s). Metabolism and Nutrition in Liver Disease. Lancaster, UK: MTP Press, Ltd, 1985:361‐8. ">Calvey 1985</a>; <a href="./references#CD001939-bbs2-0002" title="CerraFB . Disease‐specific amino acid infusion (F080) in hepatic encephalopathy: a prospective, randomized, double‐blind, controlled trial [personal communication]. Correspondence with authorsSeptember 2002. CerraFB , CheungNK , FischerJE , KaplowitzN , SchiffE‐R , DienstagJL , et al. Disease‐specific amino acid infusion (F080) in hepatic encephalopathy: a prospective, randomized, double‐blind, controlled trial. JPEN. Journal of Parenteral and Enteral Nutrition1985;9:288‐95. CerraFB , CheungNK , FischerJE , KaplowitzN , SchiffER , DienstagJL , et al. A multicenter trial of branched chain enriched amino acid infusion (F080) in hepatic encephalopathy (HE). Hepatology (Baltimore, Md.)1982;2:699. CerraFB , McMillenM , AngelicoR , ClineB , LyonsJ , FaulkenbachL , et al. Cirrhosis, encephalopathy, and improved results with metabolic support. Surgery1983;94:612‐9. ">Cerra 1985</a>; <a href="./references#CD001939-bbs2-0003" title="EgbertsEH , HamsterW , SchomeerusH , JürgensP . Effect of branched chain amino acids on latent porto‐systemic‐encephalopathy (PSE). JPEN. Journal of Parenteral and Enteral Nutrition1981;5:5. EgbertsEH , SchomeerusH , HamsterW , JürgensP . Effective treatment of latens porto‐systemic encephalopathy with oral branched chain amino acids. In: CapocacciaL , FischerJE , Rossi‐FanelliF editor(s). Hepatic Encephalopathy in Chronic Liver Failure. New York: Plenum Press, 1984:351‐7. EgbertsEH , SchomerusH , HamsterW , JurgensP . Branched chain amino acids in the treatment of latent portosystemic encephalopathy. A double‐blind placebo‐controlled crossover study. Gastroenterology1985;88:887‐95. EgbertsEH , SchomerusH , HamsterW , JürgensP . Branched‐chain amino acids in the treatment of latent porto‐systemic encephalopathy. A placebo‐controlled double‐blind cross‐over study [Verzweigtkettige Aminosäuren bei der behandlung der latenten portosystemischen enzephalopathie. Eine placebokontrollierte doppelblind‐cross‐over‐studie]. Zeitschrift für Ernährungswissenschaft1986;25:9‐28. HamsterW , EgbertsEH , HamsterH . Treatment with branched‐chain amino acids and effect on psycho‐physical capacity functions in latent porto‐systemic encephalopathy [Behandlung mit verzweigtkettigen aminosäuren und ihre auswirkung auf psychophysische leistungsfunktionen bei latenter portosystemischer enzephalopathie]. Arzneimittelforschung1982;32:901‐2. ">Egberts 1985</a>; <a href="./references#CD001939-bbs2-0011" title="MichelH , BoriesP , AubinJP , Pomier‐LayrarguesG , BauretP , Bellet‐HermanH . Treatment of acute hepatic encephalopathy in cirrhotics with a branched‐chain amino acids enriched versus a conventional amino acids mixture. A controlled study of 70 patients. Liver1985;5:282‐9. MichelH , Pomier‐LayrarguesG , AubinJP , BoriesP , MirouzeD , Bellet‐HermanH . Treatment of hepatic encephalopathy by infusion of a modified amino acid solution: results of a controlled study in 47 cirrhotic patients. In: CapocacciaL , FischerJE , Rossi‐FanelliF editor(s). Hepatic Encephalopathy in Chronic Liver Failure. New York: Plenum Press, 1984:301‐10. MichelH , Pomier‐LayrarguesG , DuhamelO , LacombeB , CuilleretG , Bellet‐HermannH . Intravenous infusion of ordinary and modified amino‐acid solutions in the management of hepatic encephalopathy (controlled study, 30 patients). Gastroenterology1980;79:1038. Pomier‐LayrarguesG , DuhamelO , LacombeB , CuilleretG , BelletH , MichelH . Intravenous infusion of ordinary and modified amino‐acid solutions in the management of hepatic encephalopathy. Liver1981;1:140. ">Michel 1985</a>; <a href="./references#CD001939-bbs2-0015" title="StraussE , Cartapatti Da SilvaE , LacetCM , CapacciMLL , BernardiniAP . Treatment of hepatic encephalopathy: a randomized clinical trial comparing a branched chain enriched amino acid solution to oral neomycin. Nutritional Support Services1986;6:18‐21. StraussE , SantosWR , DaSilvaEC , LacetCM , CapacciLL , BernardiniAP . A randomized controlled clinical trial for the evaluation of the efficacy of an enriched branched‐chain amino‐acid solution compared to neomycin in hepatic encephalopathy. Hepatology (Baltimore, Md.)1983;3:862. ">Strauss 1986</a>; <a href="./references#CD001939-bbs2-0007" title="HwangSJ , ChanCY , WuJC , LeeSD , HuanYS , TsaiYT , et al. A randomized controlled trial for the evaluation of the efficacy of branched chain amino acid‐enriched amino acid solution in the treatment of patients with hepatic encephalopathy. Chinese Journal of Gastroenterology1988;5:185‐92. ">Hwang 1988</a>; <a href="./references#CD001939-bbs2-0009" title="BianchiGP , MarchesiniG , ZoliM , AbbiatiR , FerrarioE , FabbriA , et al. Oral BCAA supplementation in cirrhosis with chronic encephalopathy: effects on prolactin and estradiol levels. Hepato‐gastroenterology1992;39:443‐6. MarchesiniG , BianchiG , MerliM , AmodioP , PanellaC , LoguercioC , et al. Nutritional supplementation with branched‐chain amino acids in advanced cirrhosis: a double‐blind, randomized trial. Gastroenterology2003;124:1792‐801. MarchesiniG , DioguardiFS , BianchiGP , ZoliM , BellatiG , RoffiL , et al. Long‐term oral branched‐chain amino acid treatment in chronic hepatic encephalopathy. A randomized double‐blind casein controlled trial. The Italian Multicenter Study Group. Journal of Hepatology1990;11:92‐101. ">Marchesini 1990</a>; <a href="./references#CD001939-bbs2-0013" title="PlauthM , EgbertsE‐H , HamsterW , TörökM , MüllerP , BrandO , et al. Long‐term treatment with branched‐chain amino acids (BCA) improves the portosystemic encephalopathy (PSE) in ambulant patients. Results of a double blind, placebo controlled crossover study. Klinische Wochenschrift1992;69:126. PlauthM , EgbertsEH , HamsterW , TörökM , MüllerPH , BrandO , et al. Long‐term treatment of latent portosystemic encephalopathy with branched‐chain amino acids. A double‐blind placebo‐crossover study. Journal of Hepatology1993;17:308‐14. ">Plauth 1993</a>; <a href="./references#CD001939-bbs2-0010" title="MarchesiniG , BianchiG , MerliM , AmodioP , PanellaC , LoguercioC , et al. Nutritional supplementation with branched‐chain amino acids in advanced cirrhosis: a double‐blind, randomized trial. Gastroenterology2003;124:1980‐2. ">Marchesini 2003</a>; <a href="./references#CD001939-bbs2-0012" title="Horie‐TakashiI . Effects of oral branched‐chain amino acid granules on event‐free survival in patients with liver cirrhosis. Clinical Gastroenterology and Hepatology2005; Vol. 3:705‐13 (additional information and data received November 2011). MutoY , SatoS , WatanabeA , MoriwakiH , SuzukiK , KatoA , et al. Effects of oral branched‐chain amino acid granules on event‐free survival in patients with liver cirrhosis. Clinical Gastroenterology and Hepatology2005;3:705‐13. SatoS , WatanabeA , MutoY , SuzukiK , KatoA , MoriwakiH , et al. Clinical comparison of branched‐chain amino acid (l‐Leucine, l‐Isoleucine, l‐Valine) granules and oral nutrition for hepatic insufficiency in patients with decompensated liver cirrhosis (LIV‐EN study). Hepatology Research2005;31:232‐40. ">Muto 2005</a>; <a href="./references#CD001939-bbs2-0008" title="LesI , DovalE , Garcia‐MartinezR , PlanasM , CardenasG , GomezP , et al. Effects of branched‐chain amino acids supplementation in patients with cirrhosis and a previous episode of hepatic encephalopathy: a randomized study. American Journal of Gastroenterology2011;106:1081‐8. ">Les 2011</a>). </p> </section> <section id="CD001939-sec-0074"> <h4 class="title">Selective reporting</h4> <p>One trial published in abstract form did not report mortality (<a href="./references#CD001939-bbs2-0005" title="HayashiS , AoyagiY , FujiwaraK , OkaH , OdaT . A randomized controlled trial of branched‐chain amino acid (BCAA)‐enriched elemental diet (ED‐H) for hepatic encephalopathy. Journal of Gastroenterology and Hepatology1991;6:191. ">Hayashi 1991</a>). We classed the trial as having a high risk of reporting bias. We had access to protocols for four trials (<a href="./references#CD001939-bbs2-0009" title="BianchiGP , MarchesiniG , ZoliM , AbbiatiR , FerrarioE , FabbriA , et al. Oral BCAA supplementation in cirrhosis with chronic encephalopathy: effects on prolactin and estradiol levels. Hepato‐gastroenterology1992;39:443‐6. MarchesiniG , BianchiG , MerliM , AmodioP , PanellaC , LoguercioC , et al. Nutritional supplementation with branched‐chain amino acids in advanced cirrhosis: a double‐blind, randomized trial. Gastroenterology2003;124:1792‐801. MarchesiniG , DioguardiFS , BianchiGP , ZoliM , BellatiG , RoffiL , et al. Long‐term oral branched‐chain amino acid treatment in chronic hepatic encephalopathy. A randomized double‐blind casein controlled trial. The Italian Multicenter Study Group. Journal of Hepatology1990;11:92‐101. ">Marchesini 1990</a>; <a href="./references#CD001939-bbs2-0016" title="GluudC , DejgaardA , HardtF , KristensenM , KøhlerO , MelgaardB , et al. Preliminary treatment results with balanced amino acid infusion to patients with hepatic encephalopathy. Scandinavian Journal of Gastroenterology1983;18:19. VilstrupH , GluudC , HardtF , KristensenM , KøhlerO , MelgaardB , et al. Branched chain enriched amino acid versus glucose treatment of hepatic encephalopathy. A double‐blind study of 65 patients with cirrhosis. Hepatology (Baltimore, Md.)1990;10:291‐6. VilstrupH , GluudC , HardtF , KristensenM , MelgaardB , KøhlerO , et al. Branched chain enriched amino acid nutrition does not change the outcome of hepatic coma in patients with cirrhosis of the liver. Journal of Hepatology1985;1:S347. ">Vilstrup 1990</a>; <a href="./references#CD001939-bbs2-0010" title="MarchesiniG , BianchiG , MerliM , AmodioP , PanellaC , LoguercioC , et al. Nutritional supplementation with branched‐chain amino acids in advanced cirrhosis: a double‐blind, randomized trial. Gastroenterology2003;124:1980‐2. ">Marchesini 2003</a>; <a href="./references#CD001939-bbs2-0008" title="LesI , DovalE , Garcia‐MartinezR , PlanasM , CardenasG , GomezP , et al. Effects of branched‐chain amino acids supplementation in patients with cirrhosis and a previous episode of hepatic encephalopathy: a randomized study. American Journal of Gastroenterology2011;106:1081‐8. ">Les 2011</a>). All four trials reported pre‐defined outcomes including mortality and hepatic encephalopathy. We found that 15 trials reported the pre‐defined outcomes (mortality and hepatic encephalopathy). We classed these 15 trials as having a low risk of reporting bias (<a href="./references#CD001939-bbs2-0004" title="FiaccadoriF . Branched chain amino acid enriched solutions in the treatment of hepatic encephalopathy: a controlled trial. Italian Journal of Gastroenterology (additional information from author November 2012). FiaccadoriF , GhinelliF , PedrettiG . Branched chain amino acid enriched solutions in the treatment of hepatic encephalopathy: a controlled trial. Italian Journal of Gastroenterology1985;17:5‐10. FiaccadoriF , GhinelliF , PedrettiG , ManciaD . Mental state course and biochemical findings in HE treated by BCAA‐enriched mixtures. In: HolmE , KasperH editor(s). Metabolism and Nutrition in Liver Disease Freiburg 1984: Proceedings of the 41st Falk Symposium. Lancaster: MTP Press, 1985:281‐5. FiaccadoriF , GhinelliF , PedrettiG , PelosiG , SacchiniD , ZeneroliML , et al. Branched chain amino acid enriched solutions in the treatment of hepatic encephalopathy: a controlled trial. In: CapocacciaL , FischerJE , Rossi‐FanelliF editor(s). Hepatic Encephalopathy in Chronic Liver Failure. New York: Plenum Press, 1984:323‐33. FiaccadoriF , GhinelliF , PelosiG , SacchiniD , VaonaG , ZeneroliML , et al. Selective amino acid solutions in hepatic encephalopathy treatment (a preliminary report). La Ricerca in Clinica e in Laboratorio1980;10:411‐22. [MEDLINE: 81102770] ">Fiaccadori 1984</a>; <a href="./references#CD001939-bbs2-0006" title="HorstD , GraceN , ConnHO , SchiffE , SchenkerS , ViteriA , et al. A double‐blind randomized comparison of dietary protein and an oral branched chain amino acid (BCAA) solution in cirrhotic patients with chronic portal‐systemic encephalopathy (PSE) [IASL abstract]. Hepatology (Baltimore, Md.)1982;2:184. HorstD , GraceND , ConnHO , SchiffE , SchenkerS , ViteriA , et al. Comparison of dietary protein with an oral, branched chain‐enriched amino acid supplement in chronic portal‐systemic encephalopathy: a randomized controlled trial. Hepatology (Baltimore, Md.)1984;4:279‐87. ">Horst 1984</a>; <a href="./references#CD001939-bbs2-0001" title="CalveyH , DavisM , WilliamsR . Controlled trial of nutritional supplementation, with and without branched chain amino acid enrichment, in treatment of acute alcoholic hepatitis. Journal of Hepatology1985;1:141‐51. CalveyH , DavisM , WilliamsR . Prospective study of nasogastric feeding via East Grinstead or Viomedex tubes compared with oral dietary supplementation in patients with cirrhosis. Clinical Nutrition1984;3:63‐6. WilliamsR , CalveyH , DavisM . Controlled trial of nutritional supplementation in acute alcoholic hepatitis. In: HolmEKH editor(s). Metabolism and Nutrition in Liver Disease. Lancaster, UK: MTP Press, Ltd, 1985:361‐8. ">Calvey 1985</a>; <a href="./references#CD001939-bbs2-0002" title="CerraFB . Disease‐specific amino acid infusion (F080) in hepatic encephalopathy: a prospective, randomized, double‐blind, controlled trial [personal communication]. Correspondence with authorsSeptember 2002. CerraFB , CheungNK , FischerJE , KaplowitzN , SchiffE‐R , DienstagJL , et al. Disease‐specific amino acid infusion (F080) in hepatic encephalopathy: a prospective, randomized, double‐blind, controlled trial. JPEN. Journal of Parenteral and Enteral Nutrition1985;9:288‐95. CerraFB , CheungNK , FischerJE , KaplowitzN , SchiffER , DienstagJL , et al. A multicenter trial of branched chain enriched amino acid infusion (F080) in hepatic encephalopathy (HE). Hepatology (Baltimore, Md.)1982;2:699. CerraFB , McMillenM , AngelicoR , ClineB , LyonsJ , FaulkenbachL , et al. Cirrhosis, encephalopathy, and improved results with metabolic support. Surgery1983;94:612‐9. ">Cerra 1985</a>; <a href="./references#CD001939-bbs2-0003" title="EgbertsEH , HamsterW , SchomeerusH , JürgensP . Effect of branched chain amino acids on latent porto‐systemic‐encephalopathy (PSE). JPEN. Journal of Parenteral and Enteral Nutrition1981;5:5. EgbertsEH , SchomeerusH , HamsterW , JürgensP . Effective treatment of latens porto‐systemic encephalopathy with oral branched chain amino acids. In: CapocacciaL , FischerJE , Rossi‐FanelliF editor(s). Hepatic Encephalopathy in Chronic Liver Failure. New York: Plenum Press, 1984:351‐7. EgbertsEH , SchomerusH , HamsterW , JurgensP . Branched chain amino acids in the treatment of latent portosystemic encephalopathy. A double‐blind placebo‐controlled crossover study. Gastroenterology1985;88:887‐95. EgbertsEH , SchomerusH , HamsterW , JürgensP . Branched‐chain amino acids in the treatment of latent porto‐systemic encephalopathy. A placebo‐controlled double‐blind cross‐over study [Verzweigtkettige Aminosäuren bei der behandlung der latenten portosystemischen enzephalopathie. Eine placebokontrollierte doppelblind‐cross‐over‐studie]. Zeitschrift für Ernährungswissenschaft1986;25:9‐28. HamsterW , EgbertsEH , HamsterH . Treatment with branched‐chain amino acids and effect on psycho‐physical capacity functions in latent porto‐systemic encephalopathy [Behandlung mit verzweigtkettigen aminosäuren und ihre auswirkung auf psychophysische leistungsfunktionen bei latenter portosystemischer enzephalopathie]. Arzneimittelforschung1982;32:901‐2. ">Egberts 1985</a>; <a href="./references#CD001939-bbs2-0011" title="MichelH , BoriesP , AubinJP , Pomier‐LayrarguesG , BauretP , Bellet‐HermanH . Treatment of acute hepatic encephalopathy in cirrhotics with a branched‐chain amino acids enriched versus a conventional amino acids mixture. A controlled study of 70 patients. Liver1985;5:282‐9. MichelH , Pomier‐LayrarguesG , AubinJP , BoriesP , MirouzeD , Bellet‐HermanH . Treatment of hepatic encephalopathy by infusion of a modified amino acid solution: results of a controlled study in 47 cirrhotic patients. In: CapocacciaL , FischerJE , Rossi‐FanelliF editor(s). Hepatic Encephalopathy in Chronic Liver Failure. New York: Plenum Press, 1984:301‐10. MichelH , Pomier‐LayrarguesG , DuhamelO , LacombeB , CuilleretG , Bellet‐HermannH . Intravenous infusion of ordinary and modified amino‐acid solutions in the management of hepatic encephalopathy (controlled study, 30 patients). Gastroenterology1980;79:1038. Pomier‐LayrarguesG , DuhamelO , LacombeB , CuilleretG , BelletH , MichelH . Intravenous infusion of ordinary and modified amino‐acid solutions in the management of hepatic encephalopathy. Liver1981;1:140. ">Michel 1985</a>; <a href="./references#CD001939-bbs2-0014" title="RiggioO , CangianoC , CascinoA , MerliM , StortoniM , Rossi‐FanelliF , et al. Long term dietary supplement with branched chain amino acids: a new approach in the prevention of hepatic encephalopathy: results of a controlled study in cirrhotics with porto‐caval anastomosis. In: Associazione Italiana per Lo Studio del Fegato. Congress, editor(s). Hepatic Encephalopathy in Chronic Liver Failure. New York: Plenum Press, 1984:183‐92. Rossi‐FanelliF , CangianoC , CapocacciaL , CascinoA , CeciF , MuscaritoliM , et al. Use of branched chain amino acids for treating hepatic encephalopathy: clinical experiences. Gut1986;27:111‐5. Rossi‐FanelliF , CangianoC , CascinoA , MerliM , RiggioO , StortoniM , et al. Branched‐chain amino acids in the treatment of severe hepatic encephalopathy. In: CapocacciaL , FischerJE , Rossi‐FanelliF editor(s). Hepatic Encephalopathy in Chronic Liver Failure. New York: Plenum Press, 1984:335‐44. Rossi‐FanelliF , RiggioO , CangianoC , CascinoA , DeConciliisD , MerliM , et al. Branched‐chain amino acids vs lactulose in the treatment of hepatic coma: a controlled study. Digestive Diseases and Sciences1982;27:929‐35. ">Rossi‐Fanelli 1986</a>; <a href="./references#CD001939-bbs2-0015" title="StraussE , Cartapatti Da SilvaE , LacetCM , CapacciMLL , BernardiniAP . Treatment of hepatic encephalopathy: a randomized clinical trial comparing a branched chain enriched amino acid solution to oral neomycin. Nutritional Support Services1986;6:18‐21. StraussE , SantosWR , DaSilvaEC , LacetCM , CapacciLL , BernardiniAP . A randomized controlled clinical trial for the evaluation of the efficacy of an enriched branched‐chain amino‐acid solution compared to neomycin in hepatic encephalopathy. Hepatology (Baltimore, Md.)1983;3:862. ">Strauss 1986</a>; <a href="./references#CD001939-bbs2-0007" title="HwangSJ , ChanCY , WuJC , LeeSD , HuanYS , TsaiYT , et al. A randomized controlled trial for the evaluation of the efficacy of branched chain amino acid‐enriched amino acid solution in the treatment of patients with hepatic encephalopathy. Chinese Journal of Gastroenterology1988;5:185‐92. ">Hwang 1988</a>; <a href="./references#CD001939-bbs2-0009" title="BianchiGP , MarchesiniG , ZoliM , AbbiatiR , FerrarioE , FabbriA , et al. Oral BCAA supplementation in cirrhosis with chronic encephalopathy: effects on prolactin and estradiol levels. Hepato‐gastroenterology1992;39:443‐6. MarchesiniG , BianchiG , MerliM , AmodioP , PanellaC , LoguercioC , et al. Nutritional supplementation with branched‐chain amino acids in advanced cirrhosis: a double‐blind, randomized trial. Gastroenterology2003;124:1792‐801. MarchesiniG , DioguardiFS , BianchiGP , ZoliM , BellatiG , RoffiL , et al. Long‐term oral branched‐chain amino acid treatment in chronic hepatic encephalopathy. A randomized double‐blind casein controlled trial. The Italian Multicenter Study Group. Journal of Hepatology1990;11:92‐101. ">Marchesini 1990</a>; <a href="./references#CD001939-bbs2-0016" title="GluudC , DejgaardA , HardtF , KristensenM , KøhlerO , MelgaardB , et al. Preliminary treatment results with balanced amino acid infusion to patients with hepatic encephalopathy. Scandinavian Journal of Gastroenterology1983;18:19. VilstrupH , GluudC , HardtF , KristensenM , KøhlerO , MelgaardB , et al. Branched chain enriched amino acid versus glucose treatment of hepatic encephalopathy. A double‐blind study of 65 patients with cirrhosis. Hepatology (Baltimore, Md.)1990;10:291‐6. VilstrupH , GluudC , HardtF , KristensenM , MelgaardB , KøhlerO , et al. Branched chain enriched amino acid nutrition does not change the outcome of hepatic coma in patients with cirrhosis of the liver. Journal of Hepatology1985;1:S347. ">Vilstrup 1990</a>; <a href="./references#CD001939-bbs2-0013" title="PlauthM , EgbertsE‐H , HamsterW , TörökM , MüllerP , BrandO , et al. Long‐term treatment with branched‐chain amino acids (BCA) improves the portosystemic encephalopathy (PSE) in ambulant patients. Results of a double blind, placebo controlled crossover study. Klinische Wochenschrift1992;69:126. PlauthM , EgbertsEH , HamsterW , TörökM , MüllerPH , BrandO , et al. Long‐term treatment of latent portosystemic encephalopathy with branched‐chain amino acids. A double‐blind placebo‐crossover study. Journal of Hepatology1993;17:308‐14. ">Plauth 1993</a>; <a href="./references#CD001939-bbs2-0010" title="MarchesiniG , BianchiG , MerliM , AmodioP , PanellaC , LoguercioC , et al. Nutritional supplementation with branched‐chain amino acids in advanced cirrhosis: a double‐blind, randomized trial. Gastroenterology2003;124:1980‐2. ">Marchesini 2003</a>; <a href="./references#CD001939-bbs2-0012" title="Horie‐TakashiI . Effects of oral branched‐chain amino acid granules on event‐free survival in patients with liver cirrhosis. Clinical Gastroenterology and Hepatology2005; Vol. 3:705‐13 (additional information and data received November 2011). MutoY , SatoS , WatanabeA , MoriwakiH , SuzukiK , KatoA , et al. Effects of oral branched‐chain amino acid granules on event‐free survival in patients with liver cirrhosis. Clinical Gastroenterology and Hepatology2005;3:705‐13. SatoS , WatanabeA , MutoY , SuzukiK , KatoA , MoriwakiH , et al. Clinical comparison of branched‐chain amino acid (l‐Leucine, l‐Isoleucine, l‐Valine) granules and oral nutrition for hepatic insufficiency in patients with decompensated liver cirrhosis (LIV‐EN study). Hepatology Research2005;31:232‐40. ">Muto 2005</a>; <a href="./references#CD001939-bbs2-0008" title="LesI , DovalE , Garcia‐MartinezR , PlanasM , CardenasG , GomezP , et al. Effects of branched‐chain amino acids supplementation in patients with cirrhosis and a previous episode of hepatic encephalopathy: a randomized study. American Journal of Gastroenterology2011;106:1081‐8. ">Les 2011</a>). </p> <section id="CD001939-sec-0075"> <h5 class="title">For‐profit funding</h5> <p>Three trials received support from for‐profit organisations in the form of interventions (<a href="./references#CD001939-bbs2-0013" title="PlauthM , EgbertsE‐H , HamsterW , TörökM , MüllerP , BrandO , et al. Long‐term treatment with branched‐chain amino acids (BCA) improves the portosystemic encephalopathy (PSE) in ambulant patients. Results of a double blind, placebo controlled crossover study. Klinische Wochenschrift1992;69:126. PlauthM , EgbertsEH , HamsterW , TörökM , MüllerPH , BrandO , et al. Long‐term treatment of latent portosystemic encephalopathy with branched‐chain amino acids. A double‐blind placebo‐crossover study. Journal of Hepatology1993;17:308‐14. ">Plauth 1993</a>; <a href="./references#CD001939-bbs2-0016" title="GluudC , DejgaardA , HardtF , KristensenM , KøhlerO , MelgaardB , et al. Preliminary treatment results with balanced amino acid infusion to patients with hepatic encephalopathy. Scandinavian Journal of Gastroenterology1983;18:19. VilstrupH , GluudC , HardtF , KristensenM , KøhlerO , MelgaardB , et al. Branched chain enriched amino acid versus glucose treatment of hepatic encephalopathy. A double‐blind study of 65 patients with cirrhosis. Hepatology (Baltimore, Md.)1990;10:291‐6. VilstrupH , GluudC , HardtF , KristensenM , MelgaardB , KøhlerO , et al. Branched chain enriched amino acid nutrition does not change the outcome of hepatic coma in patients with cirrhosis of the liver. Journal of Hepatology1985;1:S347. ">Vilstrup 1990</a>; <a href="./references#CD001939-bbs2-0012" title="Horie‐TakashiI . Effects of oral branched‐chain amino acid granules on event‐free survival in patients with liver cirrhosis. Clinical Gastroenterology and Hepatology2005; Vol. 3:705‐13 (additional information and data received November 2011). MutoY , SatoS , WatanabeA , MoriwakiH , SuzukiK , KatoA , et al. Effects of oral branched‐chain amino acid granules on event‐free survival in patients with liver cirrhosis. Clinical Gastroenterology and Hepatology2005;3:705‐13. SatoS , WatanabeA , MutoY , SuzukiK , KatoA , MoriwakiH , et al. Clinical comparison of branched‐chain amino acid (l‐Leucine, l‐Isoleucine, l‐Valine) granules and oral nutrition for hepatic insufficiency in patients with decompensated liver cirrhosis (LIV‐EN study). Hepatology Research2005;31:232‐40. ">Muto 2005</a>). We classed these trials as high risk of bias for this domain. None of the remaining 14 trials received support from for‐profit organisations (<a href="./references#CD001939-bbs2-0004" title="FiaccadoriF . Branched chain amino acid enriched solutions in the treatment of hepatic encephalopathy: a controlled trial. Italian Journal of Gastroenterology (additional information from author November 2012). FiaccadoriF , GhinelliF , PedrettiG . Branched chain amino acid enriched solutions in the treatment of hepatic encephalopathy: a controlled trial. Italian Journal of Gastroenterology1985;17:5‐10. FiaccadoriF , GhinelliF , PedrettiG , ManciaD . Mental state course and biochemical findings in HE treated by BCAA‐enriched mixtures. In: HolmE , KasperH editor(s). Metabolism and Nutrition in Liver Disease Freiburg 1984: Proceedings of the 41st Falk Symposium. Lancaster: MTP Press, 1985:281‐5. FiaccadoriF , GhinelliF , PedrettiG , PelosiG , SacchiniD , ZeneroliML , et al. Branched chain amino acid enriched solutions in the treatment of hepatic encephalopathy: a controlled trial. In: CapocacciaL , FischerJE , Rossi‐FanelliF editor(s). Hepatic Encephalopathy in Chronic Liver Failure. New York: Plenum Press, 1984:323‐33. FiaccadoriF , GhinelliF , PelosiG , SacchiniD , VaonaG , ZeneroliML , et al. Selective amino acid solutions in hepatic encephalopathy treatment (a preliminary report). La Ricerca in Clinica e in Laboratorio1980;10:411‐22. [MEDLINE: 81102770] ">Fiaccadori 1984</a>; <a href="./references#CD001939-bbs2-0006" title="HorstD , GraceN , ConnHO , SchiffE , SchenkerS , ViteriA , et al. A double‐blind randomized comparison of dietary protein and an oral branched chain amino acid (BCAA) solution in cirrhotic patients with chronic portal‐systemic encephalopathy (PSE) [IASL abstract]. Hepatology (Baltimore, Md.)1982;2:184. HorstD , GraceND , ConnHO , SchiffE , SchenkerS , ViteriA , et al. Comparison of dietary protein with an oral, branched chain‐enriched amino acid supplement in chronic portal‐systemic encephalopathy: a randomized controlled trial. Hepatology (Baltimore, Md.)1984;4:279‐87. ">Horst 1984</a>; <a href="./references#CD001939-bbs2-0001" title="CalveyH , DavisM , WilliamsR . Controlled trial of nutritional supplementation, with and without branched chain amino acid enrichment, in treatment of acute alcoholic hepatitis. Journal of Hepatology1985;1:141‐51. CalveyH , DavisM , WilliamsR . Prospective study of nasogastric feeding via East Grinstead or Viomedex tubes compared with oral dietary supplementation in patients with cirrhosis. Clinical Nutrition1984;3:63‐6. WilliamsR , CalveyH , DavisM . Controlled trial of nutritional supplementation in acute alcoholic hepatitis. In: HolmEKH editor(s). Metabolism and Nutrition in Liver Disease. Lancaster, UK: MTP Press, Ltd, 1985:361‐8. ">Calvey 1985</a>; <a href="./references#CD001939-bbs2-0002" title="CerraFB . Disease‐specific amino acid infusion (F080) in hepatic encephalopathy: a prospective, randomized, double‐blind, controlled trial [personal communication]. Correspondence with authorsSeptember 2002. CerraFB , CheungNK , FischerJE , KaplowitzN , SchiffE‐R , DienstagJL , et al. Disease‐specific amino acid infusion (F080) in hepatic encephalopathy: a prospective, randomized, double‐blind, controlled trial. JPEN. Journal of Parenteral and Enteral Nutrition1985;9:288‐95. CerraFB , CheungNK , FischerJE , KaplowitzN , SchiffER , DienstagJL , et al. A multicenter trial of branched chain enriched amino acid infusion (F080) in hepatic encephalopathy (HE). Hepatology (Baltimore, Md.)1982;2:699. CerraFB , McMillenM , AngelicoR , ClineB , LyonsJ , FaulkenbachL , et al. Cirrhosis, encephalopathy, and improved results with metabolic support. Surgery1983;94:612‐9. ">Cerra 1985</a>; <a href="./references#CD001939-bbs2-0003" title="EgbertsEH , HamsterW , SchomeerusH , JürgensP . Effect of branched chain amino acids on latent porto‐systemic‐encephalopathy (PSE). JPEN. Journal of Parenteral and Enteral Nutrition1981;5:5. EgbertsEH , SchomeerusH , HamsterW , JürgensP . Effective treatment of latens porto‐systemic encephalopathy with oral branched chain amino acids. In: CapocacciaL , FischerJE , Rossi‐FanelliF editor(s). Hepatic Encephalopathy in Chronic Liver Failure. New York: Plenum Press, 1984:351‐7. EgbertsEH , SchomerusH , HamsterW , JurgensP . Branched chain amino acids in the treatment of latent portosystemic encephalopathy. A double‐blind placebo‐controlled crossover study. Gastroenterology1985;88:887‐95. EgbertsEH , SchomerusH , HamsterW , JürgensP . Branched‐chain amino acids in the treatment of latent porto‐systemic encephalopathy. A placebo‐controlled double‐blind cross‐over study [Verzweigtkettige Aminosäuren bei der behandlung der latenten portosystemischen enzephalopathie. Eine placebokontrollierte doppelblind‐cross‐over‐studie]. Zeitschrift für Ernährungswissenschaft1986;25:9‐28. HamsterW , EgbertsEH , HamsterH . Treatment with branched‐chain amino acids and effect on psycho‐physical capacity functions in latent porto‐systemic encephalopathy [Behandlung mit verzweigtkettigen aminosäuren und ihre auswirkung auf psychophysische leistungsfunktionen bei latenter portosystemischer enzephalopathie]. Arzneimittelforschung1982;32:901‐2. ">Egberts 1985</a>; <a href="./references#CD001939-bbs2-0011" title="MichelH , BoriesP , AubinJP , Pomier‐LayrarguesG , BauretP , Bellet‐HermanH . Treatment of acute hepatic encephalopathy in cirrhotics with a branched‐chain amino acids enriched versus a conventional amino acids mixture. A controlled study of 70 patients. Liver1985;5:282‐9. MichelH , Pomier‐LayrarguesG , AubinJP , BoriesP , MirouzeD , Bellet‐HermanH . Treatment of hepatic encephalopathy by infusion of a modified amino acid solution: results of a controlled study in 47 cirrhotic patients. In: CapocacciaL , FischerJE , Rossi‐FanelliF editor(s). Hepatic Encephalopathy in Chronic Liver Failure. New York: Plenum Press, 1984:301‐10. MichelH , Pomier‐LayrarguesG , DuhamelO , LacombeB , CuilleretG , Bellet‐HermannH . Intravenous infusion of ordinary and modified amino‐acid solutions in the management of hepatic encephalopathy (controlled study, 30 patients). Gastroenterology1980;79:1038. Pomier‐LayrarguesG , DuhamelO , LacombeB , CuilleretG , BelletH , MichelH . Intravenous infusion of ordinary and modified amino‐acid solutions in the management of hepatic encephalopathy. Liver1981;1:140. ">Michel 1985</a>; <a href="./references#CD001939-bbs2-0014" title="RiggioO , CangianoC , CascinoA , MerliM , StortoniM , Rossi‐FanelliF , et al. Long term dietary supplement with branched chain amino acids: a new approach in the prevention of hepatic encephalopathy: results of a controlled study in cirrhotics with porto‐caval anastomosis. In: Associazione Italiana per Lo Studio del Fegato. Congress, editor(s). Hepatic Encephalopathy in Chronic Liver Failure. New York: Plenum Press, 1984:183‐92. Rossi‐FanelliF , CangianoC , CapocacciaL , CascinoA , CeciF , MuscaritoliM , et al. Use of branched chain amino acids for treating hepatic encephalopathy: clinical experiences. Gut1986;27:111‐5. Rossi‐FanelliF , CangianoC , CascinoA , MerliM , RiggioO , StortoniM , et al. Branched‐chain amino acids in the treatment of severe hepatic encephalopathy. In: CapocacciaL , FischerJE , Rossi‐FanelliF editor(s). Hepatic Encephalopathy in Chronic Liver Failure. New York: Plenum Press, 1984:335‐44. Rossi‐FanelliF , RiggioO , CangianoC , CascinoA , DeConciliisD , MerliM , et al. Branched‐chain amino acids vs lactulose in the treatment of hepatic coma: a controlled study. Digestive Diseases and Sciences1982;27:929‐35. ">Rossi‐Fanelli 1986</a>; <a href="./references#CD001939-bbs2-0015" title="StraussE , Cartapatti Da SilvaE , LacetCM , CapacciMLL , BernardiniAP . Treatment of hepatic encephalopathy: a randomized clinical trial comparing a branched chain enriched amino acid solution to oral neomycin. Nutritional Support Services1986;6:18‐21. StraussE , SantosWR , DaSilvaEC , LacetCM , CapacciLL , BernardiniAP . A randomized controlled clinical trial for the evaluation of the efficacy of an enriched branched‐chain amino‐acid solution compared to neomycin in hepatic encephalopathy. Hepatology (Baltimore, Md.)1983;3:862. ">Strauss 1986</a>; <a href="./references#CD001939-bbs2-0007" title="HwangSJ , ChanCY , WuJC , LeeSD , HuanYS , TsaiYT , et al. A randomized controlled trial for the evaluation of the efficacy of branched chain amino acid‐enriched amino acid solution in the treatment of patients with hepatic encephalopathy. Chinese Journal of Gastroenterology1988;5:185‐92. ">Hwang 1988</a>; <a href="./references#CD001939-bbs2-0009" title="BianchiGP , MarchesiniG , ZoliM , AbbiatiR , FerrarioE , FabbriA , et al. Oral BCAA supplementation in cirrhosis with chronic encephalopathy: effects on prolactin and estradiol levels. Hepato‐gastroenterology1992;39:443‐6. MarchesiniG , BianchiG , MerliM , AmodioP , PanellaC , LoguercioC , et al. Nutritional supplementation with branched‐chain amino acids in advanced cirrhosis: a double‐blind, randomized trial. Gastroenterology2003;124:1792‐801. MarchesiniG , DioguardiFS , BianchiGP , ZoliM , BellatiG , RoffiL , et al. Long‐term oral branched‐chain amino acid treatment in chronic hepatic encephalopathy. A randomized double‐blind casein controlled trial. The Italian Multicenter Study Group. Journal of Hepatology1990;11:92‐101. ">Marchesini 1990</a>; <a href="./references#CD001939-bbs2-0016" title="GluudC , DejgaardA , HardtF , KristensenM , KøhlerO , MelgaardB , et al. Preliminary treatment results with balanced amino acid infusion to patients with hepatic encephalopathy. Scandinavian Journal of Gastroenterology1983;18:19. VilstrupH , GluudC , HardtF , KristensenM , KøhlerO , MelgaardB , et al. Branched chain enriched amino acid versus glucose treatment of hepatic encephalopathy. A double‐blind study of 65 patients with cirrhosis. Hepatology (Baltimore, Md.)1990;10:291‐6. VilstrupH , GluudC , HardtF , KristensenM , MelgaardB , KøhlerO , et al. Branched chain enriched amino acid nutrition does not change the outcome of hepatic coma in patients with cirrhosis of the liver. Journal of Hepatology1985;1:S347. ">Vilstrup 1990</a>; <a href="./references#CD001939-bbs2-0005" title="HayashiS , AoyagiY , FujiwaraK , OkaH , OdaT . A randomized controlled trial of branched‐chain amino acid (BCAA)‐enriched elemental diet (ED‐H) for hepatic encephalopathy. Journal of Gastroenterology and Hepatology1991;6:191. ">Hayashi 1991</a>; <a href="./references#CD001939-bbs2-0010" title="MarchesiniG , BianchiG , MerliM , AmodioP , PanellaC , LoguercioC , et al. Nutritional supplementation with branched‐chain amino acids in advanced cirrhosis: a double‐blind, randomized trial. Gastroenterology2003;124:1980‐2. ">Marchesini 2003</a>; <a href="./references#CD001939-bbs2-0012" title="Horie‐TakashiI . Effects of oral branched‐chain amino acid granules on event‐free survival in patients with liver cirrhosis. Clinical Gastroenterology and Hepatology2005; Vol. 3:705‐13 (additional information and data received November 2011). MutoY , SatoS , WatanabeA , MoriwakiH , SuzukiK , KatoA , et al. Effects of oral branched‐chain amino acid granules on event‐free survival in patients with liver cirrhosis. Clinical Gastroenterology and Hepatology2005;3:705‐13. SatoS , WatanabeA , MutoY , SuzukiK , KatoA , MoriwakiH , et al. Clinical comparison of branched‐chain amino acid (l‐Leucine, l‐Isoleucine, l‐Valine) granules and oral nutrition for hepatic insufficiency in patients with decompensated liver cirrhosis (LIV‐EN study). Hepatology Research2005;31:232‐40. ">Muto 2005</a>; <a href="./references#CD001939-bbs2-0008" title="LesI , DovalE , Garcia‐MartinezR , PlanasM , CardenasG , GomezP , et al. Effects of branched‐chain amino acids supplementation in patients with cirrhosis and a previous episode of hepatic encephalopathy: a randomized study. American Journal of Gastroenterology2011;106:1081‐8. ">Les 2011</a>). </p> </section> </section> <section id="CD001939-sec-0076"> <h4 class="title">Other potential sources of bias</h4> <p>We did not identify other biases for any of the included trials.</p> </section> </section> <section id="CD001939-sec-0077"> <h3 class="title" id="CD001939-sec-0077">Effects of interventions</h3> <p>See: <a href="./full#CD001939-tbl-0001"><b>Summary of findings for the main comparison</b> Branched‐chain amino acids (BCAA) versus control for hepatic encephalopathy</a> </p> <section id="CD001939-sec-0078"> <h4 class="title">Mortality</h4> <p>In total, 78 of 367 participants in the BCAA group versus 89 of 393 participants in the control group died (<a href="./references#CD001939-fig-0006" title="">Analysis 1.1</a>). Random‐effects meta‐analysis showed no difference between the groups (RR 0.88, 95% CI 0.69 to 1.11; 760 participants; 15 trials). The between‐trial heterogeneity was unimportant (I<sup>2</sup> = 9%). The trial sequential analysis ignored the monitoring boundaries because the information in the cumulative meta‐analysis was insufficient (<a href="#CD001939-fig-0004">Figure 4</a>). Accordingly, the analysis suggested that we do not have firm evidence to support or refute the effect of BCAA on mortality. Subgroup analyses of mortality found no difference between oral or intravenous BCAA (RR 0.90, 95% CI 0.50 to 1.63 for oral; RR 0.90, 95% CI 0.63 to 1.28; for intravenous; <a href="./references#CD001939-fig-0007" title="">Analysis 1.2</a>), overt or minimal hepatic encephalopathy (<a href="./references#CD001939-fig-0008" title="">Analysis 1.3</a>), different types of control interventions (<a href="./references#CD001939-fig-0009" title="">Analysis 1.4</a>), or the type of data (<a href="./references#CD001939-fig-0010" title="">Analysis 1.5</a>). We did not perform a subgroup analysis to determine the effect of publication status because only trials published as full‐paper articles reported mortality. The random‐effects meta‐regression found no predictors of heterogeneity for mortality (duration of therapy: P value = 0.37; dose of BCAA: P value = 0.57). In sensitivity analyses limited to trials with a low risk of bias, there was no effect of BCAA on mortality (<a href="./references#CD001939-fig-0011" title="">Analysis 1.6</a>). Mortality did not differ between the intervention groups in simple imputation with all losses to follow‐up counted as treatment failures (RR 0.95, 95% CI 0.81 to 1.12) or in a worst‐case scenario analysis with participants randomised to BCAA counted as treatment failures and controls as treatment successes (RR 0.96, 95% CI 0.76 to 1.20). There were no small‐study effects (P value = 0.40). None of the participants died in the trial that included people with or without cirrhosis (<a href="./references#CD001939-bbs2-0001" title="CalveyH , DavisM , WilliamsR . Controlled trial of nutritional supplementation, with and without branched chain amino acid enrichment, in treatment of acute alcoholic hepatitis. Journal of Hepatology1985;1:141‐51. CalveyH , DavisM , WilliamsR . Prospective study of nasogastric feeding via East Grinstead or Viomedex tubes compared with oral dietary supplementation in patients with cirrhosis. Clinical Nutrition1984;3:63‐6. WilliamsR , CalveyH , DavisM . Controlled trial of nutritional supplementation in acute alcoholic hepatitis. In: HolmEKH editor(s). Metabolism and Nutrition in Liver Disease. Lancaster, UK: MTP Press, Ltd, 1985:361‐8. ">Calvey 1985</a>), so exclusion of the trial had no influence on the overall result. </p> <div class="figure" id="CD001939-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Trial sequential analysis of branched‐chain amino acids (BCAA) versus control interventions (placebo, no intervention, neomycin, or lactulose) for mortality in people with hepatic encephalopathy. The blue line (Z‐curve) shows the cumulative meta‐analysis adding the results of individual trials based on the year of publication. The vertical green line represents the 5% level of significance. The monitoring boundary (and futility) was ignored because the number of events and participants included in the analysis was insufficient. In the sequential analysis, we set alpha to 5%, power to 80%, control group incidence to 25%, relative risk reduction to 5%, and heterogeneity correction to 17%. The estimated information size was 23,485 participants. In total, the number of participants randomised was 367 in the BCAA group and 393 in the control groups." data-id="CD001939-fig-0004" src="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/image_n/nCD001939-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p><b>Trial sequential analysis of branched‐chain amino acids (BCAA) versus control interventions (placebo, no intervention, neomycin, or lactulose) for mortality in people with hepatic encephalopathy.</b> The blue line (Z‐curve) shows the cumulative meta‐analysis adding the results of individual trials based on the year of publication. The vertical green line represents the 5% level of significance. The monitoring boundary (and futility) was ignored because the number of events and participants included in the analysis was insufficient. In the sequential analysis, we set alpha to 5%, power to 80%, control group incidence to 25%, relative risk reduction to 5%, and heterogeneity correction to 17%. The estimated information size was 23,485 participants. In total, the number of participants randomised was 367 in the BCAA group and 393 in the control groups. </p> </div> </div> </div> </section> <section id="CD001939-sec-0079"> <h4 class="title">Hepatic encephalopathy</h4> <p>We gathered data on hepatic encephalopathy from all trials (<a href="./references#CD001939-fig-0012" title="">Analysis 1.7</a>). Random‐effects meta‐analysis showed that BCAA was associated with a beneficial effect on hepatic encephalopathy compared with controls (RR 0.73, 95% CI 0.61 to 0.88; 827 participants). The between‐trial heterogeneity was moderate (I<sup>2</sup> = 51%). In trial sequential analysis (<a href="#CD001939-fig-0005">Figure 5</a>), the cumulative Z‐curve crossed the monitoring boundary before the required information size (also known as the diversity‐adjusted required information size), which was 186 participants. When we repeated the analysis with a lower control group event rate and a lower RRR (adjusted for the potential risk of bias), the Z‐curve crossed the monitoring boundary after inclusion of 546 participants before the required information size, which was 557 participants. Subgroup analysis found an effect of oral, but not intravenous BCAA (oral: RR 0.67, 95% CI 0.52 to 0.88; 430 participants; intravenous: RR 0.81, 95% CI 0.61 to 1.08; 397 participants; test for subgroup differences P value = 0.34; <a href="./references#CD001939-fig-0013" title="">Analysis 1.8</a>). There were no differences between trials stratified in subgroups based on the type of hepatic encephalopathy (P value = 0.83; <a href="./references#CD001939-fig-0014" title="">Analysis 1.9</a>), control groups (P value = 0.26; <a href="./references#CD001939-fig-0015" title="">Analysis 1.10</a>), published or re‐calculated data (P value = 0.47; <a href="./references#CD001939-fig-0016" title="">Analysis 1.11</a>), or publication status (P value = 0.47; <a href="./references#CD001939-fig-0017" title="">Analysis 1.12</a>). In sensitivity analyses, BCAA had a beneficial effect on hepatic encephalopathy in trials with a low risk of bias (<a href="./references#CD001939-fig-0018" title="">Analysis 1.13</a>). There were no small‐study effects (P value = 0.22). The benefit of BCAA on hepatic encephalopathy was confirmed in an analysis that counted all participants with missing outcomes as treatment failures (RR 1.32, 95% CI 1.15 to 1.51) and in a worst‐case scenario analysis that counted participants randomised to BCAA as treatment failures and controls as treatment successes (RR 1.19, 95% CI 1.08 to 1.31). In one post‐hoc analysis that excluded the trial on people with acute liver disease with or without cirrhosis (<a href="./references#CD001939-bbs2-0001" title="CalveyH , DavisM , WilliamsR . Controlled trial of nutritional supplementation, with and without branched chain amino acid enrichment, in treatment of acute alcoholic hepatitis. Journal of Hepatology1985;1:141‐51. CalveyH , DavisM , WilliamsR . Prospective study of nasogastric feeding via East Grinstead or Viomedex tubes compared with oral dietary supplementation in patients with cirrhosis. Clinical Nutrition1984;3:63‐6. WilliamsR , CalveyH , DavisM . Controlled trial of nutritional supplementation in acute alcoholic hepatitis. In: HolmEKH editor(s). Metabolism and Nutrition in Liver Disease. Lancaster, UK: MTP Press, Ltd, 1985:361‐8. ">Calvey 1985</a>), BCAA had a beneficial effect on hepatic encephalopathy (RR 0.74, 95% CI 0.62 to 0.89; <a href="./references#CD001939-fig-0019" title="">Analysis 1.14</a>). BCAA was also associated with a beneficial effect on mortality when excluding trials with a lactulose or neomycin control group (RR 0.76, 95% CI 0.63 to 0.92; 610 participants; 11 trials; I<sup>2</sup> = 52%; <a href="./references#CD001939-fig-0020" title="">Analysis 1.15</a>), but not when the analysis only included trials with a lactulose or neomycin control (RR 0.66, 95% CI 0.34 to 1.30; 195 participants; 4 trials; I<sup>2</sup> = 46%; <a href="./references#CD001939-fig-0021" title="">Analysis 1.16</a>). </p> <div class="figure" id="CD001939-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Trial sequential analysis of branched‐chain amino acids (BCAA) versus control interventions (placebo, no intervention, neomycin, or lactulose) for hepatic encephalopathy. The blue line (Z‐curve) shows the cumulative meta‐analysis adding the results of individual trials based on the year of publication. The vertical line represents the 5% level of significance. The monitoring boundary (inward sloping red line) shows the significance level after adjusting for the cumulative analysis. The horizontal green line shows the required information size (the number of participants needed to determine if firm evidence was established). We conducted the trial sequential analysis with alpha set to 5%, power to 80%, control group event rate to 63%, relative risk reduction to 45%, and heterogeneity correction to 47%. The estimated required information size was 186 participants (diversity adjusted). In total, the cumulative meta‐analysis included 402 participants in the BCAA group and 425 in the control groups." data-id="CD001939-fig-0005" src="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/image_n/nCD001939-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p><b>Trial sequential analysis of branched‐chain amino acids (BCAA) versus control interventions (placebo, no intervention, neomycin, or lactulose) for hepatic encephalopathy.</b> The blue line (Z‐curve) shows the cumulative meta‐analysis adding the results of individual trials based on the year of publication. The vertical line represents the 5% level of significance. The monitoring boundary (inward sloping red line) shows the significance level after adjusting for the cumulative analysis. The horizontal green line shows the required information size (the number of participants needed to determine if firm evidence was established). We conducted the trial sequential analysis with alpha set to 5%, power to 80%, control group event rate to 63%, relative risk reduction to 45%, and heterogeneity correction to 47%. The estimated required information size was 186 participants (diversity adjusted). In total, the cumulative meta‐analysis included 402 participants in the BCAA group and 425 in the control groups. </p> </div> </div> </div> <p>In univariable meta‐regression analyses, we found no effect of the dose of BCAA (P value = 0.09), duration of treatment (P value = 0.21), or mode of administration (P value = 0.35). When combining the three potential predictors, multi‐level meta‐regression analysis showed no effect of the dose (P value = 0.50), mode of administration (P value = 0.82), or treatment duration (P value = 0.57). In univariable meta‐regression analyses on participant characteristics, we reached a similar conclusion for the type of hepatic encephalopathy (P value = 0.07), mean age of included participants (P value = 0.50), proportion of men (P value = 0.94), proportion of people with alcoholic liver disease (P value = 0.09), and proportion of people with viral hepatitis (P value = 0.94). Likewise, we found no effect of the type of control group when analysed combined (placebo/no intervention, diet, lactulose, neomycin; P value = 0.75) or in separate assessments of placebo/no intervention (P value = 0.75), any diet (P value = 0.20), isonitrogenous isocaloric diet (P value = 0.80), neomycin (P value = 0.24), or lactulose (P value = 0.11). In multi‐level meta‐regression analyses with backwards elimination of all potential predictors, none remained in the model. </p> </section> <section id="CD001939-sec-0080"> <h4 class="title">Adverse events</h4> <p>The trials did not report serious adverse events (apart from mortality). The most common non‐serious adverse event was gastrointestinal discomfort (non‐specific gastrointestinal symptoms that included both nausea and diarrhoea), which occurred in about 50 of 442 (11%) participants in the BCAA group and 11 of 503 (2%) participants randomised to control diets (<a href="./references#CD001939-fig-0022" title="">Analysis 1.17</a>). BCAA increased the risk of nausea and diarrhoea in fixed‐effect meta‐analysis (RR 5.56, 95% CI 2.93 to 10.55), but not in random‐effects meta‐analysis (RR 3.39, 95% CI 0.70 to 16.46). </p> </section> <section id="CD001939-sec-0081"> <h4 class="title">Quality of life</h4> <p>Three trials studying oral BCAA supplements evaluated the quality of life scores at baseline and end of treatment based on the 36‐item Short Form (SF‐36) questionnaire (<a href="./references#CD001939-bbs2-0010" title="MarchesiniG , BianchiG , MerliM , AmodioP , PanellaC , LoguercioC , et al. Nutritional supplementation with branched‐chain amino acids in advanced cirrhosis: a double‐blind, randomized trial. Gastroenterology2003;124:1980‐2. ">Marchesini 2003</a>; <a href="./references#CD001939-bbs2-0012" title="Horie‐TakashiI . Effects of oral branched‐chain amino acid granules on event‐free survival in patients with liver cirrhosis. Clinical Gastroenterology and Hepatology2005; Vol. 3:705‐13 (additional information and data received November 2011). MutoY , SatoS , WatanabeA , MoriwakiH , SuzukiK , KatoA , et al. Effects of oral branched‐chain amino acid granules on event‐free survival in patients with liver cirrhosis. Clinical Gastroenterology and Hepatology2005;3:705‐13. SatoS , WatanabeA , MutoY , SuzukiK , KatoA , MoriwakiH , et al. Clinical comparison of branched‐chain amino acid (l‐Leucine, l‐Isoleucine, l‐Valine) granules and oral nutrition for hepatic insufficiency in patients with decompensated liver cirrhosis (LIV‐EN study). Hepatology Research2005;31:232‐40. ">Muto 2005</a>; <a href="./references#CD001939-bbs2-0008" title="LesI , DovalE , Garcia‐MartinezR , PlanasM , CardenasG , GomezP , et al. Effects of branched‐chain amino acids supplementation in patients with cirrhosis and a previous episode of hepatic encephalopathy: a randomized study. American Journal of Gastroenterology2011;106:1081‐8. ">Les 2011</a>). Due to the methods used to register scores, we were unable to combine the results in meta‐analyses. All trials included people with cirrhosis. Some of the included participants did not have hepatic encephalopathy at baseline. When the analyses were limited to people with hepatic encephalopathy, none of the trials found beneficial or harmful effect of BCAA on the global SF‐36 score or any of the subscales. </p> </section> <section id="CD001939-sec-0082"> <h4 class="title">Nutritional outcomes</h4> <p>The included trials did not perform comparable assessments of nutritional parameters. A meta‐analysis of three trials with diet controls showed no difference in post‐treatment albumin between the BCAA and control groups (MD 0.60, 95% CI ‐0.90 to 2.09; <a href="./references#CD001939-fig-0023" title="">Analysis 1.18</a>). Analysis of one trial with a neomycin control group and two trials with isonitrogenous controls showed no difference between intervention groups regarding nitrogen balance (SMD 0.81, 95% CI 0.07 to 1.56; <a href="./references#CD001939-fig-0024" title="">Analysis 1.19</a>). </p> </section> <section id="CD001939-sec-0083"> <h4 class="title">Summary of findings</h4> <p>We have presented the key results on the outcomes mortality, hepatic encephalopathy, adverse events, and nutritional outcomes, and grading of the quality of the evidence in <a href="./full#CD001939-tbl-0001">summary of findings Table for the main comparison</a>. We showed the result of the primary meta‐analysis for each outcome measure. As shown in the table, we only graded the quality of the evidence as 'high' for the outcome hepatic encephalopathy. We downgraded the evidence quality to 'moderate' for the remaining outcome measures, mainly due to imprecision. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD001939-sec-0084" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD001939-sec-0084"></div> <section id="CD001939-sec-0085"> <h3 class="title" id="CD001939-sec-0085">Summary of main results</h3> <p>This review included 16 randomised clinical trials published from 1984 to 2011. Nearly all included participants had cirrhosis (97%). The trials compared BCAA versus placebo/no intervention, diets, lactulose, or neomycin. The results showed that BCAA have a beneficial effect on manifestations of hepatic encephalopathy. The between‐trial heterogeneity was moderate, but none of the subgroup, sensitivity, or regression analyses was able to explain the heterogeneity. Different subgroup analyses showed a beneficial effect of oral, but not intravenous BCAA, and an effect of BCAA in trials on overt hepatic encephalopathy, but not on minimal hepatic encephalopathy. BCAA had a beneficial effect on hepatic encephalopathy when excluding trials with a lactulose or neomycin control group, but not in an analysis limited to trials with these two type of controls. However, the relatively small number of trials in the different subgroups limited the strength of the findings. Furthermore, none of the trials included several intervention arms comparing different types of BCAA or different control regimens. Additional analyses found that BCAA were associated with the gastrointestinal adverse events, diarrhoea and nausea, which occurred in about 1 in 10 people. We found no beneficial or detrimental effects of BCAA on the quality of life or nutritional outcomes. </p> </section> <section id="CD001939-sec-0086"> <h3 class="title" id="CD001939-sec-0086">Overall completeness and applicability of evidence</h3> <p>Recent guidelines recommend routine treatment of people with overt hepatic encephalopathy (<a href="./references#CD001939-bbs2-0024" title="VilstrupH , AmodioP , BajajJ , CordobaJ , FerenciP , MullenKD , et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology (Baltimore, Md.)2014;60:715‐35. ">AASLD and EASL guideline 2014a</a>; <a href="./references#CD001939-bbs2-0025" title="American Association for the Study of Liver Diseases, European Association for the Study of the Liver. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases. Journal of Hepatology2014;61:642‐59. ">AASLD and EASL guideline 2014b</a>). Oral BCAA are recommended as an alternative or add‐on therapy to the first‐line treatment, which is non‐absorbable disaccharides. Our findings support the use of BCAA in clinical practice, but do not provide enough evidence to evaluate the benefit of BCAA compared with other interventions. </p> <p>The cost effectiveness of interventions for the management of people with hepatic encephalopathy is important. Economic studies show that the total charges related to hepatic encephalopathy in the United States increased from $USD 4676.7 million in 2005 to $USD 7244.7 million in 2009 (<a href="./references#CD001939-bbs2-0073" title="StepanovaM , MishraA , VenkatesanC , YounossiZM . In‐hospital mortality and economic burden associated with hepatic encephalopathy in the United States from 2005 to 2009. Clinical Gastroenterology and Hepatology2012;10(9):1034‐41.e1. [PUBMED: 22642955] ">Stepanova 2012</a>). We did not assess the costs associated with hepatic encephalopathy, but our data may be used in future pharmacoeconomic reviews. </p> <p>The present systematic review (as well as the previous version) included a heterogeneous group of trials. We decided to keep the broad scope of the review to identify common features within similar interventions. Grouping increases the external validity and consistency of the findings making it possible to assess the intervention effect across a wider range of settings and patient populations. The strategy also reduces chance results that can occur when analysing several smaller subgroups (<a href="./references#CD001939-bbs2-0078" title="WeirMC , GrimshawJM , MayhewA , FergussonD . Decisions about lumping vs. splitting of the scope of systematic reviews of complex interventions are not well justified: a case study in systematic reviews of health care professional reminders. Journal of Clinical Epidemiology2012;65(7):756‐63. [PUBMED: 22498429] ">Weir 2012</a>). In theory, grouping makes it possible to make better judgements about the consistency of observed effects across trials and to look for differences between interventions, settings, and participant characteristics. We did not identify predictors of between‐trial heterogeneity. None of the intervention or participant characteristics explained heterogeneity. However, we did not have enough data to exclude the possibility that there may be specific patient populations who benefit more or less from BCAA. </p> <p>The diagnostic criteria used in individual trials varied. The variation largely reflected the differences that were occurred between the publication of the first trials in 1984 to (<a href="./references#CD001939-bbs2-0004" title="FiaccadoriF . Branched chain amino acid enriched solutions in the treatment of hepatic encephalopathy: a controlled trial. Italian Journal of Gastroenterology (additional information from author November 2012). FiaccadoriF , GhinelliF , PedrettiG . Branched chain amino acid enriched solutions in the treatment of hepatic encephalopathy: a controlled trial. Italian Journal of Gastroenterology1985;17:5‐10. FiaccadoriF , GhinelliF , PedrettiG , ManciaD . Mental state course and biochemical findings in HE treated by BCAA‐enriched mixtures. In: HolmE , KasperH editor(s). Metabolism and Nutrition in Liver Disease Freiburg 1984: Proceedings of the 41st Falk Symposium. Lancaster: MTP Press, 1985:281‐5. FiaccadoriF , GhinelliF , PedrettiG , PelosiG , SacchiniD , ZeneroliML , et al. Branched chain amino acid enriched solutions in the treatment of hepatic encephalopathy: a controlled trial. In: CapocacciaL , FischerJE , Rossi‐FanelliF editor(s). Hepatic Encephalopathy in Chronic Liver Failure. New York: Plenum Press, 1984:323‐33. FiaccadoriF , GhinelliF , PelosiG , SacchiniD , VaonaG , ZeneroliML , et al. Selective amino acid solutions in hepatic encephalopathy treatment (a preliminary report). La Ricerca in Clinica e in Laboratorio1980;10:411‐22. [MEDLINE: 81102770] ">Fiaccadori 1984</a>; <a href="./references#CD001939-bbs2-0006" title="HorstD , GraceN , ConnHO , SchiffE , SchenkerS , ViteriA , et al. A double‐blind randomized comparison of dietary protein and an oral branched chain amino acid (BCAA) solution in cirrhotic patients with chronic portal‐systemic encephalopathy (PSE) [IASL abstract]. Hepatology (Baltimore, Md.)1982;2:184. HorstD , GraceND , ConnHO , SchiffE , SchenkerS , ViteriA , et al. Comparison of dietary protein with an oral, branched chain‐enriched amino acid supplement in chronic portal‐systemic encephalopathy: a randomized controlled trial. Hepatology (Baltimore, Md.)1984;4:279‐87. ">Horst 1984</a>) to the publication of the latest trial in 2005 (<a href="./references#CD001939-bbs2-0012" title="Horie‐TakashiI . Effects of oral branched‐chain amino acid granules on event‐free survival in patients with liver cirrhosis. Clinical Gastroenterology and Hepatology2005; Vol. 3:705‐13 (additional information and data received November 2011). MutoY , SatoS , WatanabeA , MoriwakiH , SuzukiK , KatoA , et al. Effects of oral branched‐chain amino acid granules on event‐free survival in patients with liver cirrhosis. Clinical Gastroenterology and Hepatology2005;3:705‐13. SatoS , WatanabeA , MutoY , SuzukiK , KatoA , MoriwakiH , et al. Clinical comparison of branched‐chain amino acid (l‐Leucine, l‐Isoleucine, l‐Valine) granules and oral nutrition for hepatic insufficiency in patients with decompensated liver cirrhosis (LIV‐EN study). Hepatology Research2005;31:232‐40. ">Muto 2005</a>). Using a systematic approach to the assessment of hepatic encephalopathy was essential (<a href="./references#CD001939-bbs2-0030" title="BajajJS , CordobaJ , MullenKD , AmodioP , ShawcrossDL , ButterworthRF , et al. Review article: the design of clinical trials in hepatic encephalopathy ‐ an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement. Alimentary Pharmacology &amp; Therapeutics2011;33(7):739‐47. [PUBMED: 21306407] ">Bajaj 2011</a>). The included trials used methods such as the West Haven Criteria that are used in clinical practice (<a href="./references#CD001939-bbs2-0036" title="FerenciP , LockwoodA , MullenK , TarterR , WeissenbornK , BleiAT . Hepatic encephalopathy ‐ definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology (Baltimore, Md.)2002;35(3):716‐21. [PUBMED: 11870389] ">Ferenci 2002</a>; <a href="./references#CD001939-bbs2-0063" title="MullenKD . Review of the final report of the 1998 Working Party on definition, nomenclature and diagnosis of hepatic encephalopathy. Alimentary Pharmacology &amp; Therapeutics2007;25(Suppl 1):11‐6. [PUBMED: 17295847] ">Mullen 2007</a>; <a href="./references#CD001939-bbs2-0028" title="BajajJS . Minimal encephalopathy matters in daily life. World Journal of Gastroenterology2008;14(23):3609‐15. ">Bajaj 2008</a>). This system grades symptoms from a clinically normal mental state (grade 0) over trivial signs such as shortened attention span to deep coma (grade 4). The clinically normal state includes people without overt hepatic encephalopathy and people with minimal hepatic encephalopathy that can be identified through psychometric testing such as the number connection test (<a href="./references#CD001939-bbs2-0028" title="BajajJS . Minimal encephalopathy matters in daily life. World Journal of Gastroenterology2008;14(23):3609‐15. ">Bajaj 2008</a>; <a href="./references#CD001939-bbs2-0030" title="BajajJS , CordobaJ , MullenKD , AmodioP , ShawcrossDL , ButterworthRF , et al. Review article: the design of clinical trials in hepatic encephalopathy ‐ an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement. Alimentary Pharmacology &amp; Therapeutics2011;33(7):739‐47. [PUBMED: 21306407] ">Bajaj 2011</a>). In one cohort study of 217 people with cirrhosis, repeated evaluations showed that hepatic encephalopathy was not classed correctly in more than one third of people (<a href="./references#CD001939-bbs2-0058" title="KircheisG , FleigWE , GortelmeyerR , GrafeS , HaussingerD . Assessment of low‐grade hepatic encephalopathy: a critical analysis. Journal of Hepatology2007;47(5):642‐50. [PUBMED: 17869373] ">Kircheis 2007</a>). Therefore, thorough assessments are important. Likewise, careful evaluation is required to evaluate whether manifestations of hepatic encephalopathy is improved. Based on the differences in the diagnostic criteria, the assessment of this outcome measure varied in included trials. We chose to use the information and evaluation made by the original investigators. The extent to which manifestations improved will depend on the pre‐defined criteria and the overall assessment is likely to involve some degree of subjective assessment. In spite of these limitations, the definition and assessment of outcomes reflect current clinical practice (<a href="./references#CD001939-bbs2-0079" title="WeissenbornK . Psychometric tests for diagnosing minimal hepatic encephalopathy. Metabolic Brain Disease2013;28:227‐9. ">Weissenborn 2013</a>). </p> <p>One study found that BCAA supplementation increased ammonia levels in people with cirrhosis and healthy participants (<a href="./references#CD001939-bbs2-0034" title="DamG , KeidingS , MunkOL , OttP , BuhlM , VilstrupH , et al. Branched‐chain amino acids increase arterial blood ammonia in spite of enhanced intrinsic muscle ammonia metabolism in patients with cirrhosis and healthy subjects. American Journal of Physiology. Gastrointestinal and Liver Physiology2011;301(2):G269‐77. [PUBMED: 21636533] ">Dam 2011</a>). BCAA have a stimulatory effect on ammonia detoxification to glutamine and decreased concentrations in liver cirrhosis (<a href="./references#CD001939-bbs2-0053" title="HolecekM . Branched‐chain amino acids and ammonia metabolism in liver disease: therapeutic implications. Nutrition (Burbank, Los Angeles County, Calif.)2013;29(10):1186‐91. [PUBMED: 23756281] ">Holecek 2013</a>). The reasons for the BCAA deficiency in cirrhosis include consumption in skeletal muscle for synthesis of glutamate. We were unable to determine the effect of BCAA in relation to the baseline BCAA concentrations or sarcopenia or ammonia levels. We found few data to determine the effect of BCAA on nutrition. </p> </section> <section id="CD001939-sec-0087"> <h3 class="title" id="CD001939-sec-0087">Quality of the evidence</h3> <p>When assessing the quality of the included trials, the internal as well as the external validity was important. Without adequate internal validity, the question of external validity becomes unimportant. Without adequate external validity, the trial may be clinically irrelevant in spite of an excellent basic methodology. In the assessment of internal validity, the control of bias associated with randomisation and blinding is important because it may lead to overestimated intervention effects (<a href="./references#CD001939-bbs2-0082" title="WoodL , EggerM , GluudLL , SchulzKF , JuniP , AltmanDG , et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta‐epidemiological study. BMJ (Clinical Research Ed.)2008;336(7644):601‐5. [PUBMED: 18316340] ">Wood 2008</a>; <a href="./references#CD001939-bbs2-0071" title="SavovicJ , JonesHE , AltmanDG , HarrisRJ , JuniP , PildalJ , et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Annals of Internal Medicine2012;157(6):429‐38. [PUBMED: 22945832] ">Savovic 2012</a>). When evaluating the effect of bias, we estimated that lack of blinding would not affect the assessment of mortality or laboratory parameters. In a study including 1973 randomised clinical trials from 234 meta‐analyses (<a href="./references#CD001939-bbs2-0071" title="SavovicJ , JonesHE , AltmanDG , HarrisRJ , JuniP , PildalJ , et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Annals of Internal Medicine2012;157(6):429‐38. [PUBMED: 22945832] ">Savovic 2012</a>), authors found trials with inadequate or unclear (compared with adequate) sequence generation or allocation concealment overestimated intervention effects. The degree of bias was greatest for subjective outcomes and there was little evidence of bias for all‐cause mortality (relative odds ratio 0.89, credibility interval 0.75 to 1.05). Lack of, or unclear, double blinding (compared with double blinding) was associated with a mean 13% exaggeration of intervention effects. Again, bias was detected in analyses of subjective outcomes and not for all‐cause mortality. When we included the trials with a low risk of bias, we found no effect of BCAA on mortality, but a beneficial effect on hepatic encephalopathy when analysing bias domains separately or combined. </p> <p>Some trials on BCAA used a cross‐over design (<a href="./references#CD001939-bbs2-0003" title="EgbertsEH , HamsterW , SchomeerusH , JürgensP . Effect of branched chain amino acids on latent porto‐systemic‐encephalopathy (PSE). JPEN. Journal of Parenteral and Enteral Nutrition1981;5:5. EgbertsEH , SchomeerusH , HamsterW , JürgensP . Effective treatment of latens porto‐systemic encephalopathy with oral branched chain amino acids. In: CapocacciaL , FischerJE , Rossi‐FanelliF editor(s). Hepatic Encephalopathy in Chronic Liver Failure. New York: Plenum Press, 1984:351‐7. EgbertsEH , SchomerusH , HamsterW , JurgensP . Branched chain amino acids in the treatment of latent portosystemic encephalopathy. A double‐blind placebo‐controlled crossover study. Gastroenterology1985;88:887‐95. EgbertsEH , SchomerusH , HamsterW , JürgensP . Branched‐chain amino acids in the treatment of latent porto‐systemic encephalopathy. A placebo‐controlled double‐blind cross‐over study [Verzweigtkettige Aminosäuren bei der behandlung der latenten portosystemischen enzephalopathie. Eine placebokontrollierte doppelblind‐cross‐over‐studie]. Zeitschrift für Ernährungswissenschaft1986;25:9‐28. HamsterW , EgbertsEH , HamsterH . Treatment with branched‐chain amino acids and effect on psycho‐physical capacity functions in latent porto‐systemic encephalopathy [Behandlung mit verzweigtkettigen aminosäuren und ihre auswirkung auf psychophysische leistungsfunktionen bei latenter portosystemischer enzephalopathie]. Arzneimittelforschung1982;32:901‐2. ">Egberts 1985</a>; <a href="./references#CD001939-bbs2-0013" title="PlauthM , EgbertsE‐H , HamsterW , TörökM , MüllerP , BrandO , et al. Long‐term treatment with branched‐chain amino acids (BCA) improves the portosystemic encephalopathy (PSE) in ambulant patients. Results of a double blind, placebo controlled crossover study. Klinische Wochenschrift1992;69:126. PlauthM , EgbertsEH , HamsterW , TörökM , MüllerPH , BrandO , et al. Long‐term treatment of latent portosystemic encephalopathy with branched‐chain amino acids. A double‐blind placebo‐crossover study. Journal of Hepatology1993;17:308‐14. ">Plauth 1993</a>).The benefit of the design includes comparable control groups and increased statistical power. The use of the design in hepatic encephalopathy is debatable because the condition is a naturally fluctuating disease and because people may die during the first treatment period. Therefore, we chose to use only the first period of the cross‐over trials in spite of the potential loss of information that this strategy entails (<a href="./references#CD001939-bbs2-0060" title="LathyrisDN , TrikalinosTA , IoannidisJP . Evidence from crossover trials: empirical evaluation and comparison against parallel arm trials. International Journal of Epidemiology2007;36(2):422‐30. [PUBMED: 17301102] ">Lathyris 2007</a>). The duration of therapy ranged from one to 104 weeks. Because we used the first treatment period from cross‐over trials, the information that we included from the cross‐over trials was based on a relatively shorter follow‐up than trials using a parallel arm design. In our subgroup analyses, we found no difference between cross‐over and parallel arm trials, and the duration of follow‐up did not predict the treatment effect in our meta‐regression. However, we cannot exclude the possibility that the duration of follow‐up and trial design may be important. </p> </section> <section id="CD001939-sec-0088"> <h3 class="title" id="CD001939-sec-0088">Potential biases in the review process</h3> <p>The main potential bias in the review process is that we only had access to the published data from some of the included trials. We found no difference between the subgroups of trials with published summary data and trials for which we re‐calculated outcomes for people with hepatic encephalopathy at baseline. On the one hand, this supports the strength of our findings. On the other hand, we cannot exclude that we would have been able to retrieve additional information if we had access to unpublished as well as published data from all trials. Two of the included trials were only published in abstract form (<a href="./references#CD001939-bbs2-0004" title="FiaccadoriF . Branched chain amino acid enriched solutions in the treatment of hepatic encephalopathy: a controlled trial. Italian Journal of Gastroenterology (additional information from author November 2012). FiaccadoriF , GhinelliF , PedrettiG . Branched chain amino acid enriched solutions in the treatment of hepatic encephalopathy: a controlled trial. Italian Journal of Gastroenterology1985;17:5‐10. FiaccadoriF , GhinelliF , PedrettiG , ManciaD . Mental state course and biochemical findings in HE treated by BCAA‐enriched mixtures. In: HolmE , KasperH editor(s). Metabolism and Nutrition in Liver Disease Freiburg 1984: Proceedings of the 41st Falk Symposium. Lancaster: MTP Press, 1985:281‐5. FiaccadoriF , GhinelliF , PedrettiG , PelosiG , SacchiniD , ZeneroliML , et al. Branched chain amino acid enriched solutions in the treatment of hepatic encephalopathy: a controlled trial. In: CapocacciaL , FischerJE , Rossi‐FanelliF editor(s). Hepatic Encephalopathy in Chronic Liver Failure. New York: Plenum Press, 1984:323‐33. FiaccadoriF , GhinelliF , PelosiG , SacchiniD , VaonaG , ZeneroliML , et al. Selective amino acid solutions in hepatic encephalopathy treatment (a preliminary report). La Ricerca in Clinica e in Laboratorio1980;10:411‐22. [MEDLINE: 81102770] ">Fiaccadori 1984</a>; <a href="./references#CD001939-bbs2-0005" title="HayashiS , AoyagiY , FujiwaraK , OkaH , OdaT . A randomized controlled trial of branched‐chain amino acid (BCAA)‐enriched elemental diet (ED‐H) for hepatic encephalopathy. Journal of Gastroenterology and Hepatology1991;6:191. ">Hayashi 1991</a>). In some trials, the complete results presented in the final full‐text article differed from the initial analyses presented in abstract form (<a href="./references#CD001939-bbs2-0040" title="GluudLL , LangholzE , KragA . Meta‐analysis: isosorbide‐mononitrate alone or with either beta‐blockers or endoscopic therapy for the management of oesophageal varices. Alimentary Pharmacology &amp; Therapeutics2010;32(7):859‐71. [PUBMED: 20839387] ">Gluud 2010</a>). Access to the original patient data from trials published in abstract form may increase the strength of the analyses. Due to the risk of publication bias, we did not exclude unpublished trials and trials published in abstract form to avoid overestimation of intervention benefits. </p> </section> <section id="CD001939-sec-0089"> <h3 class="title" id="CD001939-sec-0089">Agreements and disagreements with other studies or reviews</h3> <p>The previous version of this review included 11 randomised clinical trials with 556 participants (<a href="./references#CD001939-bbs2-0084" title="Als‐NielsenB , KoretzRL , GluudLL , GluudC . Branched‐chain amino acids for hepatic encephalopathy. Cochrane Database of Systematic Reviews2003, Issue 1. [DOI: 10.1002/14651858.CD001939] ">Als‐Nielsen 2003</a>). This updated review included 16 trials with 827 participants. Both versions of the review included trials on oral or intravenous BCAA versus any control intervention. In both reviews, BCAA was not associated with reduced mortality. Likewise, both reviews found that BCAA was associated with a beneficial effect on hepatic encephalopathy. The previous review found that BCAA had a beneficial effect on improved manifestations of hepatic encephalopathy with an RR of 1.31 and an I<sup>2</sup> of 51%. The analysis included nine trials with a placebo/no intervention, diet, lactulose, or neomycin control group. In an analysis that included the same control groups, we included 16 trials and found that BCAA was associated with a beneficial effect on hepatic encephalopathy assessed based on the number of participants without improved manifestations with a RR of 0.73 and an I<sup>2</sup> of 51%. The previous review concluded that the evidence was not convincing mainly because the subgroup analyses found no effect of BCAA on hepatic encephalopathy when analysing each domain separately. In the present review, an analysis that was limited to trials with a low risk of bias confirmed that BCAA has a beneficial effect on hepatic encephalopathy. Accordingly, the overall quantitative result of the two reviews concur, but only the updated review provided enough evidence from trials with an adequate control of bias. </p> <p>One comprehensive Cochrane review from 2012 included randomised clinical trials on any type of nutritional support for any type of liver disease (<a href="./references#CD001939-bbs2-0059" title="KoretzRL , AvenellA , LipmanTO . Nutritional support for liver disease. Cochrane Database of Systematic Reviews2012, Issue 5. [DOI: 10.1002/14651858.CD008344.pub2; PUBMED: 22592729] ">Koretz 2012</a>). The review found no difference in mortality between nutritional therapy versus no nutritional therapy for liver disease in a medical setting. One meta‐analysis of six trials (total 119 participants) found that nutritional supplements had a beneficial effect on resolution of hepatic encephalopathy. Two of the six trials evaluated BCAA (<a href="./references#CD001939-bbs2-0001" title="CalveyH , DavisM , WilliamsR . Controlled trial of nutritional supplementation, with and without branched chain amino acid enrichment, in treatment of acute alcoholic hepatitis. Journal of Hepatology1985;1:141‐51. CalveyH , DavisM , WilliamsR . Prospective study of nasogastric feeding via East Grinstead or Viomedex tubes compared with oral dietary supplementation in patients with cirrhosis. Clinical Nutrition1984;3:63‐6. WilliamsR , CalveyH , DavisM . Controlled trial of nutritional supplementation in acute alcoholic hepatitis. In: HolmEKH editor(s). Metabolism and Nutrition in Liver Disease. Lancaster, UK: MTP Press, Ltd, 1985:361‐8. ">Calvey 1985</a>; <a href="./references#CD001939-bbs2-0005" title="HayashiS , AoyagiY , FujiwaraK , OkaH , OdaT . A randomized controlled trial of branched‐chain amino acid (BCAA)‐enriched elemental diet (ED‐H) for hepatic encephalopathy. Journal of Gastroenterology and Hepatology1991;6:191. ">Hayashi 1991</a>). One of the trials included people with acute alcoholic hepatitis (<a href="./references#CD001939-bbs2-0001" title="CalveyH , DavisM , WilliamsR . Controlled trial of nutritional supplementation, with and without branched chain amino acid enrichment, in treatment of acute alcoholic hepatitis. Journal of Hepatology1985;1:141‐51. CalveyH , DavisM , WilliamsR . Prospective study of nasogastric feeding via East Grinstead or Viomedex tubes compared with oral dietary supplementation in patients with cirrhosis. Clinical Nutrition1984;3:63‐6. WilliamsR , CalveyH , DavisM . Controlled trial of nutritional supplementation in acute alcoholic hepatitis. In: HolmEKH editor(s). Metabolism and Nutrition in Liver Disease. Lancaster, UK: MTP Press, Ltd, 1985:361‐8. ">Calvey 1985</a>). The trial found no differences between BCAA and control groups regarding mortality, hepatic encephalopathy, or nutritional parameters. The second trial included people with cirrhosis and found a beneficial effect of BCAA on improvement of hepatic encephalopathy (<a href="./references#CD001939-bbs2-0005" title="HayashiS , AoyagiY , FujiwaraK , OkaH , OdaT . A randomized controlled trial of branched‐chain amino acid (BCAA)‐enriched elemental diet (ED‐H) for hepatic encephalopathy. Journal of Gastroenterology and Hepatology1991;6:191. ">Hayashi 1991</a>). The systematic review found that the effect of nutritional supplements on hepatic encephalopathy was more pronounced in subgroup analyses of trials with a high concentration of BCAA (<a href="./references#CD001939-bbs2-0059" title="KoretzRL , AvenellA , LipmanTO . Nutritional support for liver disease. Cochrane Database of Systematic Reviews2012, Issue 5. [DOI: 10.1002/14651858.CD008344.pub2; PUBMED: 22592729] ">Koretz 2012</a>). However, there was unclear control of bias and the total number of participants was small. Still the overall result concurred with our findings. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD001939-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/urn:x-wiley:14651858:media:CD001939:CD001939-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/image_t/tCD001939-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram. BCAA: branched‐chain amino acids." data-id="CD001939-fig-0001" src="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/image_n/nCD001939-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram. BCAA: branched‐chain amino acids.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/full#CD001939-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/image_n/nCD001939-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001939-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/urn:x-wiley:14651858:media:CD001939:CD001939-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/image_t/tCD001939-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Methodological quality summary: review authors' judgements about each methodological quality item for each included study. CHBG: Cochrane Hepato‐Biliary Group." data-id="CD001939-fig-0002" src="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/image_n/nCD001939-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Methodological quality summary: review authors' judgements about each methodological quality item for each included study. CHBG: Cochrane Hepato‐Biliary Group. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/full#CD001939-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/image_n/nCD001939-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001939-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/urn:x-wiley:14651858:media:CD001939:CD001939-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/image_t/tCD001939-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. CHBG: Cochrane Hepato‐Biliary Group." data-id="CD001939-fig-0003" src="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/image_n/nCD001939-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. CHBG: Cochrane Hepato‐Biliary Group. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/full#CD001939-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/image_n/nCD001939-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001939-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/urn:x-wiley:14651858:media:CD001939:CD001939-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/image_t/tCD001939-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Trial sequential analysis of branched‐chain amino acids (BCAA) versus control interventions (placebo, no intervention, neomycin, or lactulose) for mortality in people with hepatic encephalopathy. The blue line (Z‐curve) shows the cumulative meta‐analysis adding the results of individual trials based on the year of publication. The vertical green line represents the 5% level of significance. The monitoring boundary (and futility) was ignored because the number of events and participants included in the analysis was insufficient. In the sequential analysis, we set alpha to 5%, power to 80%, control group incidence to 25%, relative risk reduction to 5%, and heterogeneity correction to 17%. The estimated information size was 23,485 participants. In total, the number of participants randomised was 367 in the BCAA group and 393 in the control groups." data-id="CD001939-fig-0004" src="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/image_n/nCD001939-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p><b>Trial sequential analysis of branched‐chain amino acids (BCAA) versus control interventions (placebo, no intervention, neomycin, or lactulose) for mortality in people with hepatic encephalopathy.</b> The blue line (Z‐curve) shows the cumulative meta‐analysis adding the results of individual trials based on the year of publication. The vertical green line represents the 5% level of significance. The monitoring boundary (and futility) was ignored because the number of events and participants included in the analysis was insufficient. In the sequential analysis, we set alpha to 5%, power to 80%, control group incidence to 25%, relative risk reduction to 5%, and heterogeneity correction to 17%. The estimated information size was 23,485 participants. In total, the number of participants randomised was 367 in the BCAA group and 393 in the control groups. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/full#CD001939-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/image_n/nCD001939-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001939-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/urn:x-wiley:14651858:media:CD001939:CD001939-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/image_t/tCD001939-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Trial sequential analysis of branched‐chain amino acids (BCAA) versus control interventions (placebo, no intervention, neomycin, or lactulose) for hepatic encephalopathy. The blue line (Z‐curve) shows the cumulative meta‐analysis adding the results of individual trials based on the year of publication. The vertical line represents the 5% level of significance. The monitoring boundary (inward sloping red line) shows the significance level after adjusting for the cumulative analysis. The horizontal green line shows the required information size (the number of participants needed to determine if firm evidence was established). We conducted the trial sequential analysis with alpha set to 5%, power to 80%, control group event rate to 63%, relative risk reduction to 45%, and heterogeneity correction to 47%. The estimated required information size was 186 participants (diversity adjusted). In total, the cumulative meta‐analysis included 402 participants in the BCAA group and 425 in the control groups." data-id="CD001939-fig-0005" src="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/image_n/nCD001939-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p><b>Trial sequential analysis of branched‐chain amino acids (BCAA) versus control interventions (placebo, no intervention, neomycin, or lactulose) for hepatic encephalopathy.</b> The blue line (Z‐curve) shows the cumulative meta‐analysis adding the results of individual trials based on the year of publication. The vertical line represents the 5% level of significance. The monitoring boundary (inward sloping red line) shows the significance level after adjusting for the cumulative analysis. The horizontal green line shows the required information size (the number of participants needed to determine if firm evidence was established). We conducted the trial sequential analysis with alpha set to 5%, power to 80%, control group event rate to 63%, relative risk reduction to 45%, and heterogeneity correction to 47%. The estimated required information size was 186 participants (diversity adjusted). In total, the cumulative meta‐analysis included 402 participants in the BCAA group and 425 in the control groups. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/full#CD001939-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/image_n/nCD001939-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001939-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/urn:x-wiley:14651858:media:CD001939:CD001939-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/image_t/tCD001939-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Branched‐chain amino acids (BCAA) versus control, Outcome 1 Mortality." data-id="CD001939-fig-0006" src="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/image_n/nCD001939-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Branched‐chain amino acids (BCAA) versus control, Outcome 1 Mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/references#CD001939-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/image_n/nCD001939-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001939-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/urn:x-wiley:14651858:media:CD001939:CD001939-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/image_t/tCD001939-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Branched‐chain amino acids (BCAA) versus control, Outcome 2 Mortality: mode of administration." data-id="CD001939-fig-0007" src="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/image_n/nCD001939-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Branched‐chain amino acids (BCAA) versus control, Outcome 2 Mortality: mode of administration. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/references#CD001939-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/image_n/nCD001939-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001939-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/urn:x-wiley:14651858:media:CD001939:CD001939-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/image_t/tCD001939-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Branched‐chain amino acids (BCAA) versus control, Outcome 3 Mortality: type of hepatic encephalopathy." data-id="CD001939-fig-0008" src="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/image_n/nCD001939-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Branched‐chain amino acids (BCAA) versus control, Outcome 3 Mortality: type of hepatic encephalopathy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/references#CD001939-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/image_n/nCD001939-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001939-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/urn:x-wiley:14651858:media:CD001939:CD001939-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/image_t/tCD001939-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Branched‐chain amino acids (BCAA) versus control, Outcome 4 Mortality: type of control." data-id="CD001939-fig-0009" src="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/image_n/nCD001939-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Branched‐chain amino acids (BCAA) versus control, Outcome 4 Mortality: type of control. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/references#CD001939-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/image_n/nCD001939-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001939-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/urn:x-wiley:14651858:media:CD001939:CD001939-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/image_t/tCD001939-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Branched‐chain amino acids (BCAA) versus control, Outcome 5 Mortality: type of data." data-id="CD001939-fig-0010" src="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/image_n/nCD001939-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Branched‐chain amino acids (BCAA) versus control, Outcome 5 Mortality: type of data. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/references#CD001939-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/image_n/nCD001939-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001939-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/urn:x-wiley:14651858:media:CD001939:CD001939-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/image_t/tCD001939-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Branched‐chain amino acids (BCAA) versus control, Outcome 6 Mortality: bias control." data-id="CD001939-fig-0011" src="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/image_n/nCD001939-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Branched‐chain amino acids (BCAA) versus control, Outcome 6 Mortality: bias control. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/references#CD001939-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/image_n/nCD001939-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001939-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/urn:x-wiley:14651858:media:CD001939:CD001939-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/image_t/tCD001939-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Branched‐chain amino acids (BCAA) versus control, Outcome 7 Hepatic encephalopathy." data-id="CD001939-fig-0012" src="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/image_n/nCD001939-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Branched‐chain amino acids (BCAA) versus control, Outcome 7 Hepatic encephalopathy.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/references#CD001939-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/image_n/nCD001939-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001939-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/urn:x-wiley:14651858:media:CD001939:CD001939-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/image_t/tCD001939-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Branched‐chain amino acids (BCAA) versus control, Outcome 8 Hepatic encephalopathy: mode of administration." data-id="CD001939-fig-0013" src="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/image_n/nCD001939-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Branched‐chain amino acids (BCAA) versus control, Outcome 8 Hepatic encephalopathy: mode of administration. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/references#CD001939-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/image_n/nCD001939-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001939-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/urn:x-wiley:14651858:media:CD001939:CD001939-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/image_t/tCD001939-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Branched‐chain amino acids (BCAA) versus control, Outcome 9 Overt or minimal hepatic encephalopathy." data-id="CD001939-fig-0014" src="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/image_n/nCD001939-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Branched‐chain amino acids (BCAA) versus control, Outcome 9 Overt or minimal hepatic encephalopathy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/references#CD001939-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/image_n/nCD001939-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001939-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/urn:x-wiley:14651858:media:CD001939:CD001939-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/image_t/tCD001939-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Branched‐chain amino acids (BCAA) versus control, Outcome 10 Hepatic encephalopathy: type of control." data-id="CD001939-fig-0015" src="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/image_n/nCD001939-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Branched‐chain amino acids (BCAA) versus control, Outcome 10 Hepatic encephalopathy: type of control. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/references#CD001939-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/image_n/nCD001939-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001939-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/urn:x-wiley:14651858:media:CD001939:CD001939-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/image_t/tCD001939-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Branched‐chain amino acids (BCAA) versus control, Outcome 11 Hepatic encephalopathy: type of data." data-id="CD001939-fig-0016" src="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/image_n/nCD001939-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Branched‐chain amino acids (BCAA) versus control, Outcome 11 Hepatic encephalopathy: type of data. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/references#CD001939-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/image_n/nCD001939-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001939-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/urn:x-wiley:14651858:media:CD001939:CD001939-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/image_t/tCD001939-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Branched‐chain amino acids (BCAA) versus control, Outcome 12 Hepatic encephalopathy: publication status." data-id="CD001939-fig-0017" src="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/image_n/nCD001939-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 Branched‐chain amino acids (BCAA) versus control, Outcome 12 Hepatic encephalopathy: publication status. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/references#CD001939-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/image_n/nCD001939-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001939-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/urn:x-wiley:14651858:media:CD001939:CD001939-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/image_t/tCD001939-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Branched‐chain amino acids (BCAA) versus control, Outcome 13 Hepatic encephalopathy: bias control." data-id="CD001939-fig-0018" src="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/image_n/nCD001939-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 Branched‐chain amino acids (BCAA) versus control, Outcome 13 Hepatic encephalopathy: bias control. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/references#CD001939-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/image_n/nCD001939-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001939-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/urn:x-wiley:14651858:media:CD001939:CD001939-CMP-001-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/image_t/tCD001939-CMP-001-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Branched‐chain amino acids (BCAA) versus control, Outcome 14 Hepatic encephalopathy: excluding 1 trial on people with or without cirrhosis." data-id="CD001939-fig-0019" src="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/image_n/nCD001939-CMP-001-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1 Branched‐chain amino acids (BCAA) versus control, Outcome 14 Hepatic encephalopathy: excluding 1 trial on people with or without cirrhosis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/references#CD001939-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/image_n/nCD001939-CMP-001-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001939-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/urn:x-wiley:14651858:media:CD001939:CD001939-CMP-001-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/image_t/tCD001939-CMP-001-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Branched‐chain amino acids (BCAA) versus control, Outcome 15 Hepatic encephalopathy: excluding trials with lactulose or neomycin controls." data-id="CD001939-fig-0020" src="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/image_n/nCD001939-CMP-001-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1 Branched‐chain amino acids (BCAA) versus control, Outcome 15 Hepatic encephalopathy: excluding trials with lactulose or neomycin controls. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/references#CD001939-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/image_n/nCD001939-CMP-001-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001939-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/urn:x-wiley:14651858:media:CD001939:CD001939-CMP-001-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/image_t/tCD001939-CMP-001-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Branched‐chain amino acids (BCAA) versus control, Outcome 16 Hepatic encephalopathy: trials with lactulose or neomycin control." data-id="CD001939-fig-0021" src="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/image_n/nCD001939-CMP-001-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1 Branched‐chain amino acids (BCAA) versus control, Outcome 16 Hepatic encephalopathy: trials with lactulose or neomycin control. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/references#CD001939-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/image_n/nCD001939-CMP-001-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001939-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/urn:x-wiley:14651858:media:CD001939:CD001939-CMP-001-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/image_t/tCD001939-CMP-001-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Branched‐chain amino acids (BCAA) versus control, Outcome 17 Nausea and diarrhoea." data-id="CD001939-fig-0022" src="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/image_n/nCD001939-CMP-001-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1 Branched‐chain amino acids (BCAA) versus control, Outcome 17 Nausea and diarrhoea. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/references#CD001939-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/image_n/nCD001939-CMP-001-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001939-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/urn:x-wiley:14651858:media:CD001939:CD001939-CMP-001-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/image_t/tCD001939-CMP-001-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Branched‐chain amino acids (BCAA) versus control, Outcome 18 Albumin." data-id="CD001939-fig-0023" src="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/image_n/nCD001939-CMP-001-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1 Branched‐chain amino acids (BCAA) versus control, Outcome 18 Albumin.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/references#CD001939-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/image_n/nCD001939-CMP-001-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001939-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/urn:x-wiley:14651858:media:CD001939:CD001939-CMP-001-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/image_t/tCD001939-CMP-001-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Branched‐chain amino acids (BCAA) versus control, Outcome 19 Nitrogen balance." data-id="CD001939-fig-0024" src="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/image_n/nCD001939-CMP-001-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.19</div> <div class="figure-caption"> <p>Comparison 1 Branched‐chain amino acids (BCAA) versus control, Outcome 19 Nitrogen balance. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/references#CD001939-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/media/CDSR/CD001939/image_n/nCD001939-CMP-001-19.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD001939-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Branched‐chain amino acids (BCAA) versus control for hepatic encephalopathy</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>BCAA versus control for hepatic encephalopathy.</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with hepatic encephalopathy.<br/> <b>Settings:</b> <br/> <b>Intervention:</b> BCAA versus control. </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>BCAA versus control</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Mortality</b><br/> Clinically<br/> Follow‐up: 1 to 104 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.88</b> <br/> (0.69 to 1.11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>760<br/> (15 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>226 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>199 per 1000</b><br/> (156 to 251) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>171 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>150 per 1000</b><br/> (118 to 190) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Hepatic encephalopathy</b><br/> Psychometric and clinical assessments<br/> Follow‐up: 1 to 104 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.73</b> <br/> (0.61 to 0.88) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>827<br/> (16 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>633 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>462 per 1000</b><br/> (386 to 557) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>624 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>456 per 1000</b><br/> (381 to 549) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Nausea and diarrhoea</b><br/> Clinically<br/> Follow‐up: 1 to 104 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 3.39</b> <br/> (0.7 to 16.46) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>945<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>22 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>74 per 1000</b><br/> (15 to 360) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>35 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>119 per 1000</b><br/> (24 to 576) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Albumin</b><br/> Laboratory assessment<br/> Follow‐up: 1 to 104 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean albumin in the intervention groups was<br/> <b>0.6 higher</b><br/> (0.9 lower to 2.09 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>176<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>4,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Nitrogen balance</b><br/> Laboratory assessment<br/> Follow‐up: 1 to 104 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean nitrogen balance in the intervention groups was<br/> <b>0.81 standard deviations higher</b><br/> (0.07 to 1.56 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>108<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>4,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD 0.81 (95% CI 0.07 to 1.56)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g., the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>BCAA:</b> branched‐chain amino acids; <b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>SMD:</b> standardised mean difference. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> The trial sequential analysis showed that additional evidence is needed and that we have not yet reached the required information size.<br/> <sup>2</sup> An analysis of trials with a low risk of bias (RR 0.71; 95% CI 0.52 to 0.96) and trial sequential analysis confirmed the result. No publication bias detected in funnel plots or regression analyses. </p> <p><sup>3</sup> Downgraded due to imprecision and lack of trials with a low risk of bias in the overall assessment.<br/> <sup>4</sup> Indirect outcome used as a surrogate estimate of nutritional status.<br/> <sup>5</sup> Due to the small number of trials, we were unable to determine the risk of publication bias. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Branched‐chain amino acids (BCAA) versus control for hepatic encephalopathy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/full#CD001939-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001939-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Branched‐chain amino acids (BCAA) versus control</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>760</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.69, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Mortality: mode of administration <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>760</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.71, 1.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>363</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.50, 1.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Intravenous</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>397</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.63, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Mortality: type of hepatic encephalopathy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>760</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.71, 1.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Overt</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>563</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.61, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Minimal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>197</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.57, 2.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Mortality: type of control <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>783</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.71, 1.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Placebo/no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.40, 1.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Isonitrogenous</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>230</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.80, 1.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Non‐isonitrogenous</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>280</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.54, 1.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 Lactulose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.28 [0.04, 2.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5 Neomycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [0.54, 2.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Mortality: type of data <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>760</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.71, 1.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Re‐calculated outcomes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>255</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.47, 1.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Trial reports</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>505</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.65, 1.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Mortality: bias control <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Selection bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>521</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.70, 1.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Attrition bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>595</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.77, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Reporting bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>760</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.71, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4 For‐profit bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>621</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.68, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.5 Other bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>760</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.71, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.6 Combined bias assessment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>437</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.65, 1.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Hepatic encephalopathy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>827</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.61, 0.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Hepatic encephalopathy: mode of administration <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>827</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.61, 0.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>430</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.52, 0.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Intravenous</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>397</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.61, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Overt or minimal hepatic encephalopathy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>827</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.61, 0.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Overt</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>630</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.58, 0.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Minimal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>197</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.50, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Hepatic encephalopathy: type of control <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>805</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.63, 0.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Placebo/no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.31, 1.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Isonitrogenous diet</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>350</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.57, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3 Non‐isonitrogenous diet</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.49, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.4 Lactulose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.03, 2.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.5 Neomycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.53, 1.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Hepatic encephalopathy: type of data <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>827</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.61, 0.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 Published data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>572</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.62, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 Re‐calculated based on unpublished data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>255</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.34, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Hepatic encephalopathy: publication status <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>827</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.62, 0.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 Full‐paper articles</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>760</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.63, 0.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 Abstracts</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.48, 0.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Hepatic encephalopathy: bias control <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 Selection bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>521</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.62, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 Performance and detection bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>450</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.59, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.3 Attrition bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>595</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.60, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.4 Reporting bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>595</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.60, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.5 For‐profit bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>711</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.56, 0.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.6 Other bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>827</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.61, 0.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.7 Combined bias assessment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>373</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.52, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Hepatic encephalopathy: excluding 1 trial on people with or without cirrhosis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>801</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.62, 0.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Hepatic encephalopathy: excluding trials with lactulose or neomycin controls <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>610</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.63, 0.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Hepatic encephalopathy: trials with lactulose or neomycin control <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>195</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.34, 1.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 Lactulose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.03, 2.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2 Neomycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.53, 1.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Nausea and diarrhoea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>945</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 90% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.39 [0.70, 16.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Albumin <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [‐0.90, 2.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Nitrogen balance <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.07, 1.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Branched‐chain amino acids (BCAA) versus control</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001939.pub4/references#CD001939-tbl-0002">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD001939.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD001939-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD001939-note-0006">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD001939-note-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD001939-note-0004">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD001939-note-0003">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD001939-note-0002">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD001939-note-0005">Polski</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD001939-note-0011">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001939\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001939\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001939\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001939\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001939\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001939\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001939\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001939\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001939\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001939\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001939\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001939\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001939\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001939\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001939\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001939\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001939\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001939\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=7a2tKMcJ&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001939.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD001939.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD001939.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD001939.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001939.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740715624235"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD001939.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740715624238"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD001939.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d8ba45a339371',t:'MTc0MDcxNTYyNC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 